BioMedLib Search Engine
[ goto HOMEPAGE ]
Locate the most relevant articles, quickly.
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
adenocarcinoma of colon stage iii 2005:2010[pubdate] *count=100
163 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
adenocarcinoma of colon stage iii
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 163
1.
Silva RG, Dahmoush L, Gerke H:
Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
JOP
; 2006;7(1):66-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
CASE REPORT: We describe a 69-year-old female with concomitant Duke's C
adenocarcinoma of
the
colon
and
stage III
-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
Although ovarian
adenocarcinoma
has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
Genetic Alliance.
consumer health - Malignant mixed Mullerian tumor
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16407622.001).
[ISSN]
1590-8577
[Journal-full-title]
JOP : Journal of the pancreas
[ISO-abbreviation]
JOP
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Italy
2.
Nabi U, Nagi AH, Riaz S, Sami W:
Morphological evaluation of colorectal carcinoma with grading staging and histological types.
J Pak Med Assoc
; 2010 Dec;60(12):998-1001
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Haematoxylin and Eosin stained slides were examined to determine the histological type, grade and
stage of
CRC.
RESULTS: Among the 100 cases, 59 were non mucinous adenocarcinomas, of which 4 were in Dukes'
stage
A, 51 were in Dukes'
stage
B and 4 were in Dukes'
stage
C.
In thirty cases of mucinous carcinomas, 18 were in Dukes'
stage
B and 12 were in Dukes'
stage
C, of these 2 were of grade I, 20 were of grade II and 8 were of grade
III
.
All the 11 signet ring cell carcinomas were of grade
III
and in Dukes'
stage
C.
CONCLUSION: Mucin secreting and signet-ring cell adenocarcinomas
of colon
and rectum are high grade tumours and presented at an advanced
stage
.
[MeSH-major]
Adenocarcinoma
/ classification.
Adenocarcinoma
/ pathology. Colorectal Neoplasms / classification. Colorectal Neoplasms / pathology. Neoplasm Staging
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21381550.001).
[ISSN]
0030-9982
[Journal-full-title]
JPMA. The Journal of the Pakistan Medical Association
[ISO-abbreviation]
J Pak Med Assoc
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
Pakistan
3.
van Leeuwen BL, Påhlman L, Gunnarsson U, Sjövall A, Martling A:
The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region.
Crit Rev Oncol Hematol
; 2008 Sep;67(3):229-36
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The effect of age and gender on outcome after treatment for
colon
carcinoma. A population-based study in the Uppsala and Stockholm region.
RATIONALE: The aim of this study was to assess whether there are differences in treatment strategy and outcome between different age cohorts among men and women with
colon
cancer.
METHODS: All patients with
colon
cancer included in the regional quality registry in Uppsala/Orebro and Stockholm between 1996 and December 2004 were analysed (n=11002).
RESULTS: Overall and cancer-specific survival decreased with increasing age for stages II and
III colon
cancer but was not influenced by gender.
Older patients with
stage III
tumours were less likely to be referred for chemotherapeutic treatment and there was a decrease in cancer-specific survival with increasing age, from 63.7% to 51.0% to 38.4% in the three age groups.
[MeSH-minor]
Adenocarcinoma
. Age Distribution. Age Factors. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Registries. Sex Factors. Survival Analysis. Sweden. Treatment Outcome
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18440820.001).
[ISSN]
1040-8428
[Journal-full-title]
Critical reviews in oncology/hematology
[ISO-abbreviation]
Crit. Rev. Oncol. Hematol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Ireland
Advertisement
4.
Nash GM, Gimbel M, Cohen AM, Zeng ZS, Ndubuisi MI, Nathanson DR, Ott J, Barany F, Paty PB:
KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer.
Ann Surg Oncol
; 2010 Feb;17(2):416-24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PATIENTS AND METHODS: MSI and KRAS mutation status were assessed in 532 primary adenocarcinomas (
stage
I-IV) from patients treated by
colon
resection.
MSI was more common in early-
stage
disease (I, 15%; II, 21%;
III
, 10%; IV, 2%; P = 0.0001).
Prevalence of KRAS mutation did not vary with
stage
(I, 36%; II, 34%;
III
, 35%; IV, 40%; P = ns).
Using Cox regression analysis MSI, KRAS mutation, and
stage
were strong independent predictors of survival in the entire patient population.
A high-mortality group with MSS/KRAS-mutant tumors was identified within the
stage
I and II cohort.
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19813061.001).
[ISSN]
1534-4681
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P01 CA065930; United States / NCI NIH HHS / CA / 2 P01 CA65930-05A2
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Genetic Markers; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
[Other-IDs]
NLM/ NIHMS674393; NLM/ PMC4380015
5.
Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG:
Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
J Clin Oncol
; 2005 Dec 1;23(34):8706-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Colon
cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
PATIENTS AND METHODS: We analyzed data from Intergroup trial 0089 of adjuvant chemotherapy for
stage
II and
III
patients with
colon
cancer, in which all patients received fluorouracil-based therapy.
Covariates included in the models were age, sex, tumor
stage
, grade, histology, number of positive LNs, number of LNs removed, and LNR.
[MeSH-major]
Adenocarcinoma
/ therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / therapy. Lymphatic Metastasis / pathology
Genetic Alliance.
consumer health - Metastatic cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16314630.001).
[ISSN]
0732-183X
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
6.
Jensen SA, Vilmar A, Sørensen JB:
Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.
Med Oncol
; 2006;23(4):521-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for
colon
cancer
stage III
compared to younger patients: toxicity and prognosis.
PURPOSE: To compare benefits and risks to adjuvant chemotherapy following complete resection of node-positive
colon
cancer
stage III
for patients aged >or=75 yr and younger.
CONCLUSIONS: Adjuvant 5-FU chemotherapy should be considered for elderly patients aged >or=75 yr in good performance at high risk of recurrence
of colon
carcinoma after resection.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2002 Oct 1;20(19):3992-8
[
12351596.001
]
[Cites]
Ann Intern Med. 2002 Mar 5;136(5):349-57
[
11874307.001
]
[Cites]
Cancer Control. 1995 Mar;2(2 Suppl 1):36-38
[
10887408.001
]
[Cites]
Pharmacol Rev. 2004 Jun;56(2):163-84
[
15169926.001
]
[Cites]
J Natl Cancer Inst. 2001 Jun 6;93(11):850-7
[
11390534.001
]
[Cites]
J Clin Oncol. 1999 May;17(5):1349-55
[
10334518.001
]
[Cites]
Gastroenterology. 1994 Apr;106(4):899-906
[
8143995.001
]
[Cites]
Lancet. 1999 Jan 30;353(9150):391-9
[
9950460.001
]
[Cites]
Cancer. 2002 Apr 1;94(7):1931-8
[
11932894.001
]
[Cites]
Lancet. 2000 May 6;355(9215):1588-96
[
10821362.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2412-8
[
10561304.001
]
[Cites]
N Engl J Med. 2001 Oct 11;345(15):1091-7
[
11596588.001
]
[Cites]
Ann Oncol. 2004 Apr;15(4):568-73
[
15033660.001
]
[Cites]
J Clin Oncol. 2003 Aug 1;21(15):2896-903
[
12885807.001
]
[Cites]
Am J Clin Oncol. 2003 Feb;26(1):103-6
[
12576935.001
]
[Cites]
J Clin Oncol. 1999 May;17(5):1356-63
[
10334519.001
]
[Cites]
Ann Oncol. 2005 May;16(5):767-72
[
15817594.001
]
[Cites]
N Engl J Med. 1999 Dec 30;341(27):2061-7
[
10615079.001
]
[Cites]
N Engl J Med. 1990 Feb 8;322(6):352-8
[
2300087.001
]
[Cites]
JAMA. 1990 Sep 19;264(11):1444-50
[
2202842.001
]
[Cites]
Cancer J. 2001 May-Jun;7(3):213-8
[
11419029.001
]
[Cites]
Lancet. 1995 Apr 15;345(8955):939-44
[
7715291.001
]
[Cites]
J Clin Oncol. 1989 Oct;7(10):1447-56
[
2778478.001
]
[Cites]
Am J Clin Oncol. 1982 Apr;5(2):227-36
[
7091044.001
]
[Cites]
Ann Oncol. 2000 Aug;11(8):947-55
[
11038030.001
]
[Cites]
J Clin Oncol. 1984 Jul;2(7):849-55
[
6737023.001
]
[Cites]
J Clin Oncol. 1998 Jan;16(1):295-300
[
9440756.001
]
[Cites]
J Clin Oncol. 1999 Nov;17(11):3553-9
[
10550154.001
]
[Cites]
Cancer. 1995 Feb 1;75(3):775-81
[
7828127.001
]
[Cites]
Cancer. 1996 Aug 15;78(4):918-26
[
8756390.001
]
[Cites]
Lancet. 2000 May 20;355(9217):1745-50
[
10832824.001
]
[Cites]
J Clin Oncol. 1993 Oct;11(10):1879-87
[
8410113.001
]
(PMID = 17303911.001).
[ISSN]
1357-0560
[Journal-full-title]
Medical oncology (Northwood, London, England)
[ISO-abbreviation]
Med. Oncol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
7.
Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM, Norwegian Gastrointestinal Cancer Group:
Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Acta Oncol
; 2009;48(3):368-76
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Final results of a randomised phase
III
study on adjuvant chemotherapy with 5 FU and levamisol in
colon
and rectum cancer
stage
II and
III
by the Norwegian Gastrointestinal Cancer Group.
BACKGROUND: The recommendation of adjuvant chemotherapy for
colon
cancer with lymph node metastases, based on two studies from USA, was reluctantly accepted by Norwegian medical doctors.
MATERIAL AND METHODS: Four hundred and twenty five patients with operable
colon
and rectum cancer,
Stage
II and
III
(Dukes'
stage
B and C), were from January 1993 to October 1996, included in a randomised multicentre trial in Norway.
There was no difference between the two groups when analysed for
colon
and rectum separately.
However, the subgroup
of colon
cancer with
stage III
exhibited a statistically significant difference both for DFS, 58% vs. 37% (p=0.012) and CSS, 65% vs. 47% (p=0.032) in favour of adjuvant chemotherapy.
CONCLUSIONS:
Colon
cancer patients with lymph node metastases benefit from adjuvant chemotherapy with 5-FU/Lev with acceptable toxicity.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antineoplastic Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Levamisole / therapeutic use. Rectal Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19242829.001).
[ISSN]
1651-226X
[Journal-full-title]
Acta oncologica (Stockholm, Sweden)
[ISO-abbreviation]
Acta Oncol
[Language]
eng
[Publication-type]
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
Norway
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
8.
Snaebjörnsson P, Jónasson L, Jónsson T, Möller PH, Theodórs A, Jónasson JG:
[Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference].
Laeknabladid
; 2009 Jun;95(6):423-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Colon
cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference].
OBJECTIVE:
Colon
cancer is the third most common cancer in Iceland.
The aim of this study was to analyze the epidemiology and histopathology
of colon
cancer in Iceland, resection rate and the difference between men and women.
MATERIAL AND METHODS: Pathology and autopsy reports for all patients diagnosed with
colon
cancer between 1955 and 2004 where reviewed.
Most tumors were located in the sigmoid
colon
(35%).
Adenocarcinomas where 84% and mucinous
adenocarcinoma
7%.
Altogether 7% of cases were TNM-
stage
I, 32% were
stage
II, 24%
stage III
, 21% in
stage
IV and
stage
was unknown in 16% of cases.
CONCLUSION: Incidence
of colon
cancer increased considerably, mainly for men.
Surgical rate and pathology
of colon
cancer is similar to that reported elsewhere except that there are somewhat fewer cases in TNM-
stage
I.
[MeSH-major]
Adenocarcinoma
/ epidemiology.
Adenocarcinoma
, Mucinous / epidemiology. Colonic Neoplasms / epidemiology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Laeknabladid. 2009 Jun;95(6):419
[
19491405.001
]
(PMID = 19491407.001).
[ISSN]
0023-7213
[Journal-full-title]
Læknablađiđ
[ISO-abbreviation]
Laeknabladid
[Language]
ice
[Publication-type]
Comparative Study; English Abstract; Journal Article
[Publication-country]
Iceland
9.
Silvéra L, Galula G, Tiret E, Louvet C, Leroux JL, Trutt B:
Assessment of management practices for colonic cancer in the Paris metropolitan area in 2002.
Gastroenterol Clin Biol
; 2006 Jun-Jul;30(6-7):852-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: To assess the management of patients aged 18 years or older with colonic
adenocarcinoma
(including the rectosigmoid junction), compared with French guidelines (ANAES and SOR).
METHODS: This retrospective study carried out in 2003 by the Ile-
de
-France regional union of health insurance funds from hospital discharge and operative and pathology reports of patients exempted from copayment between April 2001 and March 2002.
37.7%
of stage
II patients had chemotherapy while 10.8%
of stage III
and 9.8%
of stage
IV patients did not.
CONCLUSION: Implementation of guidelines for the management
of colon
cancer can be improved, notably regarding pathologic analysis and indications of chemotherapy.
[MeSH-major]
Adenocarcinoma
/ therapy. Colonic Neoplasms / therapy
[MeSH-minor]
Adult. Age Factors. Aged. Aged, 80 and over.
Colon
/ pathology. Data Collection. Data Interpretation, Statistical. Female. Guideline Adherence. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / therapy. Paris. Practice Guidelines as Topic. Retrospective Studies. Surveys and Questionnaires
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16885869.001).
[ISSN]
0399-8320
[Journal-full-title]
Gastroentérologie clinique et biologique
[ISO-abbreviation]
Gastroenterol. Clin. Biol.
[Language]
eng
[Publication-type]
Comparative Study; Evaluation Studies; Journal Article
[Publication-country]
France
10.
Colomer A, Erill N, Vidal A, Calvo M, Roman R, Verdú M, Cordon-Cardo C, Puig X:
A novel logistic model based on clinicopathological features predicts microsatellite instability in colorectal carcinomas.
Diagn Mol Pathol
; 2005 Dec;14(4):213-23
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
High-frequency microsatellite instability has been reported to be associated with good prognosis in colorectal
adenocarcinoma
.
Clinicopathological features of a cohort of 204 patients with primary
colon
cancer were retrospectively reviewed following predetermined criteria.
Implementation of this tool to routine histopathological studies could improve the management of patients with colorectal cancer, especially those presenting with
stage
II and
III of
the disease.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16319691.001).
[ISSN]
1052-9551
[Journal-full-title]
Diagnostic molecular pathology : the American journal of surgical pathology, part B
[ISO-abbreviation]
Diagn. Mol. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Ki-67 Antigen
11.
Shaikh AJ, Raza S, Shaikh AA, Idress R, Kumar S, Rasheed YA, Lal A, Masood N:
Demographics, pathologic patterns and long-term survival in operable colon cancers: local experience in Pakistan.
Asian Pac J Cancer Prev
; 2009 Jul-Sep;10(3):361-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Demographics, pathologic patterns and long-term survival in operable
colon
cancers: local experience in Pakistan.
BACKGROUND:
Colon
cancer is a common malignancy with its incidence reportedly rising in Asian countries, including Pakistan.
There are no comprehensive data available from Pakistan which focus on associations of various factors with long-term survival
of colon
cancer.
METHODOLOGY: In this retrospective study adult patients with
colon
cancer diagnosed through 2000-2003 were included.
Of the total, 49.5% of the patients had right sided (mortality rate 51.6%), 10.8% had transverse
colon
, (mortality rate 37.5%), 7.5% had descending
colon
(mortality rate 66.7%) and 32.2% had sigmoid
colon
(mortality rate 40.9%) cancers.
Stage
I disease on diagnosis was found in 16%,
stage
II in 42.7 (mortality 40 %) and
stage III
in 41.3% (mortality 70 %).
Most patients had pure
adenocarcinoma
while a mucinous type differentiation was seen in 19.7%, 3% had signet ring morphology, 1.5% adeno-squamous carcinoma and similar number with neuroendocrine differentiation.
CONCLUSION:
Colon
cancer in Pakistan commonly presents at an advanced
stage
, there is a male preponderance, and relatively mean younger age at presentation for males is seen.
Advanced
stage
and lymph node involvement along with poorly differentiated pathology, signet ring or mucinous morphology, location in descending
colon
, positive surgical margins and removal of less than twelve lymph nodes are factors associated with poor long term survival.
There is a need to reinforce information about
colon
cancer and larger studies from the region are needed to confirm the factors analyzed here.
[MeSH-major]
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Recurrence, Local / mortality. Survivors
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19640173.001).
[ISSN]
2476-762X
[Journal-full-title]
Asian Pacific journal of cancer prevention : APJCP
[ISO-abbreviation]
Asian Pac. J. Cancer Prev.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Thailand
12.
Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS:
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Cancer Chemother Pharmacol
; 2010 Sep;66(4):659-67
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinical impact of microsatellite instability in
colon
cancer following adjuvant FOLFOX therapy.
PURPOSE:
Colon
cancer with DNA mismatch repair (MMR) defects reveals indistinguishable clinical and pathologic aspects, including better prognosis and reduced response to 5-fluorouracil (5-FU)-based chemotherapy.
This study investigated the clinical implication of MSI-H/MMR-D and p53 expression in R0-resected
colon
cancer patients who received adjuvant oxaliplatin/5-FU/leucovorin (FOLFOX) therapy.
EXPERIMENTAL DESIGN: We analyzed 135 patients, who had been treated by adjuvant chemotherapy containing 5-FU and oxaliplatin (FOLFOX) after curative resection (R0) for
colon adenocarcinoma
between May 2004 and November 2007.
RESULTS: There were 13 (9.6%) patients with
stage
II, 108 (80%) with
stage III
, and 14 (10.4%) with
stage
IV.
Fourteen patients with
stage
IV (10.3%) had metastases to liver only, all of whom underwent complete metastasectomy for liver metastases.
MMR status was not significantly associated with DFS (P = 0.56) or OS (P = 0.61) in patients with
colon
cancer (n = 135) receiving adjuvant FOLFOX.
CONCLUSION: The MMR status or p53 positivity was not significantly associated with outcomes to FOLFOX as adjuvant chemotherapy in
colon
cancer patients with R0 resection.
Adding oxaliplatin in adjuvant chemotherapy may overcome negative impact of 5-FU on
colon
cancers with MSI-H/MMR-D.
[MeSH-major]
Adenocarcinoma
/ drug therapy.
Adenocarcinoma
/ genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Microsatellite Instability / drug effects
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20033812.001).
[ISSN]
1432-0843
[Journal-full-title]
Cancer chemotherapy and pharmacology
[ISO-abbreviation]
Cancer Chemother. Pharmacol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Genetic Markers; 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
13.
Dahlqvist C, Fremault A, Carrasco J, Colinet B:
[Obliterative bronchiolitis with organising pneumonia following FOLFOX 4 chemotherapy].
Rev Mal Respir
; 2010;27(1):84-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Transliterated title]
Bronchiolite oblitérante avec pneumonie organisée après chimiothérapie
de
type FOLFOX 4.
INTRODUCTION: FOLFOX 4 chemotherapy (5-fluorouracil, leucovorin and oxaliplatin) is the standard adjuvant treatment for
stage III colon
cancer.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antineoplastic Combined Chemotherapy Protocols / toxicity. Colonic Neoplasms / drug therapy. Cryptogenic Organizing Pneumonia / chemically induced
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20146958.001).
[ISSN]
1776-2588
[Journal-full-title]
Revue des maladies respiratoires
[ISO-abbreviation]
Rev Mal Respir
[Language]
fre
[Publication-type]
English Abstract; Journal Article
[Publication-country]
France
[Chemical-registry-number]
0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
14.
Brosens RP, Oomen JL, Glas AS, van Bochove A, Cuesta MA, Engel AF:
POSSUM predicts decreased overall survival in curative resection for colorectal cancer.
Dis Colon Rectum
; 2006 Jun;49(6):825-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: A total of 542 patients survived a radical resection for Stages I, II, or
III
colorectal cancer.
Differences in overall survival also were found when patients in Stages I, II, and
III
were analyzed separately.
Risk factors for overall survival were advanced
stage of
disease, poor tumor differentiation, mucinous
adenocarcinoma
, older than age 70 years, and poor condition of the patient at time of operation.
[MeSH-major]
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / surgery. Severity of Illness Index
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16550320.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
15.
Yamada K, Ogata S, Saiki Y, Fukunaga M, Tsuji Y, Takano M:
Long-term results of intersphincteric resection for low rectal cancer.
Dis Colon Rectum
; 2009 Jun;52(6):1065-71
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The five-year disease-free survival rates classified according to the TNM
stage
were 100 percent for
stage
I, 83.5 percent for
stage
II, and 72.0 percent for
stage III
cases.
[MeSH-major]
Adenocarcinoma
/ surgery. Rectal Neoplasms / surgery
Genetic Alliance.
consumer health - Rectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19581848.001).
[ISSN]
1530-0358
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
16.
Min BS, Kim NK, Ko YT, Baek SH, Lee KY, Sohn SK, Cho CH, Kang DR:
Clinicopathological features of signet-ring cell carcinoma of the colon and rectum: a case-matched study.
Hepatogastroenterology
; 2009 Jul-Aug;56(93):984-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinicopathological features of signet-ring cell carcinoma of the
colon
and rectum: a case-matched study.
BACKGROUND/AIMS: Primary colorectal signet-ring cell carcinoma (SRC) is a rare type of mucin-containing
adenocarcinoma
and little information exists about its clinicopathological features.
METHODS: The clinicopathological features of 27 patients with primary colorectal SRC were compared with non-signet-ring cell mucinous carcinoma (MC) and non-mucinous
adenocarcinoma
(NMC).
In
stage
II and
III
, SRC was found to be associated with a worse cancer-specific survival and a higher systemic recurrence rates than either NMC or MC.
[MeSH-major]
Adenocarcinoma
, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology
Genetic Alliance.
consumer health - Signet ring cell carcinoma
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19760925.001).
[ISSN]
0172-6390
[Journal-full-title]
Hepato-gastroenterology
[ISO-abbreviation]
Hepatogastroenterology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
17.
Grabowski P, Sturm I, Schelwies K, Maaser K, Buhr HJ, Dörken B, Zeitz M, Daniel PT, Scherübl H:
Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis.
Int J Colorectal Dis
; 2006 Apr;21(3):221-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC
stage III
colorectal carcinoma identifies patients with good prognosis.
Moreover, an altered p53/BAX pathway is associated with a poor clinical outcome in Union Internationale Contre le Cancer (UICC)
stage III
disease.
PATIENTS AND METHODS: Specimens were analyzed from 59 patients with UICC
stage III
disease who underwent surgery for colorectal
adenocarcinoma
at our institution and were followed up for 5 years or until death.
RESULTS: p53 status/BAX expression and neuroendocrine differentiation are not correlated in
stage III
colorectal cancers.
Both represent independent prognostic markers in UICC
stage III
disease.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann N Y Acad Sci. 1994 Sep 15;733:46-55
[
7978895.001
]
[Cites]
Leukemia. 2001 Jul;15(7):1022-32
[
11455969.001
]
[Cites]
Int J Cancer. 2000 Aug 15;87(4):517-21
[
10918191.001
]
[Cites]
Acta Oncol. 1993;32(2):115-24
[
8323752.001
]
[Cites]
Clin Cancer Res. 2002 Oct;8(10):3205-9
[
12374690.001
]
[Cites]
CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
[
14974761.001
]
[Cites]
Leukemia. 2000 Dec;14(12):2035-44
[
11187890.001
]
[Cites]
Essays Biochem. 2003;39:73-88
[
14585075.001
]
[Cites]
Arch Pathol Lab Med. 2000 Jul;124(7):979-94
[
10888773.001
]
[Cites]
Int J Cancer. 2000 Oct 15;88(2):281-6
[
11004681.001
]
[Cites]
Br J Cancer. 2001 Mar 2;84(5):651-8
[
11237386.001
]
[Cites]
Int J Cancer. 2002 Jun 1;99(4):589-96
[
11992551.001
]
[Cites]
J Clin Pathol. 1995 Aug;48(8):754-8
[
7560204.001
]
[Cites]
Virchows Arch. 2002 Sep;441(3):256-63
[
12242522.001
]
[Cites]
Ann Surg Oncol. 1996 Nov;3(6):574-9
[
8915491.001
]
[Cites]
Int J Cancer. 1993 Jul 9;54(5):765-71
[
8100808.001
]
[Cites]
Br J Cancer. 1999 Jan;79(2):191-203
[
9888457.001
]
[Cites]
Cell. 1997 Nov 14;91(4):479-89
[
9390557.001
]
[Cites]
Cancer. 1991 Apr 1;67(7):1859-61
[
2004298.001
]
[Cites]
Oncogene. 2001 May 17;20(22):2749-60
[
11420687.001
]
[Cites]
J Clin Oncol. 2001 Apr 15;19(8):2272-81
[
11304781.001
]
[Cites]
Anticancer Res. 2001 Jan-Feb;21(1A):253-9
[
11299743.001
]
[Cites]
Expert Opin Investig Drugs. 2001 Jun;10(6):1011-9
[
11772231.001
]
[Cites]
Gut. 2004 Jun;53(6):899-910
[
15138220.001
]
[Cites]
Endocr Rev. 2003 Aug;24(4):389-427
[
12920149.001
]
[Cites]
APMIS. 2004 Jan;112(1):49-56
[
14961975.001
]
[Cites]
Eur J Gastroenterol Hepatol. 2001 Apr;13(4):405-11
[
11338071.001
]
[Cites]
Cell. 1995 Jan 27;80(2):293-9
[
7834749.001
]
[Cites]
Int J Cancer. 2002 Feb 1;97(4):403-9
[
11802199.001
]
[Cites]
World J Surg. 2002 Jan;26(1):59-66
[
11898035.001
]
[Cites]
Cancer. 1992 Jun 1;69(11):2641-6
[
1571893.001
]
[Cites]
Dis Colon Rectum. 2001 Apr;44(4):523-33
[
11330579.001
]
[Cites]
Eur J Clin Invest. 1998 Dec;28(12):1038-49
[
9893017.001
]
[Cites]
J Clin Oncol. 1999 May;17(5):1364-74
[
10334520.001
]
[Cites]
Br J Cancer. 2003 Nov 3;89(9):1766-75
[
14583782.001
]
[Cites]
Physiol Rev. 1988 Apr;68(2):456-502
[
3282244.001
]
[Cites]
Digestion. 2000;62 Suppl 1:3-18
[
10940682.001
]
[Cites]
J Biol Chem. 2004 Jan 16;279(3):1713-9
[
14593113.001
]
[Cites]
Int J Cancer. 2003 Feb 10;103(4):445-54
[
12478659.001
]
[Cites]
Int J Cancer. 1995 Mar 3;60(5):645-51
[
7860139.001
]
[Cites]
Cancer Res. 2000 Aug 15;60(16):4573-81
[
10969809.001
]
[Cites]
Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(5):293-6
[
8287125.001
]
[Cites]
J Biol Chem. 2002 Aug 2;277(31):27643-50
[
12011069.001
]
[Cites]
Histopathology. 1998 Feb;32(2):133-8
[
9543669.001
]
[Cites]
Arch Pathol Lab Med. 2001 Jan;125(1):91-8
[
11151060.001
]
[Cites]
Arch Pathol Lab Med. 1998 Oct;122(10):912-4
[
9786353.001
]
[Cites]
J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53
[
9326914.001
]
[Cites]
J Clin Oncol. 2003 Sep 15;21(18):3391-401
[
12885834.001
]
(PMID = 16485142.001).
[ISSN]
0179-1958
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / bcl-2-Associated X Protein
18.
Liang JT, Lai HS, Lee PH:
Multimedia article. Laparoscopic abdominoperineal resection for lower rectal cancers: how do we do it?
Surg Endosc
; 2006 Apr;20(4):695-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: The appropriateness of the laparoscopic approach for the resection of rectal cancer has been controversial, although it is well established in
colon
cancer.
METHODS: Patients with lower rectal
adenocarcinoma
located within 6 cm above the anal verge were recruited and subjected to laparoscopic APR.
Physical status (American Society of Anesthesiology classification) was class I in 12, class II in eight, and class
III
in two patients.
Two patients were in pathologic TNM
stage
I, 14 in
stage
II, and six in
stage III
.
[MeSH-major]
Abdomen / surgery.
Adenocarcinoma
/ surgery. Laparoscopy / methods. Perineum / surgery. Rectal Neoplasms / surgery
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 2004 May 13;350(20):2050-9
[
15141043.001
]
[Cites]
Dis Colon Rectum. 2002 Nov;45(11):1481-5
[
12432295.001
]
[Cites]
World J Surg. 2002 Mar;26(3):377-83
[
11865378.001
]
[Cites]
Lancet. 2004 Apr 10;363(9416):1187-92
[
15081650.001
]
[Cites]
J Am Coll Surg. 1998 Jul;187(1):46-54; discussion 54-5
[
9660024.001
]
[Cites]
Lancet. 2002 Jun 29;359(9325):2224-9
[
12103285.001
]
[Cites]
J Laparoendosc Adv Surg Tech A. 2000 Feb;10(1):47-53
[
10706303.001
]
[Cites]
World J Surg. 2003 Feb;27(2):190-6
[
12616435.001
]
[Cites]
Ann Surg. 1967 Sep;166(3):420-7
[
6039601.001
]
(PMID = 16502195.001).
[ISSN]
1432-2218
[Journal-full-title]
Surgical endoscopy
[ISO-abbreviation]
Surg Endosc
[Language]
eng
[Publication-type]
Journal Article; Video-Audio Media
[Publication-country]
Germany
19.
Yokoi K, Tanaka N, Furukawa K, Seya T, Ohaki Y, Tajiri T:
Case of adenosquamous carcinoma of the ascending colon.
J Nippon Med Sch
; 2008 Aug;75(4):242-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Case of adenosquamous carcinoma of the ascending
colon
.
Adenocarcinoma
accounts for most of the malignant tumors originating from the
colon
, whereas adenosquamous carcinoma is rare, accounting for about 0.1% of all
colon
cancers.
We present herein a case of adenosquamous carcinoma of the ascending
colon
.
A barium enema examination and lower gastrointestinal endoscopy showed a type 3 tumor in the ascending
colon
, and a biopsy confirmed the diagnosis of adenosquamous carcinoma.
Right hemicolectomy was performed, and the tumor was diagnosed as a
stage III
advanced
colon
cancer.
A search of Japanese literature over the past 25 years yielded 70 patients with adenosquamous carcinoma of the
colon
, and the clinicopathological features are discussed herein.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18781050.001).
[ISSN]
1345-4676
[Journal-full-title]
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
[ISO-abbreviation]
J Nippon Med Sch
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
20.
Li M, Li JY, Zhao AL, He JS, Zhou LX, Li YA, Gu J:
Survival stratification panel of colorectal carcinoma with combined expression of carcinoembryonic antigen, matrix metalloproteinases-2, and p27 kip1.
Dis Colon Rectum
; 2007 Nov;50(11):1887-98
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PURPOSE: The prognosis varies greatly in colorectal carcinoma patients, even in the same
stage
.
In different stages, coexpression tumor markers functioned in Stages II and
III
but not in the 19 cases
of Stage
I.
[MeSH-major]
Adenocarcinoma
/ metabolism.
Adenocarcinoma
/ nursing. Carcinoembryonic Antigen / metabolism. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / mortality. Intracellular Signaling Peptides and Proteins / metabolism. Matrix Metalloproteinase 2 / metabolism
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17882488.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / CDKN1B protein, human; 0 / Carcinoembryonic Antigen; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.4.24.24 / Matrix Metalloproteinase 2
21.
Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B:
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Croat Med J
; 2006 Oct;47(5):693-700
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Between June 2004 and January 2005, 57 patients with operable, clinical
stage
II-
III adenocarcinoma
of the rectum entered the prospective phase II study.
[MeSH-major]
Adenocarcinoma
/ drug therapy.
Adenocarcinoma
/ radiotherapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Radiation-Sensitizing Agents / therapeutic use. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
Genetic Alliance.
consumer health - Rectal Cancer
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
CAPECITABINE
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Chemother Pharmacol. 2000;45(4):291-7
[
10755317.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53
[
15913913.001
]
[Cites]
Bioorg Med Chem. 2000 Jul;8(7):1697-706
[
10976516.001
]
[Cites]
Eur J Cancer. 2001 Mar;37(5):597-604
[
11290435.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):675-9
[
12062611.001
]
[Cites]
Lancet Oncol. 2002 Jul;3(7):415-24
[
12142171.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):403-8
[
12243814.001
]
[Cites]
Clin Ther. 2004 Apr;26(4):579-89
[
15189755.001
]
[Cites]
N Engl J Med. 2004 Oct 21;351(17):1731-40
[
15496622.001
]
[Cites]
J Clin Oncol. 1997 Jan;15(1):110-5
[
8996131.001
]
[Cites]
N Engl J Med. 1997 Apr 3;336(14):980-7
[
9091798.001
]
[Cites]
Dis Colon Rectum. 1997 Feb;40(2):131-9
[
9075745.001
]
[Cites]
Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-8-S18-18
[
9420016.001
]
[Cites]
J Clin Oncol. 1998 Jan;16(1):301-8
[
9440757.001
]
[Cites]
Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51
[
9593234.001
]
[Cites]
Biochem Pharmacol. 1998 Apr 1;55(7):1091-7
[
9605432.001
]
[Cites]
Eur J Cancer. 1998 Jul;34(8):1274-81
[
9849491.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47
[
10758303.001
]
(PMID = 17042060.001).
[ISSN]
1332-8166
[Journal-full-title]
Croatian medical journal
[ISO-abbreviation]
Croat. Med. J.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article
[Publication-country]
Croatia
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
[Other-IDs]
NLM/ PMC2080466
22.
Gavioli M, Luppi G, Losi L, Bertolini F, Santantonio M, Falchi AM, D'Amico R, Conte PF, Natalini G:
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer.
Dis Colon Rectum
; 2005 Oct;48(10):1851-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We evaluated ypTNM
stage
and tumoral regression, according to the five degrees proposed by Dworak, with special attention to 4 and 3 (sterilized and minimal residual disease).
[MeSH-major]
Adenocarcinoma
/ therapy. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local. Neoplasm, Residual / epidemiology. Rectal Neoplasms / therapy
Genetic Alliance.
consumer health - Rectal Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16132481.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
23.
Selvindos PB, Ho YH:
Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
Dis Colon Rectum
; 2008 Nov;51(11):1710-1
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Patients with
adenocarcinoma
underwent preoperative endorectal ultrasound to individualize for neoadjuvant chemoradiotherapy, based on local extent and lymph nodes seen.
Ten patients (18 percent) had an American Society of Anesthesiologists' classification
of III
.
The indications were
adenocarcinoma
(n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
The histologic grading or the
adenocarcinoma
patients were:
Stage
I, n = 14;
Stage
II, n = 23;
Stage III
, n = 11;
Stage
IV, n = 3.
Of those who underwent curative resection (Stages I-
III
), the distal resection margin was 2.9 +/- 0.7 cm (mean +/- standard error) and the radial resection margins were at least 2 mm in all patients.
At a median follow-up of 14 (2-33) months, none of the
adenocarcinoma
patients who had undergone curative resection had recurrences.
Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced
stage of
cancer (P = 0.047).
[MeSH-major]
Adenocarcinoma
/ surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18679748.001).
[ISSN]
1530-0358
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Interactive Tutorial
[Publication-country]
United States
24.
Sinicrope FA, Rego RL, Foster N, Sargent DJ, Windschitl HE, Burgart LJ, Witzig TE, Thibodeau SN:
Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers.
Am J Gastroenterol
; 2006 Dec;101(12):2818-25
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human
colon
cancers.
OBJECTIVE:
Colon
cancers with high frequency microsatellite instability (MSI-H) are preferentially located in the proximal
colon
.
Given that 15-20% of sporadic
colon
cancers are MSI-H, we determined whether tumor site-specific differences in clinicopathological variables, biomarkers, and prognosis are due to inclusion of MSI-H cases.
METHODS: TNM
stage
II and
III
primary
colon
carcinomas (N = 528) from patients enrolled in 5-fluorouracil-based adjuvant trials were analyzed for MSI using 11 microsatellite markers.
RESULTS: MSI-H was found in 95 (18%)
colon
cancers.
CONCLUSIONS: Tumor site-related differences in clinicopathological variables, biomarkers, and prognosis of sporadic
colon
cancers can be explained by the inclusion of MSI-H cases.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17026563.001).
[ISSN]
0002-9270
[Journal-full-title]
The American journal of gastroenterology
[ISO-abbreviation]
Am. J. Gastroenterol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U01 CA074800; United States / NCI NIH HHS / CA / CA 104683
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
25.
Mori T, Hirota T, Ohashi Y, Kodaira S, Prospective Trial of Adjuvant Chemotherapy for Colon Cancer Study Group (PAC):
Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
Dis Colon Rectum
; 2006 Jul;49(7):982-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in
stage III colon
cancer.
PURPOSE: This study was designed to investigate whether the histologic types of the primary lesion and of metastatic lymph nodes in
Stage III colon
cancer are useful as prognostic factors.
METHODS:
Stage III colon
cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated
adenocarcinoma
; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated.
CONCLUSIONS: In
Stage III colon
cancer, the prognosis of cases whose primary lesion and lymph node tissues are both well differentiated is extremely good.
[MeSH-major]
Adenocarcinoma
/ pathology. Colonic Neoplasms / pathology
Genetic Alliance.
consumer health - Metastatic cancer
.
Hazardous Substances Data Bank.
MITOMYCIN C
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16625329.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Randomized Controlled Trial
[Publication-country]
United States
[Chemical-registry-number]
0 / Alkylating Agents; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
26.
Mammen JM, James LE, Molloy M, Williams A, Wray CJ, Sussman JJ:
The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry.
Am J Surg
; 2007 Sep;194(3):349-54
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The relationship of lymph node dissection and
colon
cancer survival in the Veterans Affairs Central Cancer Registry.
BACKGROUND: The extent of lymphadenectomy in
colon
cancer may impact potential to cure and accuracy of staging.
METHODS: The Veterans Affairs Central Cancer Registry database was queried for TNM
stage
I-
III colon adenocarcinoma
patients and yielded 5,823 individuals.
RESULTS: The overall survival (OS) in
stage
II patients was greater with the higher number of lymph node (LN) examined.
For
stage
II patients, the 5-year OS was 34%, 43%, 47%, and 55% for the lowest to highest quartiles (P = .007).
For
stage III
patients, the 5-year OS was 31%, 27%, 38%, and 53% for the lowest to highest quartiles (not significant overall).
CONCLUSIONS: More extensive lymphadenectomy is associated with improved OS in
stage
II
colon
cancer patients.
[MeSH-major]
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ surgery. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Lymph Node Excision
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17693281.001).
[ISSN]
1879-1883
[Journal-full-title]
American journal of surgery
[ISO-abbreviation]
Am. J. Surg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
27.
Gibson TB, Ranganathan A, Grothey A:
Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.
Clin Colorectal Cancer
; 2006 May;6(1):29-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Randomized phase
III
trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.
The results of a phase
III
trial which compared panitumumab as a single agent to best supportive care in patients with previously treated metastatic CRC have recently been reported Pantitumumab therapy resulted in a 46% reduction in the risk of tumor progression and a partial response rate of 8%.
Further clinical studies re ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-
stage
CRC and adjuvant treatment
of colon
cancer.
[MeSH-major]
Adenocarcinoma
/ drug therapy.
Adenocarcinoma
/ secondary. Antibodies, Monoclonal / therapeutic use. Colorectal Neoplasms / pathology
Genetic Alliance.
consumer health - Colorectal Cancer
.
Genetic Alliance.
consumer health - Metastatic cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Clin Colorectal Cancer. 2006 May;6(1):13
[
16796785.001
]
(PMID = 16796788.001).
[ISSN]
1533-0028
[Journal-full-title]
Clinical colorectal cancer
[ISO-abbreviation]
Clin Colorectal Cancer
[Language]
eng
[Publication-type]
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / panitumumab
28.
Niedzielska I, Niedzielski Z, Tkacz M, Orawczyk T, Ziaja K, Starzewski J, Mazurek U, Markowski J:
Toll-like receptors and the tendency of normal mucous membrane to transform to polyp or colorectal cancer.
J Physiol Pharmacol
; 2009 May;60 Suppl 1:65-71
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Sixteen HG-U133A oligonucleotide microarrays were analysed including four of colonic polyps, four
of adenocarcinoma
with different degree of histological differentiation (2 poorly and 2 highly differentiated), and eight of macroscopically normal tissue.
An analysis of all per cent variability values with regard to malignancy
stage
increasing from polyp to stages I to
III adenocarcinoma
, and normal
colon
mucosa shows a statistically significant relationship for TLR2 (increasing) and TLR3 (decreasing).
In normal
colon
mucosa of polyposis patients the highest mRNA copy numbers were observed for TLR3, and the lowest for TLR7.
TLR3 may serve as a marker
of colon
tissue metaplasia and may indicate the tendency of normal tissue to form polyps transforming to colorectal cancer.
[MeSH-major]
Adenocarcinoma
/ metabolism. Colonic Polyps / metabolism. Colorectal Neoplasms / metabolism. Mucous Membrane / metabolism. Toll-Like Receptors / biosynthesis
[MeSH-minor]
Adult. Aged.
Colon
/ metabolism.
Colon
/ pathology. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / biosynthesis
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colonic Polyps
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19609015.001).
[ISSN]
1899-1505
[Journal-full-title]
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
[ISO-abbreviation]
J. Physiol. Pharmacol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Poland
[Chemical-registry-number]
0 / RNA, Messenger; 0 / Toll-Like Receptors
29.
Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, Toyoda S, Chen L, Hazra A, Giovannucci EL, Fuchs CS, Ogino S:
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Mod Pathol
; 2009 Jul;22(7):922-32
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The class
III
histone deacetylase SIRT1 (sir2) is important in epigenetic gene silencing.
SIRT1 was not significantly related with age, sex, tumor location,
stage
, signet ring cells, cyclooxygenase-2 (COX-2), LINE-1 hypomethylation, KRAS, BRAF, BMI, PIK3CA, HDAC, p53, beta-catenin, COX-2, or patient prognosis.
In conclusion, SIRT1 expression is associated with CIMP-high MSI-high
colon
cancer, suggesting involvement of SIRT1 in gene silencing in this unique tumor subtype.
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
PLoS One. 2008;3(4):e2020
[
18414679.001
]
[Cites]
Int J Cancer. 2008 Jun 15;122(12):2767-73
[
18366060.001
]
[Cites]
Neoplasia. 2008 Jun;10(6):534-41
[
18516290.001
]
[Cites]
Cancer Lett. 2008 Sep 18;268(2):177-86
[
18471961.001
]
[Cites]
PLoS One. 2008;3(11):e3698
[
19002263.001
]
[Cites]
Mod Pathol. 2008 Dec;21(12):1533-41
[
18849918.001
]
[Cites]
J Natl Cancer Inst. 2008 Dec 3;100(23):1734-8
[
19033568.001
]
[Cites]
J Clin Oncol. 2008 Dec 10;26(35):5713-20
[
18955444.001
]
[Cites]
Mod Pathol. 2008 Nov;21(11):1403-12
[
18587323.001
]
[Cites]
Gut. 2009 Jan;58(1):90-6
[
18832519.001
]
[Cites]
Mod Pathol. 2009 Jan;22(1):151-60
[
19011600.001
]
[Cites]
Science. 2004 Jul 16;305(5682):390-2
[
15205477.001
]
[Cites]
Stat Med. 1989 May;8(5):551-61
[
2657958.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6
[
10411935.001
]
[Cites]
Science. 2004 Dec 17;306(5704):2105-8
[
15604409.001
]
[Cites]
Cell. 2005 Feb 25;120(4):473-82
[
15734680.001
]
[Cites]
Nat Rev Cancer. 2005 May;5(5):388-96
[
15864280.001
]
[Cites]
J Mol Diagn. 2005 Aug;7(3):413-21
[
16049314.001
]
[Cites]
Gastroenterology. 2005 Sep;129(3):837-45
[
16143123.001
]
[Cites]
Gastroenterology. 2005 Sep;129(3):1121-4
[
16143149.001
]
[Cites]
Cell. 2005 Nov 4;123(3):437-48
[
16269335.001
]
[Cites]
Mod Pathol. 2006 Jan;19(1):59-68
[
16118624.001
]
[Cites]
PLoS Genet. 2006 Mar;2(3):e40
[
16596166.001
]
[Cites]
Nat Genet. 2006 May;38(5):566-9
[
16642021.001
]
[Cites]
J Mol Diagn. 2006 May;8(2):209-17
[
16645207.001
]
[Cites]
PLoS Genet. 2005 Dec;1(6):e77
[
16362078.001
]
[Cites]
Gut. 2006 Jul;55(7):1000-6
[
16407376.001
]
[Cites]
Nat Genet. 2006 Jul;38(7):787-93
[
16804544.001
]
[Cites]
J Mol Diagn. 2006 Nov;8(5):582-8
[
17065427.001
]
[Cites]
Mod Pathol. 2007 Jan;20(1):15-22
[
17086168.001
]
[Cites]
Mod Pathol. 2007 Mar;20(3):375-83
[
17277760.001
]
[Cites]
Nucleic Acids Res. 2000 Apr 15;28(8):E32
[
10734209.001
]
[Cites]
Genes Dev. 2000 May 1;14(9):1021-6
[
10809662.001
]
[Cites]
Nature. 2000 Nov 9;408(6809):255-62
[
11089983.001
]
[Cites]
Cell. 2001 Oct 19;107(2):137-48
[
11672522.001
]
[Cites]
Cell. 2001 Oct 19;107(2):149-59
[
11672523.001
]
[Cites]
EMBO J. 2002 May 15;21(10):2383-96
[
12006491.001
]
[Cites]
Nat Genet. 2002 Nov;32(3):378-83
[
12379856.001
]
[Cites]
Nat Genet. 2002 Nov;32(3):370-7
[
12410229.001
]
[Cites]
Cancer Res. 2002 Nov 1;62(21):6011-4
[
12414620.001
]
[Cites]
Nucleic Acids Res. 2004;32(3):e38
[
14973332.001
]
[Cites]
Cell. 2004 Feb 20;116(4):551-63
[
14980222.001
]
[Cites]
Mod Pathol. 2007 Mar;20(3):331-8
[
17277767.001
]
[Cites]
Nat Rev Genet. 2007 Apr;8(4):286-98
[
17339880.001
]
[Cites]
Biochem J. 2007 May 15;404(1):1-13
[
17447894.001
]
[Cites]
Cancer J. 2007 Jan-Feb;13(1):49-55
[
17464246.001
]
[Cites]
N Engl J Med. 2007 May 24;356(21):2131-42
[
17522398.001
]
[Cites]
J Mol Diagn. 2007 Jul;9(3):305-14
[
17591929.001
]
[Cites]
Neoplasia. 2007 Jul;9(7):569-77
[
17710160.001
]
[Cites]
Gut. 2007 Nov;56(11):1498-500
[
17938428.001
]
[Cites]
Mod Pathol. 2007 Nov;20(11):1183-90
[
17873897.001
]
[Cites]
Nat Rev Genet. 2007 Nov;8(11):829-33
[
17909537.001
]
[Cites]
Nat Rev Genet. 2007 Nov;8(11):835-44
[
17909538.001
]
[Cites]
Biotechnol J. 2007 Nov;2(11):1360-8
[
17806102.001
]
[Cites]
J Mol Diagn. 2008 Jan;10(1):13-27
[
18165277.001
]
[Cites]
Carcinogenesis. 2008 Feb;29(2):434-9
[
18048385.001
]
[Cites]
Epigenetics. 2008 Jan-Feb;3(1):28-37
[
18326939.001
]
[Cites]
Mod Pathol. 2008 May;21 Suppl 2:S23-30
[
18437170.001
]
(PMID = 19430421.001).
[ISSN]
1530-0285
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / K07 CA122826-02; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / CA122826-02; United States / NCI NIH HHS / CA / K07 CA122826; United States / NCI NIH HHS / CA / CA055075-15; United States / NCI NIH HHS / CA / P50 CA127003-02; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / P01 CA55075; United States / NCI NIH HHS / CA / P01 CA087969-09; United States / NCI NIH HHS / CA / P50 CA127003; United States / NCI NIH HHS / CA / P01 CA055075-15
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA, Neoplasm; EC 2.3.1.85 / Fatty Acid Synthases; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
[Other-IDs]
NLM/ NIHMS100427; NLM/ PMC2704253
30.
Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K:
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression.
Mol Cancer
; 2006;5:62
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: The involvement of the cyclooxygenases (COX), in particular COX-2, is well documented for many tumours, e.g.
colon
, breast and prostate cancer, by both experimental and clinical studies.
The increase of COX-2 was also correlated to
stage
(FIGO classification) with significant elevations in stages II and
III
.
EP1 was increased in
stage III
while no significant alterations were demonstrated for COX-1, mPGES-1 or EP2 for
stage
.
[MeSH-minor]
Adenocarcinoma
/ metabolism.
Adenocarcinoma
/ pathology. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Densitometry. Disease Progression. Epithelial Cells / pathology. Female. Humans. Immunoblotting. Immunohistochemistry. Intramolecular Oxidoreductases / metabolism. Neoplasm Staging. Ovary / metabolism. Receptors, Prostaglandin E / metabolism
Genetic Alliance.
consumer health - Ovarian cancer
.
Genetic Alliance.
consumer health - Ovarian epithelial cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73
[
12009392.001
]
[Cites]
J Environ Pathol Toxicol Oncol. 2002;21(2):149-53
[
12086401.001
]
[Cites]
Ann Oncol. 2002 Aug;13(8):1205-11
[
12181243.001
]
[Cites]
J Reprod Immunol. 2002 Oct-Nov;57(1-2):47-60
[
12385833.001
]
[Cites]
Cancer Res. 2003 Mar 1;63(5):906-11
[
12615701.001
]
[Cites]
Cancer. 2003 Oct 1;98(7):1423-9
[
14508829.001
]
[Cites]
Br J Cancer. 2003 Oct 6;89(7):1298-304
[
14520463.001
]
[Cites]
Prog Lipid Res. 2004 Jan;43(1):3-35
[
14636669.001
]
[Cites]
Oncogene. 2003 Nov 27;22(54):8653-61
[
14647459.001
]
[Cites]
Cancer. 2003 Dec 15;98(12):2607-23
[
14669280.001
]
[Cites]
Oncol Rep. 2004 Feb;11(2):309-13
[
14719060.001
]
[Cites]
Clin Cancer Res. 2004 Jan 15;10(2):538-45
[
14760075.001
]
[Cites]
Gynecol Oncol. 2004 Feb;92(2):622-7
[
14766256.001
]
[Cites]
Clin Cancer Res. 2004 Jul 15;10(14):4670-9
[
15269139.001
]
[Cites]
Acta Obstet Gynecol Scand. 2004 Sep;83(9):783-95
[
15315588.001
]
[Cites]
Reproduction. 2004 Nov;128(5):607-14
[
15509706.001
]
[Cites]
Lancet. 1971 Jul 17;2(7716):163
[
4104488.001
]
[Cites]
Gynecol Oncol. 1983 Dec;16(3):340-5
[
6360817.001
]
[Cites]
Gynecol Obstet Invest. 1984;18(5):225-9
[
6396175.001
]
[Cites]
Prostaglandins. 1985 May;29(5):665-72
[
3859890.001
]
[Cites]
Int J Cancer. 1997 Jun 20;74(3):275-80
[
9221804.001
]
[Cites]
J Histochem Cytochem. 1998 Jan;46(1):77-84
[
9405496.001
]
[Cites]
Br J Cancer. 1999 Mar;79(7-8):1240-8
[
10098766.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6
[
10468638.001
]
[Cites]
J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67
[
10469746.001
]
[Cites]
Nature. 2004 Nov 18;432(7015):332-7
[
15549095.001
]
[Cites]
Br J Cancer. 2005 May 23;92(10):1927-33
[
15870720.001
]
[Cites]
Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):103-11
[
15963707.001
]
[Cites]
Oncogene. 2005 Dec 1;24(54):7991-8002
[
16044148.001
]
[Cites]
Nucleic Acids Res. 2006;34(1):217-31
[
16397300.001
]
[Cites]
Int J Cancer. 2006 Apr 15;118(8):1884-91
[
16287068.001
]
[Cites]
Nat Rev Cancer. 2006 Feb;6(2):130-40
[
16491072.001
]
[Cites]
Cancer Res. 2006 Mar 1;66(5):2527-31
[
16510568.001
]
[Cites]
Curr Pharm Des. 2006;12(8):943-54
[
16533161.001
]
[Cites]
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
[
15661684.001
]
[Cites]
Am J Obstet Gynecol. 2005 Mar;192(3):819-25
[
15746677.001
]
[Cites]
Oncol Rep. 2005 Apr;13(4):559-83
[
15756426.001
]
[Cites]
Cancer Res. 2005 Mar 15;65(6):2234-42
[
15781636.001
]
[Cites]
Cancer Res. 2005 May 1;65(9):3735-44
[
15867369.001
]
[Cites]
Clin Cancer Res. 2005 May 1;11(9):3250-6
[
15867220.001
]
[Cites]
J Reprod Fertil. 2000 Mar;118(2):375-85
[
10864803.001
]
[Cites]
Epidemiology. 2000 Mar;11(2):111-7
[
11021606.001
]
[Cites]
Am J Pathol. 2001 Mar;158(3):849-53
[
11238034.001
]
[Cites]
Annu Rev Pharmacol Toxicol. 2001;41:661-90
[
11264472.001
]
[Cites]
Cancer Res. 2001 Mar 1;61(5):2328-34
[
11280806.001
]
[Cites]
Endocr Rev. 2001 Apr;22(2):255-88
[
11294827.001
]
[Cites]
Int J Mol Med. 2001 Jul;8(1):31-6
[
11408945.001
]
[Cites]
Clin Cancer Res. 2001 Aug;7(8):2496-504
[
11489832.001
]
[Cites]
Nat Med. 2001 Sep;7(9):1048-51
[
11533709.001
]
[Cites]
Cancer Res. 2001 Oct 1;61(19):7305-9
[
11585770.001
]
[Cites]
Int J Mol Med. 2001 Dec;8(6):603-6
[
11712072.001
]
[Cites]
Clin Cancer Res. 2002 Jan;8(1):202-9
[
11801560.001
]
[Cites]
Annu Rev Physiol. 2002;64:69-92
[
11826264.001
]
[Cites]
Am J Pathol. 2002 Mar;160(3):893-903
[
11891188.001
]
(PMID = 17107625.001).
[ISSN]
1476-4598
[Journal-full-title]
Molecular cancer
[ISO-abbreviation]
Mol. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Receptors, Prostaglandin E; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
[Other-IDs]
NLM/ PMC1657027
31.
Habr-Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro U Jr, Silva E Sousa AH Jr, Campos FG, Kiss DR, Gama-Rodrigues J:
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
J Gastrointest Surg
; 2005 Jan;9(1):90-9; discussion 99-101
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final
stage
and survival.
The purpose of the present study was to determine the correlation between final
stage
and survival in these patients regardless of initial disease
stage
.
Two hundred sixty patients with distal (0-7 cm from anal verge) rectal
adenocarcinoma
considered resectable were treated by neoadjuvant CRT with 5-FU and leucovorin plus 5040 cGy.
Overall survival and disease-free survival were compared according to Kaplan-Meier curves and log-rank tests according to final
stage
.
Seventy-one patients (28%) showed complete clinical response (clinical
stage
0).
In 22 of these patients (9%), pathologic examination revealed pT0 N0 M0 (
stage
p0), 59 patients (22%) had
stage
I, 68 patients (26%) had
stage
II, and 40 patients (15%) had
stage III
disease.
Overall survival rates were significantly higher in
stage
c0 (P=0.01) compared with
stage
p0.
Disease-free survival rate showed better results in
stage
c0, but the results were not significant.
Five-year overall and disease-free survival rates were 97.7% and 84% (
stage
0); 94% and 74% (
stage
I); 83% and 50% (
stage
II); and 56% and 28% (
stage III
), respectively.
Also,
stage
0 is significantly associated with improved outcome.
[MeSH-major]
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ surgery. Neoadjuvant Therapy. Rectal Neoplasms / mortality. Rectal Neoplasms / surgery
Genetic Alliance.
consumer health - Rectal Cancer
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lancet. 1993 Feb 20;341(8843):457-60
[
8094488.001
]
[Cites]
Br J Surg. 2003 Aug;90(8):999-1003
[
12905555.001
]
[Cites]
J Gastrointest Surg. 2004 Jan;8(1):56-62; discussion 62-3
[
14746836.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027-38
[
10421535.001
]
[Cites]
Eur J Surg Oncol. 2001 Jun;27(4):349-53
[
11417978.001
]
[Cites]
N Engl J Med. 2001 Aug 30;345(9):638-46
[
11547717.001
]
[Cites]
Rev Invest Clin. 2001 Sep-Oct;53(5):388-95
[
11795103.001
]
[Cites]
J Natl Cancer Inst. 1988 Mar 2;80(1):21-9
[
3276900.001
]
[Cites]
Rev Invest Clin. 2001 Jan-Feb;53(1):65-76
[
11332053.001
]
[Cites]
Br J Surg. 2001 Jul;88(7):988-93
[
11442533.001
]
[Cites]
World J Surg. 2001 Aug;25(8):1006-11
[
11571965.001
]
[Cites]
Br J Surg. 1986 Sep;73(9):732-5
[
3756437.001
]
[Cites]
Cancer. 2002 Feb 15;94(4):1121-30
[
11920483.001
]
[Cites]
Lancet. 1986 Jun 28;1(8496):1479-82
[
2425199.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):935-41
[
9869213.001
]
[Cites]
J Clin Oncol. 1995 Jun;13(6):1417-24
[
7751887.001
]
[Cites]
Dis Colon Rectum. 1997 May;40(5):515-22
[
9152176.001
]
[Cites]
Dis Colon Rectum. 2001 Aug;44(8):1123-8
[
11535851.001
]
[Cites]
Dis Colon Rectum. 2000 Dec;43(12):1695-1701; discussion 1701-3
[
11156453.001
]
[Cites]
Radiother Oncol. 1999 May;51(2):153-60
[
10435807.001
]
[Cites]
J Surg Oncol. 2003 Jul;83(3):133-9
[
12827680.001
]
[Cites]
Arch Surg. 2002 Feb;137(2):206-10
[
11822961.001
]
[Cites]
Cancer. 1994 Feb 1;73(3):563-9
[
7507795.001
]
[Cites]
J Am Coll Surg. 2002 Feb;194(2):131-5; discussion 135-6
[
11848629.001
]
[Cites]
Dis Colon Rectum. 2004 Mar;47(3):279-86
[
14991488.001
]
[Cites]
Dis Colon Rectum. 1998 Sep;41(9):1087-96
[
9749491.001
]
[Cites]
J Pathol. 1994 Feb;172(2):183-7
[
7513353.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):21-7
[
9588913.001
]
[Cites]
Dis Colon Rectum. 1997 Feb;40(2):131-9
[
9075745.001
]
(PMID = 15623449.001).
[ISSN]
1091-255X
[Journal-full-title]
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
[ISO-abbreviation]
J. Gastrointest. Surg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
32.
Tsigkou A, Marrelli D, Reis FM, Luisi S, Silva-Filho AL, Roviello F, Triginelli SA, Petraglia F:
Total inhibin is a potential serum marker for epithelial ovarian cancer.
J Clin Endocrinol Metab
; 2007 Jul;92(7):2526-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
1) epithelial ovarian cancer,
stage
II-
III
(n = 89);.
3) breast (n = 10),
colon
(n = 10), and stomach (n = 10) cancers; and 4) controls (n = 95).
In four cases of women with
stage
IIC mucinous tumor, blood specimens were collected during the follow-up time.
[MeSH-major]
Adenocarcinoma
, Mucinous / blood.
Adenocarcinoma
, Mucinous / diagnosis. Biomarkers, Tumor / blood. Immunoenzyme Techniques / methods. Inhibins / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis
[MeSH-minor]
Adenocarcinoma
/ blood.
Adenocarcinoma
/ diagnosis. Aged. Aged, 80 and over. CA-125 Antigen / blood. Cross-Sectional Studies. Epithelium / pathology. Female. Humans. Middle Aged. ROC Curve
Genetic Alliance.
consumer health - Ovarian cancer
.
Genetic Alliance.
consumer health - Ovarian epithelial cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17473066.001).
[ISSN]
0021-972X
[Journal-full-title]
The Journal of clinical endocrinology and metabolism
[ISO-abbreviation]
J. Clin. Endocrinol. Metab.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 57285-09-3 / Inhibins
33.
Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA:
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.
Br J Cancer
; 2010 Jan 5;102(1):165-72
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic effect of activated EGFR expression in human
colon
carcinomas: comparison with EGFR status.
BACKGROUND: Evidence suggests that epidermal growth factor receptor (EGFR)-activation status may better predict the clinical behaviour
of colon
cancers than does EGFR expression.
However, the prognostic effect of phospho-EGFR in primary
colon
cancer remains undefined.
METHODS: Phospho-EGFR (Tyr-1173) and EGFR expression were analysed by immunohistochemistry (IHC) in tissue microarrays of TNM
stage
II and
III colon
cancers from completed adjuvant therapy trials (n=388).
Although phospho-EGFR was unrelated to clinicopathological variables, strong EGFR intensity was associated with higher tumour
stage
(P=0.03).
Stage
and lymph node number were prognostic for DFS and OS, and histological grade for OS.
EGFR was an independent predictor of DFS (P=0.042) after adjustment for
stage
, histological grade, age, and MMR status.
COS Scholar Universe.
author profiles
.
PhosphoSitePlus.
gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2004 May 1;22(9):1572-82
[
15117979.001
]
[Cites]
Mol Cell Biol. 2003 Nov;23(21):7875-86
[
14560030.001
]
[Cites]
N Engl J Med. 2004 May 20;350(21):2129-39
[
15118073.001
]
[Cites]
Science. 2004 Jun 4;304(5676):1497-500
[
15118125.001
]
[Cites]
Clin Cancer Res. 2004 Oct 1;10(19):6487-501
[
15475436.001
]
[Cites]
Science. 1993 May 7;260(5109):816-9
[
8484122.001
]
[Cites]
Cancer Res. 1993 Dec 15;53(24):5849-52
[
8261392.001
]
[Cites]
J Biol Chem. 1994 Jul 15;269(28):18674-8
[
8034616.001
]
[Cites]
Eur J Surg Oncol. 1995 Jun;21(3):269-75
[
7781795.001
]
[Cites]
Biochemistry. 1995 Dec 19;34(50):16456-66
[
8845374.001
]
[Cites]
Gastroenterology. 1996 Mar;110(3):669-74
[
8608874.001
]
[Cites]
Cancer Res. 1998 Apr 15;58(8):1713-8
[
9563488.001
]
[Cites]
Clin Cancer Res. 1995 Jan;1(1):19-31
[
9815883.001
]
[Cites]
Cancer Res. 1998 Nov 15;58(22):5248-57
[
9823339.001
]
[Cites]
J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303
[
10433618.001
]
[Cites]
J Biol Chem. 1999 Sep 10;274(37):26091-7
[
10473558.001
]
[Cites]
Ann Oncol. 2005 Jan;16(1):102-8
[
15598946.001
]
[Cites]
J Clin Oncol. 2005 Mar 20;23(9):1803-10
[
15677699.001
]
[Cites]
Int J Oncol. 2005 Aug;27(2):317-25
[
16010411.001
]
[Cites]
Mod Pathol. 2005 Oct;18(10):1350-6
[
15832190.001
]
[Cites]
Semin Oncol. 2005 Dec;32(6 Suppl 9):S59-62
[
16399434.001
]
[Cites]
J Clin Oncol. 2006 Mar 1;24(7):1169-77
[
16505437.001
]
[Cites]
Cancer Res. 2006 Mar 1;66(5):2834-43
[
16510606.001
]
[Cites]
Clin Cancer Res. 2006 May 1;12(9):2738-44
[
16675565.001
]
[Cites]
Clin Colorectal Cancer. 2006 Jul;6(2):133-9
[
16945169.001
]
[Cites]
Gastroenterology. 2006 Sep;131(3):729-37
[
16952542.001
]
[Cites]
Br J Cancer. 2006 Dec 4;95(11):1525-8
[
17088913.001
]
[Cites]
Int J Cancer. 2007 Mar 15;120(6):1232-8
[
17187355.001
]
[Cites]
Lung Cancer. 2007 Mar;55(3):349-55
[
17161498.001
]
[Cites]
J Clin Oncol. 2007 May 1;25(13):1658-64
[
17470858.001
]
[Cites]
J Clin Oncol. 2007 Jun 1;25(16):2184-90
[
17538163.001
]
[Cites]
Clin Cancer Res. 2007 Jun 15;13(12):3597-604
[
17575224.001
]
[Cites]
J Clin Oncol. 2007 Oct 1;25(28):4405-13
[
17906204.001
]
[Cites]
Ann Oncol. 2008 Dec;19(12):2033-8
[
18632722.001
]
[Cites]
Pathology. 2009;41(4):356-60
[
19404848.001
]
[Cites]
Curr Opin Oncol. 2009 Jul;21(4):369-73
[
19444104.001
]
[Cites]
Clin Cancer Res. 2009 Jul 15;15(14):4531-7
[
19584170.001
]
[Cites]
N Engl J Med. 2000 Jan 13;342(2):69-77
[
10631274.001
]
[Cites]
Cancer. 2000 Apr 1;88(7):1739-57
[
10738234.001
]
[Cites]
Cancer Res. 2000 Apr 15;60(8):2225-31
[
10786688.001
]
[Cites]
Int J Cancer. 2000 Oct 1;88(1):77-81
[
10964085.001
]
[Cites]
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
[
11252954.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6
[
11818567.001
]
[Cites]
J Clin Oncol. 2002 Apr 1;20(7):1735-43
[
11919229.001
]
[Cites]
Clin Cancer Res. 2002 Apr;8(4):945-54
[
11948098.001
]
[Cites]
Eur J Cancer. 2002 May;38(8):1065-71
[
12008194.001
]
[Cites]
Eur J Cancer. 2002 Nov;38(17):2258-64
[
12441262.001
]
[Cites]
Eur J Cancer. 2003 Jul;39(10):1348-54
[
12826036.001
]
[Cites]
N Engl J Med. 2003 Jul 17;349(3):247-57
[
12867608.001
]
[Cites]
Virchows Arch. 2003 Aug;443(2):115-21
[
12802583.001
]
[Cites]
Clin Cancer Res. 2004 May 1;10(9):3069-75
[
15131045.001
]
(PMID = 19997103.001).
[ISSN]
1532-1827
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / P30 DK084567; United States / NCI NIH HHS / CA / R01 CA104683; United States / NCI NIH HHS / CA / CA 104683
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / Neoplasm Proteins; 21820-51-9 / Phosphotyrosine; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil
[Other-IDs]
NLM/ PMC2813748
34.
Fang YJ, Lu ZH, Wang F, Wu XJ, Li LR, Zhang LY, Pan ZZ, Wan DS:
Prognostic impact of ERβ and MMP7 expression on overall survival in colon cancer.
Tumour Biol
; 2010 Dec;31(6):651-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic impact of ERβ and MMP7 expression on overall survival in
colon
cancer.
Estrogen receptor beta (ERβ) is the most highly expressed protein in patients with
colon
cancer.
We have previously shown that endocrine therapy can inhibit MMP7 expression in
colon
cancer cells.
In this study, we aim to identify the prognostic effects and correlation of ERβ and MMP7 in the context
of colon
cancer.
ERβ and MMP7 levels were assessed by immunohistochemistry in normal mucosa and tumoral tissues from 423 patients with
stage
I-
III colon
cancer.
In the subset of patients with high expression levels of tumoral nuclear ERβ, high expression of MMP7 was related to OS and CSS among
colon
cancer patients with high expression of ERβ.
In conclusion, our results suggest that low expression of ERβ was a risk factor in
colon
cancer, and high expression of MMP7 was an independent prognostic factor of ERβ-positive patients with
colon
cancer.
[MeSH-major]
Adenocarcinoma
/ metabolism.
Adenocarcinoma
/ mortality. Colonic Neoplasms / metabolism. Colonic Neoplasms / mortality. Estrogen Receptor beta / metabolism. Matrix Metalloproteinase 7 / metabolism
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Surg. 2001 Jun;233(6):786-92
[
11371737.001
]
[Cites]
J Invest Dermatol. 1995 Aug;105(2):190-6
[
7636300.001
]
[Cites]
Eur J Cancer. 2003 Jun;39(9):1251-8
[
12763213.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Dec;82(12):4258-65
[
9398750.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30
[
8650195.001
]
[Cites]
Hum Pathol. 2001 Sep;32(9):940-4
[
11567223.001
]
[Cites]
N Engl J Med. 2004 Mar 4;350(10):991-1004
[
14999111.001
]
[Cites]
Oncol Rep. 2005 Jul;14(1):17-21
[
15944762.001
]
[Cites]
Endocr Relat Cancer. 2004 Sep;11(3):537-51
[
15369453.001
]
[Cites]
J Exp Clin Cancer Res. 2009 Sep 29;28:132
[
19785773.001
]
[Cites]
JAMA. 2002 Jul 17;288(3):321-33
[
12117397.001
]
[Cites]
Endocr Relat Cancer. 2005 Jun;12(2):455-69
[
15947116.001
]
[Cites]
Cancer. 2000 May 15;88(10):2398-424
[
10820364.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
Dig Dis Sci. 2002 Dec;47(12):2720-8
[
12498292.001
]
[Cites]
Cell Oncol. 2009;31(3):235-47
[
19478391.001
]
[Cites]
Cancer Res. 2000 Jan 15;60(2):245-8
[
10667568.001
]
[Cites]
Int J Colorectal Dis. 2009 Aug;24(8):875-84
[
19421758.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2959-64
[
16477031.001
]
[Cites]
J Pathol. 2005 Sep;207(1):53-60
[
15954165.001
]
(PMID = 20680712.001).
[ISSN]
1423-0380
[Journal-full-title]
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
[ISO-abbreviation]
Tumour Biol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Estrogen Receptor beta; EC 3.4.24.23 / Matrix Metalloproteinase 7
35.
Liang JT, Huang KC, Lai HS, Lee PH, Sun CT:
Oncologic results of laparoscopic D3 lymphadenectomy for male sigmoid and upper rectal cancer with clinically positive lymph nodes.
Ann Surg Oncol
; 2007 Jul;14(7):1980-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The study subjects were tumor, node, metastasis system
stage III
rectosigmoid cancer staged by clinical images.
The extent of D3 dissection and the postoperative lymph node mapping were according to the guidelines of the Japanese Society for Cancer of the
Colon
and Rectum.
CONCLUSIONS: The good short-term oncologic results and quick convalescence mean that the laparoscopic D3 dissection may be recommended for patients with
stage III
rectosigmoid cancer who could accept the genitourinary dysfunction.
[MeSH-major]
Adenocarcinoma
/ surgery. Lymph Node Excision / methods. Rectal Neoplasms / surgery. Sigmoid Neoplasms / surgery
Genetic Alliance.
consumer health - Rectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17458586.001).
[ISSN]
1068-9265
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article
[Publication-country]
United States
36.
Asaad SM, Jubelirer SJ, Welch CA:
Prognostic indicators for stage II (Dukes' stage B) adenocarcinoma of the colon.
W V Med J
; 2005 Sep-Oct;101(5):210-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic indicators for
stage
II (Dukes'
stage
B)
adenocarcinoma of
the
colon
.
To determine the prognostic indicators that are associated with lower disease free survival (DFS) and overall survival (OS) in
stage
II
colon
cancer patients, the tumor registry records were reviewed for all patients diagnosed with
stage
II and
III adenocarcinoma
of the
colon
at Charleston Area Medical Center from 1986 to 1994.
The prognostic indicators of 174
stage
II patients who had not undergone treatment were assessed for DFS and OS.
In addition, DFS and OS curves for
stage
II patients with < 7 LNR were not significantly different from survival curves for
stage III
patients.
Treatment decisions are made based primarily on
stage
, and
stage
II patients are not routinely offered adjuvant therapy.
[MeSH-major]
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Staging. Survival Analysis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16422269.001).
[ISSN]
0043-3284
[Journal-full-title]
The West Virginia medical journal
[ISO-abbreviation]
W V Med J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
37.
Carson HJ, Krivit JS, Eilers SG:
Metastasis of colonic adenocarcinoma to the external ear canal: an unusual case with a complex-pattern of disease progression.
Ear Nose Throat J
; 2005 Jan;84(1):36-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Metastasis of colonic
adenocarcinoma
to the external ear canal: an unusual case with a complex-pattern of disease progression.
We report on a patient who developed far-ranging metastases
of adenocarcinoma
of the
colon
that followed a gradual cephalad progression, including the right external ear canal, and led to hearing loss.
The patient was a 63-year-old white male with
stage III adenocarcinoma of
the
colon
.
Physical examination of the head and neck showed a mass in the external ear canal, and biopsy confirmed
adenocarcinoma
.
The significance of such wide-ranging metastases is that metastasis
of adenocarcinoma
to the ear did not signal imminent death, and relief of the hearing loss it caused was possible.
[MeSH-major]
Adenocarcinoma
/ secondary. Colonic Neoplasms / pathology. Ear Canal. Ear Neoplasms / secondary
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15742771.001).
[ISSN]
0145-5613
[Journal-full-title]
Ear, nose, & throat journal
[ISO-abbreviation]
Ear Nose Throat J
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
38.
Wick MR, Vitsky JL, Ritter JH, Swanson PE, Mills SE:
Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma.
Am J Clin Pathol
; 2005 Jan;123(1):56-65
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Sporadic medullary carcinoma of the
colon
: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type
adenocarcinoma
and neuroendocrine colorectal carcinoma.
We studied 68 sporadic colorectal carcinomas (CRCs) with medullary features (MCRCs) and compared them with 35 poorly differentiated purely "enteric" CRCs (ECRCs) and 15 purely neuroendocrine carcinomas (NECs) of grades II and
III
, all in patients lacking a family history of CRC.
MCRCs were significantly more common in the ascending
colon
than were ECRCs, but there was no significant dissimilarity to NECs.
Despite an infiltrative growth pattern, MCRC was less likely than ECRC to manifest with
stage III
or IV disease, but there was no
stage
-related difference from NECs.
[MeSH-major]
Adenocarcinoma
/ pathology. Carcinoma, Medullary / pathology. Carcinoma, Neuroendocrine / pathology. Colorectal Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15762280.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
39.
Billingsley KG, Morris AM, Dominitz JA, Matthews B, Dobie S, Barlow W, Wright GE, Baldwin LM:
Surgeon and hospital characteristics as predictors of major adverse outcomes following colon cancer surgery: understanding the volume-outcome relationship.
Arch Surg
; 2007 Jan;142(1):23-31; discussion 32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Surgeon and hospital characteristics as predictors of major adverse outcomes following
colon
cancer surgery: understanding the volume-outcome relationship.
PATIENTS: Patients aged 66 years and older, diagnosed and surgically treated for
stage
I, II, or
III colon
cancer between 1992 and 1996 (n = 22 672).
[MeSH-major]
Adenocarcinoma
/ surgery. Colonic Neoplasms / surgery. Digestive System Surgical Procedures / utilization. Hospitals / utilization. Outcome Assessment (Health Care)
MedlinePlus Health Information.
consumer health - Health Facilities
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17224497.001).
[ISSN]
0004-0010
[Journal-full-title]
Archives of surgery (Chicago, Ill. : 1960)
[ISO-abbreviation]
Arch Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
40.
Yano H, Saito Y, Kirihara Y, Takashima J:
Tumor invasion of lymph node capsules in patients with Dukes C colorectal adenocarcinoma.
Dis Colon Rectum
; 2006 Dec;49(12):1867-77
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Tumor invasion of lymph node capsules in patients with Dukes C colorectal
adenocarcinoma
.
METHODS: We analyzed 480 positive lymph nodes from 155 consecutive patients with
Stage III
colorectal cancer to determine the frequency and significance of lymph node capsular invasion.
CONCLUSIONS: Lymph node capsular invasion, determined by routine hematoxylin-eosin staining, is a potent prognostic factor in
Stage III
colorectal cancer.
[MeSH-major]
Adenocarcinoma
/ pathology. Colorectal Neoplasms / pathology. Lymph Nodes / pathology
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Dis Colon Rectum. 2007 Sep;50(9):1484; author reply 1484-5
[
17661142.001
]
(PMID = 17080279.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
41.
Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ:
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
J Clin Oncol
; 2005 Dec 1;23(34):8671-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase
III
study of fluorouracil, leucovorin, and levamisole in high-risk
stage
II and
III colon
cancer: final report of Intergroup 0089.
PURPOSE: In 1990, fluorouracil (FU) plus levamisole for 1 year became standard adjuvant treatment for patients with high-risk stages II and
III colon
cancer.
INT-0089 has long-term follow-up of the largest clinical trial of patients with high-risk
colon
cancer, documenting not only the durability of the treatment effects, but also the natural history of patients with high-risk
colon
cancer, and analyses of treatment based on age, race, and comorbid conditions such as obesity, diabetes, and second primary cancers.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16314627.001).
[ISSN]
0732-183X
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA15488; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA66636
[Publication-type]
Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Adjuvants, Immunologic; 12001-76-2 / Vitamin B Complex; 2880D3468G / Levamisole; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
42.
Chin CC, Wang JY, Yeh CY, Kuo YH, Huang WS, Yeh CH:
Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer.
Int J Colorectal Dis
; 2009 Nov;24(11):1297-302
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in
stage III colon
cancer.
OBJECTIVE: The objective of this study is to assess the value of metastatic lymph node ratio (LNR) in predicting disease-free survival (DFS) in patients with
stage III adenocarcinoma of
the
colon
.
MATERIALS AND METHODS: From 1995 to 2003 inclusively, a total of 624 patients featuring
stage III adenocarcinoma of
the
colon
underwent curative resection.
In T3/4LNR1 patients (n = 411), there was no difference in survival between those with N1
stage
and those with N2
stage
.
Cox proportional hazards regression analysis revealed that N
stage
(number of positive lymph nodes) was not a significant factor when LNR was taken into consideration.
CONCLUSIONS: LNR is a more precise predictor of 5-year DFS than number of positive lymph nodes (N
stage
) in patients with
stage III colon
cancer.
Genetic Alliance.
consumer health - Metastatic cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Clin Oncol. 2004 Jun;27(3):304-6
[
15170153.001
]
[Cites]
J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90
[
12504228.001
]
[Cites]
Ann Surg Oncol. 2002 Jan-Feb;9(1):27-34
[
11829427.001
]
[Cites]
Eur J Cancer. 2005 Jan;41(2):272-9
[
15661553.001
]
[Cites]
J Natl Cancer Inst. 2007 Mar 21;99(6):433-41
[
17374833.001
]
[Cites]
Ann Surg. 2002 Oct;236(4):416-21; discussion 421
[
12368669.001
]
[Cites]
Gut. 2006 Nov;55(11):1681
[
17047131.001
]
[Cites]
Ann Surg Oncol. 2007 May;14(5):1712-7
[
17253102.001
]
[Cites]
Eur J Surg Oncol. 2005 Feb;31(1):59-66
[
15642427.001
]
[Cites]
Breast Cancer Res. 2004;6(6):R680-8
[
15535850.001
]
[Cites]
Am J Surg. 2007 Dec;194(6):827-31; discussion 831-2
[
18005779.001
]
[Cites]
Eur J Surg Oncol. 2008 Jul;34(7):771-5
[
18079086.001
]
[Cites]
J Clin Oncol. 2005 Dec 1;23(34):8706-12
[
16314630.001
]
[Cites]
Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71
[
12513963.001
]
[Cites]
Ann Surg Oncol. 2008 Jun;15(6):1600-8
[
18327530.001
]
[Cites]
Ann Surg. 2002 Apr;235(4):458-63
[
11923600.001
]
[Cites]
Am J Surg Pathol. 2002 Feb;26(2):179-89
[
11812939.001
]
[Cites]
Am Surg. 2004 Mar;70(3):235-40; discussion 240
[
15055847.001
]
[Cites]
J Natl Cancer Inst. 2001 Apr 18;93(8):583-96
[
11309435.001
]
[Cites]
Cancer. 1967 Nov;20(11):1976-85
[
6061631.001
]
[Cites]
J Natl Cancer Inst. 2005 Feb 2;97(3):219-25
[
15687365.001
]
(PMID = 19479270.001).
[ISSN]
1432-1262
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
43.
West NP, Morris EJ, Rotimi O, Cairns A, Finan PJ, Quirke P:
Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study.
Lancet Oncol
; 2008 Sep;9(9):857-65
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pathology grading
of colon
cancer surgical resection and its association with survival: a retrospective observational study.
We aimed to assess the quality
of colon
cancer surgery by studying the extent of variation in the plane of surgical resection, the amount of tissue removed, and its association with survival.
METHODS: All resections for primary
colon adenocarcinoma
done at Leeds General Infirmary (Leeds, UK) between Jan 1, 1997, and June 30, 2002, were identified.
However, this association was no longer significant in the multivariate model (HR 0.86 [95% CI 0.56-1.31], p=0.472), but was especially noted in patients with
stage III
cancers (HR 0.45 [95% CI 0.24-0.85], p=0.014; multivariate analysis).
INTERPRETATION: As previously shown in the rectum, we have now shown there is marked variability in the plane of surgery achieved in
colon
cancer.
Improving the plane of dissection might improve survival, especially in patients with
stage III
disease.
If confirmed by clinical trial data, such as from the ongoing National Cancer Research Institute Fluoropyrimidine, Oxaliplatin and Targeted Receptor pre-Operative Therapy for
colon
cancer (FOxTROT) trial of neoadjuvant chemotherapy in advanced resectable
colon
cancer, improvement of the plane of dissection might be a new cost-effective method of decreasing morbidity and mortality in patients with
colon
cancer.
[MeSH-major]
Adenocarcinoma
/ surgery. Colectomy / standards. Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / prevention & control. Quality of Health Care
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Lancet Oncol. 2008 Sep;9(9):815-7
[
18760238.001
]
(PMID = 18667357.001).
[ISSN]
1474-5488
[Journal-full-title]
The Lancet. Oncology
[ISO-abbreviation]
Lancet Oncol.
[Language]
eng
[Grant]
United Kingdom / Cancer Research UK / / 9805; United Kingdom / Department of Health / /
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
44.
Liang Z, Hu WD, Gu ZD, Xiong HC, Chen KN:
[Evaluation of transhiatus esophagectomy for patients with esophageal cancer].
Zhonghua Wei Chang Wai Ke Za Zhi
; 2008 Sep;11(5):451-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RESULTS: These 46 patients included 44 esophageal squamous cell carcinomas,1 esophageal
adenocarcinoma
and 1 esophageal carcinoid.
All the patients were classified according to UICC TNM
stage
classification: 3 cases as
stage
0, 6 cases as
stage
I, 17 cases as
stage
II a, 2 cases as
stage
II b, 16 cases as
stage III
.
Reconstruction with stomach was performed in 42 cases and with
colon
interposition in 4 cases.All the tumors were resected, and there was no perioperative death.
Genetic Alliance.
consumer health - Esophageal Cancer
.
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18803048.001).
[ISSN]
1671-0274
[Journal-full-title]
Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
[ISO-abbreviation]
Zhonghua Wei Chang Wai Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Evaluation Studies; Journal Article
[Publication-country]
China
45.
Phelip JM, Molinié F, Delafosse P, Launoy G, Trétarre B, Bara S, Buémi A, Velten M, Danzon A, Ganry O, Bouvier AM, Grosclaude P, Faivre J:
A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.
Gastroenterol Clin Biol
; 2010 Feb;34(2):144-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A population-based study of adjuvant chemotherapy for
stage
-II and -
III colon
cancers.
BACKGROUND: Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for
stage
-
III colon
cancer, the benefits remain controversial for
stage
-II lesions.
The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with
stage
-II and -
III colon
cancers.
METHODS: The study population comprised 1074 patients with
stage
-II and -
III colon
cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries.
RESULTS: Overall, 20.4% of patients with
stage
II and 61.9% with
stage III
received adjuvant chemotherapy.
Among
stage
-II patients, those receiving chemotherapy decreased from 57.6% in patients aged <or=50 years to 1.1% in those aged >or=85.
The corresponding percentages with
stage III
were 93.6% and 1.4%.
In multivariate analyses, other factors found to be independently and significantly associated with administration of adjuvant chemotherapy for
stage
II were extension of the cancer (
stage
IIA vs.
stage
IIB), clinical presentation (obstruction or perforation vs. uncomplicated cancer) and discussion of the case at a multidisciplinary case-review meeting.
For
stage III
, apart from age, discussion of the case at a multidisciplinary meeting was the only factor independently associated with administration of chemotherapy.
CONCLUSION: Adjuvant chemotherapy for
stage
-
III colon
cancer is used extensively for patients under 75 years of age.
On the other hand, a substantial percentage
of stage
-II
colon
cancer patients receive adjuvant chemotherapy despite its uncertain benefits.
[MeSH-major]
Adenocarcinoma
/ drug therapy.
Adenocarcinoma
/ pathology. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
(PMID = 20079591.001).
[ISSN]
0399-8320
[Journal-full-title]
Gastroentérologie clinique et biologique
[ISO-abbreviation]
Gastroenterol. Clin. Biol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
France
46.
Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, Zampino MG, Franceschetti I, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G:
Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.
Br J Cancer
; 2007 Apr 10;96(7):1118-26
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Independent prognostic value of fascin immunoreactivity in
stage III
-IV colonic
adenocarcinoma
.
In this study, we investigated the expression of fascin in 228 advanced colonic
adenocarcinoma
patients with a long follow-up.
Fascin correlated significantly with sex, tumour grade and
stage
, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases.
[MeSH-major]
Adenocarcinoma
/ metabolism. Carrier Proteins / metabolism. Colonic Neoplasms / metabolism. Microfilament Proteins / metabolism
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 1993 Feb 15;71(4):1368-83
[
8435813.001
]
[Cites]
J Cutan Pathol. 2002 Aug;29(7):430-8
[
12139639.001
]
[Cites]
Am J Pathol. 1996 Feb;148(2):593-600
[
8579121.001
]
[Cites]
In Vivo. 1996 Mar-Apr;10(2):153-60
[
8744794.001
]
[Cites]
J Cell Biol. 1996 Sep;134(5):1271-81
[
8794867.001
]
[Cites]
Hum Pathol. 1996 Nov;27(11):1124-34
[
8912819.001
]
[Cites]
Dis Colon Rectum. 1997 Jan;40(1):15-24
[
9102255.001
]
[Cites]
Mol Biol Cell. 1997 Nov;8(11):2345-63
[
9362073.001
]
[Cites]
Mol Biol Cell. 1998 May;9(5):993-1006
[
9571235.001
]
[Cites]
J Cell Biol. 1998 Oct 5;143(1):121-33
[
9763425.001
]
[Cites]
J Biol Chem. 1999 Feb 26;274(9):5443-53
[
10026156.001
]
[Cites]
CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308
[
15537574.001
]
[Cites]
Ann Surg. 2002 Oct;236(4):416-21; discussion 421
[
12368669.001
]
[Cites]
Am J Pathol. 2003 Jan;162(1):69-80
[
12507891.001
]
[Cites]
J Clin Oncol. 2003 Jan 15;21(2):241-50
[
12525515.001
]
[Cites]
Br J Cancer. 2003 Feb 24;88(4):537-47
[
12592367.001
]
[Cites]
Eur J Cancer. 2003 Apr;39(6):718-27
[
12651195.001
]
[Cites]
Lung Cancer. 2003 Nov;42(2):203-13
[
14568688.001
]
[Cites]
J Clin Oncol. 2004 May 1;22(9):1572-82
[
15117979.001
]
[Cites]
Histopathology. 1986 May;10(5):437-59
[
3721406.001
]
[Cites]
J Cell Biol. 1986 Aug;103(2):631-40
[
3525578.001
]
[Cites]
Cell Struct Funct. 1988 Oct;13(5):373-85
[
3224379.001
]
[Cites]
Oncology. 2004;67(3-4):262-70
[
15557788.001
]
[Cites]
Surg Oncol. 2004 Aug-Nov;13(2-3):93-101
[
15572091.001
]
[Cites]
Clin Cancer Res. 2005 Jan 1;11(1):186-92
[
15671545.001
]
[Cites]
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
[
15761078.001
]
[Cites]
Clin Cancer Res. 2005 Apr 1;11(7):2597-605
[
15814639.001
]
[Cites]
Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804
[
16002322.001
]
[Cites]
Hum Pathol. 2005 Jul;36(7):741-6
[
16084942.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62
[
16185662.001
]
[Cites]
Semin Oncol. 2005 Dec;32(6 Suppl 8):11-4
[
16360006.001
]
[Cites]
Clin Colorectal Cancer. 2006 May;6(1):38-45
[
16796790.001
]
[Cites]
Eur J Cardiothorac Surg. 2006 Sep;30(3):538-42
[
16870459.001
]
[Cites]
J Clin Pathol. 2006 Sep;59(9):958-64
[
16524962.001
]
[Cites]
BMC Cancer. 2006;6:241
[
17029629.001
]
[Cites]
Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6
[
14571738.001
]
[Cites]
J Histochem Cytochem. 2000 Feb;48(2):163-6
[
10639482.001
]
[Cites]
Cancer. 2000 Apr 1;88(7):1739-57
[
10738234.001
]
[Cites]
Br J Cancer. 2000 Oct;83(7):870-3
[
10970687.001
]
[Cites]
Clin Exp Metastasis. 2000;18(1):83-8
[
11206843.001
]
[Cites]
J Cell Biol. 2001 Mar 19;152(6):1169-82
[
11257118.001
]
[Cites]
Nature. 2001 May 17;411(6835):375-9
[
11357145.001
]
[Cites]
Cancer. 2001 Dec 1;92(11):2754-9
[
11753948.001
]
[Cites]
Bioessays. 2002 Apr;24(4):350-61
[
11948621.001
]
[Cites]
Am J Clin Pathol. 2002 Jul;118(1):52-9
[
12109856.001
]
[Cites]
DNA Cell Biol. 1994 Aug;13(8):821-7
[
8068206.001
]
(PMID = 17375048.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
[Other-IDs]
NLM/ PMC2360113
47.
Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD:
Clinical implications of fibroblast activation protein in patients with colon cancer.
Clin Cancer Res
; 2007 Mar 15;13(6):1736-41
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinical implications of fibroblast activation protein in patients with
colon
cancer.
PURPOSE: Human fibroblast activation protein (FAP)/seprase is a 97-kDa surface glycoprotein expressed on tumor associated fibroblasts in the majority of epithelial cancers including
colon
adenocarcinomas.
The primary objective of this study was to evaluate the clinical significance of stromal FAP in human
colon
cancers by immunohistochemisty.
EXPERIMENTAL DESIGN: Sections of paraffin-embedded resected primary human
colon
cancer specimens from 1996 through 2001 within the Fox Chase Cancer Center tumor bank were stained with D8 antibody directed against FAP/seprase.
RESULTS: One hundred thirty-eight patients with resected specimens were available for study (mean follow-up, 1,050 days) with 6 (4%)
stage
I, 52 (38%)
stage
II, 43 (31%)
stage III
, and 37 (27%)
stage
IV patients.
Stromal FAP was found to correlate inversely with tumor
stage
(semiquantitative, P = 0.01; intensity, P = 0.009) and with tumor size of the tumor xenograft model (correlation coefficient, -0.61; P = 0.047), suggesting that stromal FAP may have a greater role in the early development of tumors.
CONCLUSION: Our data indicate that patients whose
colon
tumors have high levels of stromal FAP are more likely to have aggressive disease progression and potential development of metastases or recurrence.
It also suggests that the effects of FAP inhibition should be investigated in earlier-
stage
tumors, given its high levels and potential effect earlier in the course of the disease.
[MeSH-major]
Adenocarcinoma
/ genetics. Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Serine Endopeptidases / genetics
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17363526.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA006927; United States / NCI NIH HHS / CA / CA09035; United States / NCI NIH HHS / CA / CA090468; United States / NCI NIH HHS / CA / CA103991; United States / PHS HHS / / W81XWH-04-1-0709
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
48.
Chew MH, Yeo SA, Ng ZP, Lim KH, Koh PK, Ng KH, Eu KW:
Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers.
Int J Colorectal Dis
; 2010 Oct;25(10):1221-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
SRC and MA are more likely to have locally advanced lesions (T3/T4; SRC 100%, MA 90%, OA 83%, p = 0.002) and lymph node metastases (SRC 89%, MA 61%, OA 52%, p < 0.0001) and present with an advanced
stage
at diagnosis (
stage III
/IV SRC 94%, MA 67%, OA 56%, p < 0.0001).
[MeSH-major]
Adenocarcinoma
, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / diagnosis. Mucins / analysis
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Surg Oncol. 2000 Oct;75(2):103-7
[
11064389.001
]
[Cites]
Int J Oncol. 2009 Apr;34(4):1109-15
[
19287969.001
]
[Cites]
Dis Colon Rectum. 2005 Jun;48(6):1161-8
[
15868237.001
]
[Cites]
Dis Colon Rectum. 2008 Jan;51(1):50-5
[
18030531.001
]
[Cites]
Clin Cancer Res. 2003 Nov 15;9(15):5660-5
[
14654549.001
]
[Cites]
Gastroenterology. 1999 Jun;116(6):1453-6
[
10348829.001
]
[Cites]
Dis Colon Rectum. 2004 Jan;47(1):78-85
[
14719155.001
]
[Cites]
Int J Colorectal Dis. 2004 Mar;19(2):102-7
[
14752674.001
]
[Cites]
Hepatogastroenterology. 2006 Nov-Dec;53(72):845-9
[
17153438.001
]
[Cites]
J Surg Oncol. 2001 Aug;77(4):282-3
[
11473380.001
]
[Cites]
Gastroenterol Hepatol. 2002 Nov;25(9):534-40
[
12435303.001
]
[Cites]
Oncology. 1994 Jan-Feb;51(1):30-4
[
8265100.001
]
[Cites]
Dis Colon Rectum. 2006 Sep;49(9):1275-83
[
16912910.001
]
[Cites]
Dis Colon Rectum. 1999 Sep;42(9):1176-80
[
10496558.001
]
[Cites]
Am J Surg. 2007 Sep;194(3):294-8
[
17693269.001
]
[Cites]
AMA Arch Surg. 1951 Jan;62(1):79-91
[
14789350.001
]
[Cites]
J Surg Oncol. 2000 Feb;73(2):70-4
[
10694641.001
]
[Cites]
Chin Med J (Engl). 2009 Jul 5;122(13):1486-91
[
19719934.001
]
[Cites]
Cancer Lett. 1996 Jun 5;103(2):163-70
[
8635153.001
]
[Cites]
Dis Colon Rectum. 1993 Jan;36(1):49-54
[
8380140.001
]
[Cites]
J Pathol. 2007 Jul;212(3):278-86
[
17471475.001
]
[Cites]
Tech Coloproctol. 2004 Nov;8 Suppl 1:s123-5
[
15655594.001
]
[Cites]
Med Arh. 2007;61(1):26-9
[
17582971.001
]
[Cites]
J Gastroenterol Hepatol. 1996 Jan;11(1):77-81
[
8672747.001
]
[Cites]
Dis Colon Rectum. 1999 Dec;42(12):1618-25
[
10613484.001
]
[Cites]
Dis Colon Rectum. 2003 Feb;46(2):160-7
[
12576888.001
]
[Cites]
ANZ J Surg. 2001 Dec;71(12):703-6
[
11906382.001
]
(PMID = 20686777.001).
[ISSN]
1432-1262
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Mucins
49.
Liebig C, Ayala G, Wilks J, Verstovsek G, Liu H, Agarwal N, Berger DH, Albo D:
Perineural invasion is an independent predictor of outcome in colorectal cancer.
J Clin Oncol
; 2009 Nov 1;27(31):5131-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In a subset analysis comparing patients with node-negative disease with patients with
stage III
disease, the 5-year disease-free survival rate was 56% for
stage III
patients versus 29% for patients with node-negative, PNI-positive tumors (P = .0002).
[MeSH-major]
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ pathology. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Peripheral Nerves / pathology
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Laryngoscope. 1986 Oct;96(10):1145-8
[
3762289.001
]
[Cites]
Head Neck Surg. 1986 Jul-Aug;8(6):401-8
[
3721882.001
]
[Cites]
Dis Colon Rectum. 1991 Sep;34(9):798-804
[
1914747.001
]
[Cites]
Br J Cancer. 1992 Jan;65(1):102-7
[
1733432.001
]
[Cites]
Am J Surg Pathol. 1993 Apr;17(4):336-41
[
8494103.001
]
[Cites]
Br J Surg. 1996 Jan;83(1):46-50
[
8653361.001
]
[Cites]
Pancreas. 1996 May;12(4):357-61
[
8740402.001
]
[Cites]
Cancer. 1996 Sep 15;78(6):1267-71
[
8826950.001
]
[Cites]
Dis Colon Rectum. 1997 Mar;40(3):326-31
[
9118749.001
]
[Cites]
J Surg Oncol. 1997 Jul;65(3):164-70
[
9236924.001
]
[Cites]
Mol Cell Endocrinol. 1997 Oct 31;134(1):15-22
[
9406845.001
]
[Cites]
Oncol Rep. 1998 Jan-Feb;5(1):73-6
[
9458297.001
]
[Cites]
Arch Otolaryngol Head Neck Surg. 1998 Jun;124(6):637-40
[
9639472.001
]
[Cites]
Am J Surg. 1999 May;177(5):392-5
[
10365877.001
]
[Cites]
Clin Exp Metastasis. 2004;21(4):285-92
[
15554384.001
]
[Cites]
Arch Pathol Lab Med. 2005 Mar;129(3):354-9
[
15737030.001
]
[Cites]
Cell Death Differ. 2005 Aug;12(8):1044-56
[
16015381.001
]
[Cites]
Cancer. 2007 Jan 1;109(1):13-24
[
17123267.001
]
[Cites]
Am J Clin Oncol. 2007 Feb;30(1):93-6
[
17278901.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
Dis Colon Rectum. 2008 May;51(5):503-7
[
18322753.001
]
[Cites]
Colorectal Dis. 2008 Nov;10(9):879-86
[
19037929.001
]
[Cites]
Acta Chir Iugosl. 2008;55(3):39-44
[
19069691.001
]
[Cites]
Cancer. 2009 Aug 1;115(15):3379-91
[
19484787.001
]
[Cites]
Scand J Urol Nephrol Suppl. 2005 May;(216):34-63
[
16019758.001
]
[Cites]
Cancer. 1988 Mar 1;61(5):1018-23
[
3338045.001
]
[Cites]
Ann Otol Rhinol Laryngol. 1985 Jul-Aug;94(4 Pt 1):426-7
[
4026129.001
]
[Cites]
Dig Dis. 1999;17(2):67-79
[
10545712.001
]
[Cites]
Urology. 1999 Dec;54(6):1039-43
[
10604705.001
]
[Cites]
J Urol. 2001 Jan;165(1):114-8
[
11125378.001
]
[Cites]
Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G958-67
[
11292605.001
]
[Cites]
Eur Urol. 2001 Sep;40(3):308-12
[
11684847.001
]
[Cites]
Dis Colon Rectum. 2001 Nov;44(11):1682-8
[
11711742.001
]
[Cites]
Prostate. 2001 Nov 1;49(3):213-23
[
11746267.001
]
[Cites]
Digestion. 2002;66(2):79-88
[
12428066.001
]
[Cites]
Urology. 2003 Apr;61(4):870-5
[
12670591.001
]
[Cites]
Pancreas. 2003 May;26(4):322-5
[
12717262.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24
[
14697416.001
]
[Cites]
Jpn J Clin Oncol. 2004 Jun;34(6):323-8
[
15333684.001
]
[Cites]
Cancer Res. 2004 Sep 1;64(17):6082-90
[
15342391.001
]
[Cites]
Anat Rec A Discov Mol Cell Evol Biol. 2004 Sep;280(1):821-6
[
15382019.001
]
[CommentIn]
Z Gastroenterol. 2010 Dec;48(12):1405-6
[
21125515.001
]
[CommentIn]
J Clin Oncol. 2010 Jul 20;28(21):e358-60; author reply e361-2
[
20385977.001
]
(PMID = 19738119.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
[Other-IDs]
NLM/ PMC2773472
50.
Viehl CT, Ochsner A, von Holzen U, Cecini R, Langer I, Guller U, Laffer U, Oertli D, Zuber M:
Inadequate quality of surveillance after curative surgery for colon cancer.
Ann Surg Oncol
; 2010 Oct;17(10):2663-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Inadequate quality of surveillance after curative surgery for
colon
cancer.
BACKGROUND:
Colon
cancer patients are at risk for recurrence.
The objective of this study is to analyze the quality of surveillance after curative surgery for
colon
cancer among a cohort of Swiss patients.
PATIENTS AND METHODS: After curative surgery, 129
stage
I-
III colon
cancer patients were followed by chart review, questionnaires, and phone interviews.
CONCLUSIONS: The quality of surveillance after curative surgery for
colon
cancer among a cohort of Swiss patients is inadequate.
[MeSH-major]
Adenocarcinoma
/ surgery. Colonic Neoplasms / surgery. Continuity of Patient Care
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20429036.001).
[ISSN]
1534-4681
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
United States
[Chemical-registry-number]
0 / Carcinoembryonic Antigen
51.
Hohenberger W, Merkel S, Weber K:
[Lymphadenectomy with tumors of the lower gastrointestinal tract].
Chirurg
; 2007 Mar;78(3):217-25
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Transliterated title]
Lymphadenektomie bei Tumoren
des
unteren Gastrointestinaltraktes.
Following these rules and with no adjuvant systemic treatment, 5-year survival figures of 80% can be reached, even for UICC
stage III
disease.
[MeSH-minor]
Adenocarcinoma
/ pathology.
Adenocarcinoma
/ surgery. Anus Neoplasms / pathology. Anus Neoplasms / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / surgery. Humans. Intestines / pathology. Intestines / surgery. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Lymphoma / pathology. Lymphoma / surgery. Neoplasm Staging. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Prognosis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Surg. 2000 Jan;231(1):51-8
[
10636102.001
]
[Cites]
Jpn J Surg. 1983 Nov;13(6):557-73
[
6672390.001
]
[Cites]
Fortschr Med. 1986 Feb 27;104(8):167-70
[
3957212.001
]
[Cites]
Cancer. 2004 Aug 1;101(3):518-26
[
15274064.001
]
[Cites]
Chirurg. 2003 Oct;74(10):897-904
[
14605731.001
]
[Cites]
World J Surg. 2006 Mar;30(3):391-8; discussion 399
[
16479330.001
]
[Cites]
Cancer Causes Control. 2005 Sep;16(7):781-7
[
16132788.001
]
[Cites]
Langenbecks Arch Surg. 1998 Dec;383(6):402-8
[
9921939.001
]
[Cites]
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
[
16514137.001
]
[Cites]
Gut. 2005 Jun;54 Suppl 4:iv1-16
[
15888809.001
]
[Cites]
Br J Surg. 2003 Dec;90(12):1580-5
[
14648739.001
]
[Cites]
J Am Coll Surg. 1997 Jun;184(6):584-8
[
9179114.001
]
[Cites]
J Clin Oncol. 2003 Aug 1;21(15):2912-9
[
12885809.001
]
[Cites]
World J Surg. 1996 Feb;20(2):132-41
[
8661808.001
]
[Cites]
Chirurg. 2004 Aug;75(8):761-6
[
15232693.001
]
[Cites]
Am J Surg. 1997 Mar;173(3):237-9
[
9124635.001
]
[Cites]
J Clin Oncol. 2001 Sep 15;19(18):3861-73
[
11559724.001
]
[Cites]
Am J Surg. 2006 Mar;191(3):305-10
[
16490536.001
]
[Cites]
Cancer. 2001 Jul 1;92(1):77-84
[
11443612.001
]
[Cites]
Z Gastroenterol. 2004 Sep;42(9):1067-72
[
15455287.001
]
[Cites]
Surgery. 1998 Oct;124(4):612-7; discussion 617-8
[
9780979.001
]
[Cites]
Cancer. 2003 Feb 15;97(4):934-59
[
12569593.001
]
[Cites]
Am J Gastroenterol. 2005 Jan;100(1):162-8
[
15654796.001
]
[Cites]
Chirurg. 2007 Aug;78(8):739-47
[
17569018.001
]
[Cites]
Cancer. 1999 Dec 15;86(12):2693-706
[
10594865.001
]
[Cites]
J R Soc Med. 1988 Sep;81(9):503-8
[
3184105.001
]
[Cites]
Surg Endosc. 1989;3(2):96-9
[
2672395.001
]
[Cites]
J Am Coll Surg. 1997 May;184(5):475-80
[
9145067.001
]
[Cites]
Digestion. 1994;55 Suppl 3:11-23
[
7698533.001
]
[Cites]
Dis Colon Rectum. 2002 Nov;45(11):1496-502
[
12432298.001
]
[Cites]
Scand J Surg. 2003;92(1):45-52
[
12705550.001
]
[Cites]
Chirurg. 2006 Jan;77(1):33-40
[
16372188.001
]
[Cites]
J Clin Oncol. 2003 Jul 15;21(14):2740-6
[
12860953.001
]
(PMID = 17333036.001).
[ISSN]
0009-4722
[Journal-full-title]
Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
[ISO-abbreviation]
Chirurg
[Language]
ger
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Germany
52.
Thirunavukarasu P, Sathaiah M, Singla S, Sukumar S, Karunamurthy A, Pragatheeshwar KD, Lee KK, Zeh H 3rd, Kane KM, Bartlett DL:
Medullary carcinoma of the large intestine: a population based analysis.
Int J Oncol
; 2010 Oct;37(4):901-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Medullary carcinoma (MC) of the colorectum is a relatively new histological type
of adenocarcinoma
characterized by poor glandular differentiation and intraepithelial lymphocytic infiltrate.
We observed that MCs were rare tumors, constituting approximately 5-8 cases for every 10,000
colon
cancers diagnosed, with a mean annual incidence of 3.47 (+/-0.75) per 10 million population.
MCs were twice as common in females, who presented at a later age, with a lower
stage
and a trend towards favorable prognosis.
MCs were most common in the proximal
colon
(74%), where they present at a later age than the sigmoid
colon
.
MCs commonly presented with
Stage
II disease, with 10% presenting with metastases.
Although MCs showed a trend towards better early overall survival, undifferentiated MCs present more commonly with
Stage III
, with comparatively worse early outcomes.
[MeSH-major]
Adenocarcinoma
/ epidemiology. Carcinoma, Medullary / epidemiology. Colorectal Neoplasms / epidemiology
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 1999 Aug;17(8):2429-38
[
10561306.001
]
[Cites]
Am J Pathol. 2001 Feb;158(2):527-35
[
11159189.001
]
[Cites]
Am J Pathol. 2001 Dec;159(6):2239-48
[
11733373.001
]
[Cites]
Histopathology. 1977 Jan;1(1):77-84
[
615835.001
]
[Cites]
Am J Pathol. 1994 Jul;145(1):148-56
[
8030745.001
]
[Cites]
J Clin Oncol. 2010 Jan 10;28(2):264-71
[
19949014.001
]
[Cites]
Hum Pathol. 1999 Jul;30(7):843-8
[
10414504.001
]
[Cites]
Am J Clin Pathol. 2005 Jan;123(1):56-65
[
15762280.001
]
[Cites]
Hum Pathol. 2009 Mar;40(3):398-404
[
18992917.001
]
[Cites]
Oncology (Williston Park). 2009 Mar;23(3):288-95
[
19418830.001
]
[Cites]
Am J Pathol. 1997 May;150(5):1815-25
[
9137104.001
]
(PMID = 20811712.001).
[ISSN]
1791-2423
[Journal-full-title]
International journal of oncology
[ISO-abbreviation]
Int. J. Oncol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / T32 CA113263
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Greece
[Chemical-registry-number]
0 / Carcinoembryonic Antigen
[Other-IDs]
NLM/ NIHMS609288; NLM/ PMC4127912
53.
Arkenau HT, Rettig K, Porschen R:
Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
Int J Colorectal Dis
; 2005 May;20(3):258-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adjuvant chemotherapy in curative resected
colon
carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
BACKGROUND: Adjuvant postoperative treatment with 5-fluorouracil (5-FU) and leucovorin in curatively resected
stage III colon
cancer significantly reduces the risk of cancer recurrence and improves survival.
PATIENTS AND METHODS: Patients with a curatively resected UICC
stage III colon
cancer were stratified according to T, N and G category and randomly assigned to receive one of the three adjuvant treatment schemes: 5-FU 450 mg/m2 and leucovorin 100 mg/m2 x 5 days every 4 weeks; six cycles, arm A; 24-h infusion of high-dose 5-FU/leucovorin 2,600 mg/m2 and 500 mg/m2, two cycles of six applications, arm B; 24-h infusion of high-dose 5-FU 2,600 mg/m2, two cycles of six applications, arm C.
CONCLUSION: There is no statistical difference in efficacy and toxicity in patients receiving either high-dose 5-FU with or without leucovorin or the standard 5-FU bolus regime after a curative resection of a
stage III colon
cancer.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Colectomy / methods. Colonic Neoplasms / drug therapy. Fluorouracil / administration & dosage. Leucovorin / administration & dosage
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Minerva Chir. 2003 Aug;58(4):491-502, 502-7
[
14603161.001
]
[Cites]
Ann Oncol. 2003 Mar;14(3):395-9
[
12598344.001
]
[Cites]
Ann Oncol. 1996 Jan;7(1):42-6
[
9081390.001
]
[Cites]
J Clin Oncol. 2001 Mar 15;19(6):1787-94
[
11251010.001
]
[Cites]
Ann Oncol. 2003 Dec;14(12):1735-43
[
14630678.001
]
[Cites]
J Clin Oncol. 2004 Aug 15;22(16):3277-83
[
15249584.001
]
[Cites]
J Clin Oncol. 2003 Aug 1;21(15):2896-903
[
12885807.001
]
[Cites]
J Clin Oncol. 1995 Jun;13(6):1303-11
[
7751875.001
]
[Cites]
Int J Cancer. 1999 Sep 24;83(1):18-29
[
10449602.001
]
[Cites]
Int J Cancer. 1995 Sep 27;63(1):43-8
[
7558450.001
]
[Cites]
J Clin Oncol. 1991 Apr;9(4):625-30
[
2066758.001
]
[Cites]
Chirurg. 1994 Apr;65(4):287-97
[
8020349.001
]
(PMID = 15549327.001).
[ISSN]
0179-1958
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
54.
Georgescu SO, Neacşu CN, Vintilă D, Popa P, Forţu L, Nistor A, Ferariu D, Târcoveanu E:
[Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis].
Rev Med Chir Soc Med Nat Iasi
; 2007 Oct-Dec;111(4):932-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Long-term results after surgery for colorectal
adenocarcinoma
,
stage
I-
III
. Problems of prognosis].
[Transliterated title]
Rezultate la distanţă după tratamentul chirurgical al adenocarcinomului colo-rectal stadiile I-
III
. Probleme
de
prognostic.
STUDY DESIGN: Prospective study on 142 consecutively cases with
stage
I to
III
colorectal adenocarcinomas (TNM AJCC/UICC) in which patients underwent potentially curative surgery in one single public health service (1st Surgical Clinic Iaşi, Romania) between 2004 and 2005.
The surgical procedures performed were the following: right colectomy (n = 54; 30%); transverse colectomy (n = 2; 1.4%); left colectomy (n = 19; 13.4%); segmental
colon
resection with anastomosis (n = 5 ; 3.5%); Hartmann procedure (n = 18; 12.7%); anterior rectal resection (n = 11; 7.7%) and abdominoperineal resection (n = 33; 23.2%).
RESULTS: The factors with a significant negative influence in overall survival and 42-months survival rates were: the age over 70 years, the emergency surgery related to cancer's complications, the advanced AJCC/ UICC
stage
, vascular invasion, perineural invasion, the recurrence of disease, the moderate and lower differentiated
adenocarcinoma
and incomplete or not performed chemotherapy.
CONCLUSION: Even with a radical surgical approach the advanced
stage of
colorectal
adenocarcinoma
has a low prognostic, but some other factors have also a high significance in postoperative outcome.
[MeSH-major]
Adenocarcinoma
/ pathology.
Adenocarcinoma
/ surgery. Colectomy / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18389783.001).
[ISSN]
0048-7848
[Journal-full-title]
Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
[ISO-abbreviation]
Rev Med Chir Soc Med Nat Iasi
[Language]
rum
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Romania
55.
Kornmann M, Formentini A, Ette C, Henne-Bruns D, Kron M, Sander S, Baumann W, Kreuser ED, Staib L, Link KH:
Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
Eur J Surg Oncol
; 2008 Dec;34(12):1316-21
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic factors influencing the survival of patients with
colon
cancer receiving adjuvant 5-FU treatment.
AIM: Adjuvant chemotherapy is recommended for
stage III colon
cancer.
The aim of this study was to identify important prognostic factors among patients with
colon
cancer receiving adjuvant 5-FU-based treatment.
METHODS: Data sets of 855
colon
cancer patients treated between 1992 and 1999 within a multicenter adjuvant trial comparing 5-FU modulation with folinic acid or interfereron-alpha were examined.
In the future, this may result in adjuvant treatment
of stage III colon
cancer adjusted for the risk of substages.
[MeSH-major]
Adenocarcinoma
/ mortality. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / mortality. Fluorouracil / therapeutic use
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18313881.001).
[ISSN]
1532-2157
[Journal-full-title]
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
[ISO-abbreviation]
Eur J Surg Oncol
[Language]
eng
[Publication-type]
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0 / Immunologic Factors; 0 / Interferon-alpha; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
56.
Liang JT, Lai HS, Lee PH, Chang KJ:
Laparoscopic pelvic autonomic nerve-preserving surgery for sigmoid colon cancer.
Ann Surg Oncol
; 2008 Jun;15(6):1609-16
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Laparoscopic pelvic autonomic nerve-preserving surgery for sigmoid
colon
cancer.
BACKGROUND: To test the feasibility of laparoscopic approach in performing the simultaneous pelvic autonomic nerve preservation during standard anterior resection of sigmoid
colon
cancer.
RESULTS: A total of 112 patients (tumor, node, metastasis system
stage
I, n = 8;
stage
II, n = 54;
stage III
, n = 50; male, n = 58; female, n = 54; age [mean +/- standard deviation], 55.8 +/- 6.4 years) with good baseline genitourinary function were operated on with the intent of total preservation of pelvic autonomic nerves and curative resection of sigmoid
colon
cancer.
CONCLUSIONS: Under laparoscopy, we can clearly identify and preserve the pelvic autonomic nerves to retain genitourinary function in most patients undergoing oncologic resection of sigmoid
colon
cancer.
[MeSH-major]
Adenocarcinoma
/ surgery. Autonomic Pathways / surgery. Colectomy. Sigmoid Neoplasms / surgery. Trauma, Nervous System / prevention & control
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Surg. 2004 Apr;91(4):465-8
[
15048749.001
]
[Cites]
Tech Coloproctol. 2003 Apr;7(1):29-33
[
12750952.001
]
[Cites]
Dis Colon Rectum. 2005 Dec;48(12):2354-61
[
16408331.001
]
[Cites]
Br J Surg. 2005 Nov;92(11):1444-8
[
16184622.001
]
[Cites]
Br J Surg. 2005 Sep;92(9):1124-32
[
15997446.001
]
[Cites]
Ann Surg. 2005 Aug;242(2):212-23
[
16041212.001
]
[Cites]
World J Surg. 2003 Feb;27(2):190-6
[
12616435.001
]
[Cites]
Dis Colon Rectum. 2002 Sep;45(9):1178-85
[
12352233.001
]
[Cites]
J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208
[
10782451.001
]
[Cites]
Semin Surg Oncol. 2000 Apr-May;18(3):235-43
[
10757889.001
]
[Cites]
Hepatogastroenterology. 2004 Sep-Oct;51(59):1354-7
[
15362751.001
]
[Cites]
Hepatogastroenterology. 1998 Nov-Dec;45(24):2206-14
[
9951896.001
]
[Cites]
Ann Surg Oncol. 2007 Apr;14(4):1285-7
[
17235719.001
]
[Cites]
Ann Surg Oncol. 2007 Jan;14(1):109-17
[
17066227.001
]
[Cites]
Int J Clin Oncol. 2006 Oct;11(5):339-43
[
17058130.001
]
[Cites]
Dis Colon Rectum. 2004 Sep;47(9):1442-7
[
15486739.001
]
[Cites]
Ann Surg. 1988 Oct;208(4):391-400
[
3178328.001
]
[Cites]
Dis Colon Rectum. 1995 Nov;38(11):1162-8
[
7587758.001
]
[Cites]
Cancer. 1996 Nov 1;78(9):1871-80
[
8909305.001
]
[Cites]
Br J Surg. 1997 Apr;84(4):586-7
[
9112939.001
]
[Cites]
Urology. 1997 Jun;49(6):822-30
[
9187685.001
]
[Cites]
Br J Surg. 1998 Aug;85(8):1162
[
9718031.001
]
(PMID = 18365285.001).
[ISSN]
1534-4681
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2373867
57.
Morris M, Platell C, Iacopetta B:
Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy.
Clin Cancer Res
; 2008 Mar 1;14(5):1413-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Tumor-infiltrating lymphocytes and perforation in
colon
cancer predict positive response to 5-fluorouracil chemotherapy.
The aim of the present study was to investigate the prognostic significance of TILs and other routinely reported pathologic features in
colon
cancer, particularly in relation to the use of adjuvant chemotherapy.
EXPERIMENTAL DESIGN: Pathologic markers, disease-specific survival, and the use of adjuvant chemotherapy were recorded in a retrospective, population-based series of 1,156
stage III colon
cancer patients with a median follow-up time of 52 months.
RESULTS: In patients treated by surgery alone (n = 851), markers with significant prognostic value included poor histologic grade, T4
stage
, N2 nodal status, vascular invasion, and perforation, but not the presence of TILs.
Because the presence of TILs reflects an adaptive immune response and perforation is associated with inflammatory response, these results suggest that there may be interactions between the immune system and chemotherapy leading to improved survival
of colon
cancer patients.
[MeSH-major]
Adenocarcinoma
, Mucinous / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Intestinal Perforation / diagnosis. Lymphocytes, Tumor-Infiltrating / pathology
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18316563.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
58.
Looi LM, Ng MH, Cheah PL:
Telomerase activation in neoplastic cell immortalization and tumour progression.
Malays J Pathol
; 2007 Jun;29(1):33-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
This is in contrast to normal somatic cells which are subject to a "mitotic clock," a phenomenon that has been linked to telomeric shortening after each round of cell replication, so that eventually the loss of genetic material reaches a critical
stage
and the cells undergo senescence and cell death.
Specimens comprised 33 breast lesions (10 infiltrating breast
adenocarcinoma
, 13 fibroadenoma and 10 non-neoplastic breast tissue), 27 colonic lesions (17 colonic
adenocarcinoma
and 10 non-neoplastic colonic mucosa) and 42 cervical lesions (20 cervical carcinoma and 22 non-neoplastic cervical tissues).
Telomerase activity was found in 6 (60%) of 10 breast carcinomas, 6 (46%) of 13 fibroadenomas, none of the 10 nonneoplastic breast samples, 3 (17.6%) of 17
colon
carcinomas and none of the 10 non-neoplastic colonic mucosal samples, 12 (60%) of 20 cervical carcinoma and 3 (13.6%) of 22 non-neoplastic cervical samples.
5/10 (50%)
Stage
I, 4/7 (57%)
Stage
II, 2/2 (100%)
Stage III
and 1/1 (100%)
Stage
IV cervical carcinomas showed telomerase activity.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19105326.001).
[ISSN]
0126-8635
[Journal-full-title]
The Malaysian journal of pathology
[ISO-abbreviation]
Malays J Pathol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Malaysia
[Chemical-registry-number]
EC 2.7.7.49 / Telomerase
59.
Seo T, Tatsuguchi A, Shinji S, Yonezawa M, Mitsui K, Tanaka S, Fujimori S, Gudis K, Fukuda Y, Sakamoto C:
Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients.
Virchows Arch
; 2009 Jun;454(6):667-76
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The localization of each PGES and COX-2 protein was examined by immunohistochemistry in 155 surgical resections and correlated to clinicopathological factors and patient prognosis. mPGES-1 mRNA and protein levels were significantly higher in CRC than in paired normal tissues. mPGES-1 immunoreactivity localized in cancer cells in 43% of cases. mPGES-2 immunoreactivity was significantly more pronounced in cancer cells than in adjacent normal epithelium in 36% of cases. cPGES immunoreactivity was homogeneous in cancer cells and thus determined constitutive. mPGES-1 and mPGES-2 correlated with significantly worse prognosis in
stage
I-
III
patients.
[MeSH-major]
Adenocarcinoma
/ enzymology. Colorectal Neoplasms / enzymology. Intramolecular Oxidoreductases / metabolism. Microsomes / enzymology
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 2005 Mar 17;352(11):1092-102
[
15713943.001
]
[Cites]
J Biol Chem. 2002 May 10;277(19):16355-64
[
11847219.001
]
[Cites]
Mol Carcinog. 2006 Jun;45(6):447-54
[
16688727.001
]
[Cites]
J Biochem Mol Biol. 2005 Nov 30;38(6):633-8
[
16336776.001
]
[Cites]
Cancer Res. 1998 Feb 1;58(3):409-12
[
9458081.001
]
[Cites]
Biochem Biophys Res Commun. 2002 Mar 8;291(4):884-9
[
11866447.001
]
[Cites]
J Biol Chem. 2003 Sep 26;278(39):37937-47
[
12835322.001
]
[Cites]
J Immunol. 2001 Jul 1;167(1):469-74
[
11418684.001
]
[Cites]
Gut. 2006 Jan;55(1):54-61
[
16085694.001
]
[Cites]
Gut. 2006 Jan;55(1):115-22
[
16118353.001
]
[Cites]
N Engl J Med. 2006 Aug 31;355(9):885-95
[
16943401.001
]
[Cites]
N Engl J Med. 2007 May 24;356(21):2131-42
[
17522398.001
]
[Cites]
J Biol Chem. 2000 Oct 20;275(42):32783-92
[
10869354.001
]
[Cites]
Br J Pharmacol. 2004 Apr;141(7):1091-7
[
15023855.001
]
[Cites]
N Engl J Med. 2006 Aug 31;355(9):873-84
[
16943400.001
]
[Cites]
Nat Rev Cancer. 2006 Feb;6(2):130-40
[
16491072.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7220-5
[
10377395.001
]
[Cites]
Biochem Biophys Res Commun. 2008 Jul 18;372(1):249-53
[
18485889.001
]
[Cites]
Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):63-75
[
15000150.001
]
[Cites]
Hum Pathol. 2007 Dec;38(12 ):1826-35
[
17868774.001
]
[Cites]
Clin Cancer Res. 2005 Jul 1;11(13):4754-60
[
16000571.001
]
[Cites]
J Biol Chem. 2000 Oct 20;275(42):32775-82
[
10922363.001
]
[Cites]
Dis Colon Rectum. 2006 Aug;49(8):1184-92
[
16752205.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Jun 27;306(2):577-81
[
12804604.001
]
[Cites]
Cell. 1998 May 29;93(5):705-16
[
9630216.001
]
[Cites]
Lab Invest. 2005 Feb;85(2):225-36
[
15531909.001
]
[Cites]
Int J Cancer. 2003 Nov 20;107(4):551-6
[
14520691.001
]
[Cites]
Cancer Res. 2008 May 1;68(9):3251-9
[
18451151.001
]
[Cites]
J Biol Chem. 2003 May 23;278(21):19396-405
[
12626523.001
]
[Cites]
Gastroenterology. 2003 Aug;125(2):404-12
[
12891542.001
]
[Cites]
J Pathol. 2006 Feb;208(3):356-63
[
16353170.001
]
[Cites]
Clin Cancer Res. 2001 Dec;7(12 ):3971-6
[
11751489.001
]
[Cites]
J Clin Invest. 2006 May;116(5):1391-9
[
16614756.001
]
[Cites]
J Biol Chem. 2002 Aug 16;277(33):30253-63
[
12050152.001
]
[Cites]
Mol Cancer. 2006 Nov 16;5:62
[
17107625.001
]
[Cites]
Hum Pathol. 2004 Apr;35(4):488-95
[
15116331.001
]
(PMID = 19412621.001).
[ISSN]
1432-2307
[Journal-full-title]
Virchows Archiv : an international journal of pathology
[ISO-abbreviation]
Virchows Arch.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / RNA, Messenger; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / PTGES protein, human; EC 5.3.99.3 / PTGES2 protein, human; EC 5.3.99.3 / Prostaglandin-E Synthases
60.
Sprenger T, Rothe H, Homayounfar K, Beissbarth T, Ghadimi BM, Becker H, Liersch T:
Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens--results from a prospective evaluation with extensive pathological work-up.
J Gastrointest Surg
; 2010 Jan;14(1):96-103
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Specimens from 64 consecutive patients with
stage
II/
III
rectal cancer receiving preoperative 5-FU-based CRT were investigated.
[MeSH-major]
Adenocarcinoma
/ surgery. Lymph Nodes / pathology. Neoadjuvant Therapy. Rectal Neoplasms / surgery
Genetic Alliance.
consumer health - Rectal Cancer
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Dis Colon Rectum. 2008 Mar;51(3):277-83
[
18183463.001
]
[Cites]
Cancer. 2009 Dec 1;115(23):5432-40
[
19673001.001
]
[Cites]
J Clin Oncol. 2001 Jan 1;19(1):157-63
[
11134208.001
]
[Cites]
J Clin Oncol. 2001 Apr 1;19(7):1976-84
[
11283130.001
]
[Cites]
N Engl J Med. 2001 Aug 30;345(9):638-46
[
11547717.001
]
[Cites]
Br J Cancer. 2001 Sep 1;85(5):780
[
11531267.001
]
[Cites]
Am J Surg Pathol. 2002 Feb;26(2):179-89
[
11812939.001
]
[Cites]
Arch Surg. 2002 Feb;137(2):206-10
[
11822961.001
]
[Cites]
World J Surg. 2002 Mar;26(3):384-9
[
11865379.001
]
[Cites]
J Clin Oncol. 2002 Apr 1;20(7):1729-34
[
11919228.001
]
[Cites]
Am Surg. 2002 May;68(5):482-7
[
12013294.001
]
[Cites]
Pathologe. 2003 Feb;24(1):61-5
[
12601479.001
]
[Cites]
Semin Surg Oncol. 2003;21(1):19-22
[
12923912.001
]
[Cites]
Arch Med Res. 2003 Jul-Aug;34(4):281-6
[
12957524.001
]
[Cites]
N Engl J Med. 2004 Jun 3;350(23):2343-51
[
15175436.001
]
[Cites]
Colorectal Dis. 2004 Sep;6(5):356-61
[
15335370.001
]
[Cites]
N Engl J Med. 2004 Oct 21;351(17):1731-40
[
15496622.001
]
[Cites]
Front Radiat Ther Oncol. 1994;28:37-45
[
7982602.001
]
[Cites]
J Am Coll Surg. 1995 Oct;181(4):335-46
[
7551328.001
]
[Cites]
Int J Colorectal Dis. 1997;12(1):19-23
[
9112145.001
]
[Cites]
CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29
[
9449931.001
]
[Cites]
Cancer. 1998 Aug 15;83(4):666-72
[
9708929.001
]
[Cites]
Lancet. 1999 Jan 30;353(9150):391-9
[
9950460.001
]
[Cites]
Eur J Cancer. 2005 Jan;41(2):272-9
[
15661553.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):426-31
[
15667963.001
]
[Cites]
Surg Today. 2005;35(6):442-5
[
15912290.001
]
[Cites]
Int J Colorectal Dis. 2005 Sep;20(5):434-9
[
15759124.001
]
[Cites]
APMIS. 2006 Mar;114(3):201-10
[
16643187.001
]
[Cites]
J Clin Oncol. 2006 Sep 1;24(25):4062-8
[
16943523.001
]
[Cites]
J Clin Oncol. 2007 Jan 1;25(1):110-7
[
17194912.001
]
[Cites]
J Gastrointest Surg. 2007 May;11(5):660-5
[
17468927.001
]
[Cites]
J Clin Oncol. 2007 Jun 20;25(18):2573-9
[
17577036.001
]
[Cites]
J Clin Oncol. 2007 Oct 1;25(28):4339-40
[
17906196.001
]
[Cites]
J Clin Oncol. 2007 Oct 1;25(28):4379-86
[
17906203.001
]
[Cites]
Dis Colon Rectum. 2007 Oct;50(10):1526-34
[
17828403.001
]
[Cites]
Lancet. 2007 Dec 15;370(9604):2020-9
[
18083404.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):456-61
[
18164860.001
]
[Cites]
Tech Coloproctol. 2008 Mar;12(1):39-43
[
18512011.001
]
[Cites]
J Natl Cancer Inst. 2008 Sep 17;100(18):1310-7
[
18780863.001
]
[Cites]
J Gastrointest Surg. 2009 Feb;13(2):269-74
[
18850250.001
]
[Cites]
Ann Surg. 2009 Jun;249(6):965-72
[
19474683.001
]
[Cites]
Dis Colon Rectum. 2009 Jul;52(7):1278-84
[
19571705.001
]
[Cites]
J Clin Oncol. 2008 May 1;26(13):2106-11
[
18362367.001
]
(PMID = 19830503.001).
[ISSN]
1873-4626
[Journal-full-title]
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
[ISO-abbreviation]
J. Gastrointest. Surg.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
61.
Wirtzfeld DA, Mikula L, Gryfe R, Ravani P, Dicks EL, Parfrey P, Gallinger S, Pollett WG:
Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces.
Can J Surg
; 2009 Apr;52(2):92-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with
stage
I-
III colon
cancer: experience in 2 Canadian provinces.
The American Society of Clinical Oncology and Cancer Care Ontario have recommended adjuvant chemotherapy for patients with high-risk
stage
II
colon
cancer.
We evaluated differences in concordance with guidelines in the treatment of patients with
stage
I-
III colon
cancer in the Canadian provinces of Newfoundland and Labrador and Ontario.
METHODS: We assessed clinical data and treatment from January 1999 to December 2000 for 130 patients from Newfoundland and Labrador and 315 patients from Ontario who had
stage
I-
III colon
cancer.
We evaluated factors affecting the use of chemotherapy in patients with
stage
II disease.
RESULTS: No patients received adjuvant therapy for
stage
I disease.
Forty-five of 52 patients (87%) in Newfoundland and Labrador and 108 of 115 patients (94%) in Ontario received adjuvant chemotherapy for
stage III colon
cancer.
Twenty of 55 patients (36%) in Newfoundland and Labrador and 44 of 116 patients (38%) in Ontario received adjuvant therapy for
stage
II disease.
There was a strong trend toward using chemotherapy in patients with
stage
II disease who were 50 years or younger, independent of high-risk status.
CONCLUSION: Concordance with CPGs for adjuvant chemotherapy in patients with
stage
II
colon
cancer was not optimal.
[MeSH-minor]
Adenocarcinoma
/ drug therapy.
Adenocarcinoma
/ pathology. Adult. Age Factors. Aged. Humans. Middle Aged. Multivariate Analysis. Newfoundland and Labrador. Ontario. Patient Selection. Registries. Risk Assessment
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
JAMA. 1999 Oct 20;282(15):1458-65
[
10535437.001
]
[Cites]
Am J Gastroenterol. 2006 Jun;101(6):1320-8
[
16771956.001
]
[Cites]
Arch Pathol Lab Med. 2000 Jul;124(7):979-94
[
10888773.001
]
[Cites]
Chronic Dis Can. 2000;21(2):81-6
[
11007659.001
]
[Cites]
N Engl J Med. 2003 Jul 17;349(3):247-57
[
12867608.001
]
[Cites]
N Engl J Med. 2004 Jun 3;350(23):2335-42
[
15175435.001
]
[Cites]
N Engl J Med. 2004 Jul 22;351(4):337-45
[
15269313.001
]
[Cites]
J Clin Oncol. 2004 Aug 15;22(16):3395-407
[
15199087.001
]
[Cites]
J Clin Oncol. 2004 Aug 15;22(16):3408-19
[
15199089.001
]
[Cites]
Intern Med J. 2004 Aug;34(8):492-500
[
15317548.001
]
[Cites]
JAMA. 1990 Sep 19;264(11):1444-50
[
2202842.001
]
[Cites]
CMAJ. 1993 Feb 15;148(4):507-12
[
8431814.001
]
[Cites]
N Engl J Med. 1993 May 13;328(19):1365-71
[
8474513.001
]
[Cites]
N Engl J Med. 1993 Dec 30;329(27):1977-81
[
8247072.001
]
[Cites]
J Clin Oncol. 1995 Feb;13(2):502-12
[
7844612.001
]
[Cites]
Eur J Cancer. 1995 Jul-Aug;31A(7-8):1369-72
[
7577053.001
]
[Cites]
Nat Med. 1995 Apr;1(4):348-52
[
7585065.001
]
[Cites]
J Clin Oncol. 1999 May;17(5):1349-55
[
10334518.001
]
[Cites]
J Clin Oncol. 1999 May;17(5):1356-63
[
10334519.001
]
[Cites]
Med Care Res Rev. 2004 Dec;61(4):453-73
[
15536209.001
]
[Cites]
Health Aff (Millwood). 2005 Jan-Feb;24(1):18-28
[
15647212.001
]
[Cites]
Cancer. 2005 Apr 25;105(2):101-9
[
15643601.001
]
[Cites]
Eval Health Prof. 2006 Mar;29(1):65-88
[
16510880.001
]
[Cites]
Qual Health Care. 1999 Sep;8(3):177-83
[
10847875.001
]
(PMID = 19399202.001).
[ISSN]
1488-2310
[Journal-full-title]
Canadian journal of surgery. Journal canadien de chirurgie
[ISO-abbreviation]
Can J Surg
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Canada
[Other-IDs]
NLM/ PMC2663496
62.
Sézeur A, Châtelet FP, Cywiner Ch, de Labriolle-Vaylet C, Chastang C, Billotey C, Malafosse M, Gallot D, Betton P, Montravers F, Carvajal-Gonzalez S, Askienazy S, Talbot JN, Rain JD, Milhaud G, Saumon G, Barbet J, Gruaz-Guyon A:
Pathology underrates colon cancer extranodal and nodal metastases; ex vivo radioimmunodetection helps staging.
Clin Cancer Res
; 2007 Sep 15;13(18 Pt 2):5592s-5597s
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pathology underrates
colon
cancer extranodal and nodal metastases; ex vivo radioimmunodetection helps staging.
The benefit of adjuvant chemotherapy for patients upstaged with radioimmunodection should also be assessed because adjuvant chemotherapy improves the 5-year survival
of stage III
patients.
[MeSH-major]
Adenocarcinoma
/ radionuclide imaging. Colonic Neoplasms / radionuclide imaging. Indium Radioisotopes. Radioimmunodetection
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17875794.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Bispecific; 0 / Carcinoembryonic Antigen; 0 / Haptens; 0 / Indium Radioisotopes; 0 / Oligopeptides
63.
Mizushima T, Nomura M, Fujii M, Akamatsu H, Mizuno H, Tominaga H, Hasegawa J, Nakajima K, Yasumasa K, Yoshikawa M, Nishida T:
Primary colorectal signet-ring cell carcinoma: clinicopathological features and postoperative survival.
Surg Today
; 2010 Mar;40(3):234-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The clinicopathological data of those patients were compared with those of 5792 patients with non-signet-ring cell colorectal carcinoma (5417 with well or moderately differentiated
adenocarcinoma
and 375 with poorly differentiated
adenocarcinoma
or mucinous carcinoma).
The overall 5-year survival rate in primary signet-ring cell carcinoma was significantly lower at 24.1%, in comparison to 77.5% in well or moderately differentiated
adenocarcinoma
and 57.7% in poorly differentiated
adenocarcinoma
or mucinous carcinoma.
Likewise, the postoperative survival in
Stage III
was also significantly worse.
On the other hand, no significant difference was observed in
Stage
II or IV.
CONCLUSION: The most important feature of primary colorectal signet-ring cell carcinoma is the advanced
stage
at the time of diagnosis.
[MeSH-major]
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ pathology. Carcinoma, Signet Ring Cell / mortality. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology
Genetic Alliance.
consumer health - Signet ring cell carcinoma
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Gastroenterol. 1996 Oct;91(10):2195-9
[
8855747.001
]
[Cites]
Ann Surg Oncol. 1996 Jul;3(4):344-8
[
8790846.001
]
[Cites]
Dis Colon Rectum. 2008 Jan;51(1):50-5
[
18030531.001
]
[Cites]
Oncology. 2007;72(1-2):64-8
[
18004078.001
]
[Cites]
Hepatogastroenterology. 2006 Nov-Dec;53(72):845-9
[
17153438.001
]
[Cites]
Oncology. 1994 Jan-Feb;51(1):30-4
[
8265100.001
]
[Cites]
J Clin Oncol. 2004 Jan 15;22(2):229-37
[
14657227.001
]
[Cites]
Cancer. 1985 Dec 1;56(11):2723-6
[
2996745.001
]
[Cites]
N Engl J Med. 1990 Feb 8;322(6):352-8
[
2300087.001
]
[Cites]
Dis Colon Rectum. 1999 Sep;42(9):1176-80
[
10496558.001
]
[Cites]
AMA Arch Surg. 1951 Jan;62(1):79-91
[
14789350.001
]
[Cites]
Surg Today. 2009;39(4):290-4
[
19319634.001
]
[Cites]
N Engl J Med. 2000 Sep 28;343 (13):905-14
[
11006366.001
]
[Cites]
Cancer. 1983 Oct 15;52(8):1453-7
[
6311394.001
]
[Cites]
Ann Surg Oncol. 2008 Oct;15(10):2684-91
[
18649106.001
]
[Cites]
Langenbecks Arch Surg. 2004 Jun;389(3):178-83
[
15188084.001
]
[Cites]
Dis Colon Rectum. 1999 Dec;42(12):1618-25
[
10613484.001
]
[Cites]
Dis Colon Rectum. 1995 Nov;38(11):1189-92
[
7587762.001
]
[Cites]
J Clin Oncol. 2000 Aug;18(16):2938-47
[
10944126.001
]
[Cites]
N Engl J Med. 2004 Jun 3;350(23):2343-51
[
15175436.001
]
[Cites]
ANZ J Surg. 2001 Dec;71(12):703-6
[
11906382.001
]
(PMID = 20180076.001).
[ISSN]
1436-2813
[Journal-full-title]
Surgery today
[ISO-abbreviation]
Surg. Today
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Japan
64.
Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, Tiret E, Dumont S, Gayet B, Validire P, Fléjou JF, Duval A, Praz F:
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
Ann Oncol
; 2010 Apr;21(4):772-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Impact of p53 expression and microsatellite instability on
stage III colon
cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
BACKGROUND: The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy
of colon
cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX).
PATIENTS AND METHODS: This retrospective study included 233 unselected patients with
stage III colon
cancer treated by FL (n = 124) or FOLFOX (n = 109).
CONCLUSION: Our observations indicate that MSI status and p53 expression may influence the impact of oxaliplatin on adjuvant treatment
of stage III colon
cancer patients.
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19833818.001).
[ISSN]
1569-8041
[Journal-full-title]
Annals of oncology : official journal of the European Society for Medical Oncology
[ISO-abbreviation]
Ann. Oncol.
[Language]
ENG
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
65.
Schwandner O, Schlamp A, Broll R, Bruch HP:
Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
Int J Colorectal Dis
; 2007 Feb;22(2):127-36
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Inclusion criteria were sporadic rectal
adenocarcinoma
resected curatively (including total mesorectal excision), adjuvant radiochemotherapy in UICC stages II and
III
, and complete intra-institutional follow-up.
Neither pattern correlated with age, gender, tumor
stage
(UICC), grading, preoperative serum carcinoembryonic antigen (CEA) level, or nodal status (p>0.05).
In terms of survival, preoperative CEA level (disease-free 5-year survival 46% with increased CEA vs 70% with normal CEA, p=0.01; overall 5-year survival 43 vs 74%, p<0.01) and UICC
stage
were the only factors to be significantly related to 5-year survival by univariate analysis, whereas the metalloproteinases failed to show a significant association.
In multivariate analysis, CEA and UICC
stage
were not identified as independent factors predictive of survival.
[MeSH-major]
Adenocarcinoma
/ metabolism. Matrix Metalloproteinase 14 / biosynthesis. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 7 / biosynthesis. Rectal Neoplasms / metabolism. Tissue Inhibitor of Metalloproteinase-2 / biosynthesis
Genetic Alliance.
consumer health - Rectal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Pathol Res Pract. 2004;200(5):379-87
[
15239346.001
]
[Cites]
Mod Pathol. 1991 Mar;4(2):239-46
[
1646457.001
]
[Cites]
Mod Pathol. 1994 Feb;7(2):220-5
[
8008747.001
]
[Cites]
Br J Cancer. 1997;76(6):805-11
[
9310250.001
]
[Cites]
Br J Cancer. 2001 May 18;84(10):1317-21
[
11355941.001
]
[Cites]
J Korean Med Sci. 1999 Aug;14(4):417-23
[
10485622.001
]
[Cites]
Dis Colon Rectum. 1999 May;42(5):559-62
[
10344676.001
]
[Cites]
Ann Otol Rhinol Laryngol. 1995 Sep;104(9 Pt 1):678-84
[
7661515.001
]
[Cites]
Cancer. 1998 Sep 15;83(6):1153-62
[
9740080.001
]
[Cites]
Int J Cancer. 2001 Sep 20;95(5):290-4
[
11494227.001
]
[Cites]
Int J Colorectal Dis. 2004 Nov;19(6):518-24
[
15103490.001
]
[Cites]
Gut. 1999 Aug;45(2):252-8
[
10403738.001
]
[Cites]
Jpn J Clin Oncol. 1996 Oct;26(5):303-9
[
8895669.001
]
[Cites]
FASEB J. 1999 May;13(8):781-92
[
10224222.001
]
[Cites]
Int J Colorectal Dis. 2005 May;20(3):245-52
[
15592677.001
]
[Cites]
J Clin Oncol. 1998 Jan;16(1):324-9
[
9440760.001
]
[Cites]
World J Gastroenterol. 2005 May 28;11(20):3046-50
[
15918187.001
]
[Cites]
Br J Cancer. 2000 Jul;83(2):215-8
[
10901373.001
]
[Cites]
Langenbecks Arch Surg. 1999 Apr;384(2):167-75
[
10328170.001
]
[Cites]
Dis Colon Rectum. 1996 Nov;39(11):1255-64
[
8918435.001
]
[Cites]
Gynecol Oncol. 1999 Oct;75(1):91-8
[
10502432.001
]
[Cites]
Anticancer Res. 2005 Sep-Oct;25(5):3387-91
[
16101153.001
]
[Cites]
Matrix Biol. 1997 Mar;15(8-9):535-41
[
9138286.001
]
[Cites]
Urology. 1997 Aug;50(2):295-301
[
9255309.001
]
[Cites]
Chirurg. 2003 Oct;74(10):905-14
[
14605732.001
]
[Cites]
Anticancer Res. 2003 Sep-Oct;23(5b):4169-73
[
14666620.001
]
[Cites]
Dis Colon Rectum. 2000 Nov;43(11):1606-27
[
11089603.001
]
[Cites]
Gut. 2005 Dec;54(12):1751-8
[
16284286.001
]
[Cites]
Oncology. 2003;65(4):337-46
[
14707454.001
]
[Cites]
Dis Colon Rectum. 2002 Apr;45(4):537-43
[
12006939.001
]
[Cites]
J Biochem. 1996 Feb;119(2):209-15
[
8882706.001
]
[Cites]
Jpn J Clin Oncol. 2005 Dec;35(12):739-44
[
16314344.001
]
(PMID = 16896992.001).
[ISSN]
0179-1958
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.80 / Matrix Metalloproteinase 14
66.
D'Annibale A, Morpurgo E, Fiscon V, Termini B, Serventi A, Sovernigo G, Orsini C:
Minimally invasive resection for colorectal cancer: perioperative and medium-term results in an unselected patient group at a single institution.
Tech Coloproctol
; 2006 Dec;10(4):303-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RESULTS: In the study period, 302 patients (mean age 66.1 years; range, 32-93 years) underwent 114 left hemicolectomies, 108 low anterior resections, 61 right hemicolectomies, 12 Miles procedures, 4 subtotal colectomies, and 3 transverse
colon
resections.
Cancer-related survival curves showed a 90% survival for
stage
II, 85% for
stage III
, and 10% for
stage
IV disease, 30 months after surgery.
[MeSH-major]
Adenocarcinoma
/ surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparoscopy. Rectal Neoplasms / surgery
Genetic Alliance.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Tech Coloproctol. 2009 Mar;13(1):103
(PMID = 17115319.001).
[ISSN]
1123-6337
[Journal-full-title]
Techniques in coloproctology
[ISO-abbreviation]
Tech Coloproctol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Italy
67.
Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients.
Int Semin Surg Oncol
; 2007 Sep 20;4:23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: although preoperative RT (Radiation Therapy) is becoming the preferred approach for combined treatment of locally advanced rectal
adenocarcinoma
, no regimen can be now considered as a standard.
METHODS: patients were screened following these eligibility criteria: histology-proven
adenocarcinoma of
the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical
stage
T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
Twenty-eight patients were
stage
II and 19
stage III
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Surg. 1990 Feb;211(2):187-95
[
2405793.001
]
[Cites]
Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5
[
8311145.001
]
[Cites]
Ann Surg. 1998 Feb;227(2):157-67
[
9488510.001
]
[Cites]
J Natl Cancer Inst. 2000 Mar 1;92(5):388-96
[
10699069.001
]
[Cites]
N Engl J Med. 2001 Aug 30;345(9):638-46
[
11547717.001
]
[Cites]
Ann Surg. 2001 Nov;234(5):633-40
[
11685026.001
]
[Cites]
Lancet. 2000 Jul 8;356(9224):93-6
[
10963244.001
]
[Cites]
Ann Surg. 1994 Nov;220(5):676-82
[
7979617.001
]
[Cites]
Br J Radiol. 1989 Aug;62(740):679-94
[
2670032.001
]
[Cites]
Strahlenther Onkol. 2002 May;178(5):259-62
[
12082685.001
]
[Cites]
Br J Surg. 1996 Jul;83(7):964-8
[
8813788.001
]
[Cites]
Ann Surg. 1995 Jan;221(1):67-73
[
7826163.001
]
[Cites]
Dis Colon Rectum. 1992 Aug;35(8):757-61
[
1643999.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8
[
6735750.001
]
[Cites]
N Engl J Med. 1997 Apr 3;336(14):980-7
[
9091798.001
]
[Cites]
N Engl J Med. 1994 Aug 25;331(8):502-7
[
8041415.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2396
[
10561302.001
]
[Cites]
Strahlenther Onkol. 2004 Jan;180(1):5-14
[
14704839.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1992;23(2):387-92
[
1587760.001
]
[Cites]
Lancet. 2001 Oct 20;358(9290):1291-304
[
11684209.001
]
[Cites]
Clin Radiol. 1971 Apr;22(2):145-55
[
5575251.001
]
(PMID = 17883838.001).
[ISSN]
1477-7800
[Journal-full-title]
International seminars in surgical oncology : ISSO
[ISO-abbreviation]
Int Semin Surg Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2063497
68.
Ugurlu MM, Asoglu O, Potter DD, Barnes SA, Harmsen WS, Donohue JH:
Adenocarcinomas of the jejunum and ileum: a 25-year experience.
J Gastrointest Surg
; 2005 Nov;9(8):1182-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Because few large published experiences exist, we reviewed patients with jejunal and ileal
adenocarcinoma
treated at our institution over the last 25 years.
Between January 1976 and December 2001, 77 patients had an operation for a jejunal or ileal
adenocarcinoma
.
One (1%) patient had
stage
I, 18 (23%)
stage
II, 19 (25%)
stage III
, and 39 (51%)
stage
IV
adenocarcinoma
at diagnosis.
Tumor
stage
had a highly significant effect (P < 0.0001) on median survival (72 months for
stage
I and II, 30 months for
stage III
, and 9 months for
stage
IV disease).
In multivariate analysis of patients having curative treatment, tumor recurrence (P < 0.0001),
stage
(P < 0.0002), and weight loss (P < 0.001) were significant negative prognostic indicators.
Most patients with
adenocarcinoma of
the jejunum or ileum present with advanced disease.
Tumor
stage
, disease recurrence, and weight loss predicted patient outcome following a curative operation.
[MeSH-major]
Adenocarcinoma
/ surgery. Ileal Neoplasms / surgery. Jejunal Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Intestinal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 2004 Aug 1;101(3):518-26
[
15274064.001
]
[Cites]
Inflamm Bowel Dis. 2004 Jan;10(1):32-5
[
15058524.001
]
[Cites]
J Gastrointest Surg. 2003 Nov;7(7):925-30
[
14592670.001
]
[Cites]
J Clin Gastroenterol. 2001 Oct;33(4):267-82
[
11588539.001
]
[Cites]
Am J Surg. 1986 Jun;151(6):654-8
[
2424326.001
]
[Cites]
Ann Surg Oncol. 1994 May;1(3):183-8
[
7842287.001
]
[Cites]
Arch Surg. 2002 May;137(5):564-70; discussion 570-1
[
11982470.001
]
[Cites]
Chin Med J (Engl). 2004 Jul;117(7):1045-9
[
15265380.001
]
[Cites]
Am J Surg. 1997 Mar;173(3):237-9
[
9124635.001
]
[Cites]
Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2
[
10843358.001
]
[Cites]
Semin Oncol. 1988 Apr;15(2):116-28
[
3285475.001
]
[Cites]
Gastroenterology. 1985 Aug;89(2):438-41
[
4007431.001
]
[Cites]
Ann Surg. 1997 Mar;225(3):300-6
[
9060587.001
]
[Cites]
J Chemother. 2003 Oct;15(5):503-6
[
14598944.001
]
[Cites]
Cancer. 1999 Dec 15;86(12):2693-706
[
10594865.001
]
[Cites]
Ann Surg Oncol. 1994 Jul;1(4):290-5
[
7850527.001
]
[Cites]
Am Surg. 2000 Jan;66(1):46-51
[
10651347.001
]
[Cites]
Dis Colon Rectum. 2002 Nov;45(11):1496-502
[
12432298.001
]
(PMID = 16269390.001).
[ISSN]
1091-255X
[Journal-full-title]
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
[ISO-abbreviation]
J. Gastrointest. Surg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
69.
Sträter J, Herter I, Merkel G, Hinz U, Weitz J, Möller P:
Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis.
Int J Cancer
; 2010 Aug 15;127(4):873-80
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in
stage
II/
III colon
carcinoma: caspase-8 and caspase-9 is associated with poor prognosis.
To study their prognostic influence in
colon
carcinoma, expression of APAF-1, caspase-8 and caspase-9 was determined by immunohistochemistry in normal
colon
mucosa (n = 8) and R0-resected
stage
II/
III colon
carcinomas (n >or= 124) using a semiquantitative score.
In normal
colon
, APAF-1 and caspase-8 are most strongly expressed in the luminal surface epithelium, whereas caspase-9 is expressed all along the crypt axis.
In
colon
carcinomas, there is considerable variability in the expression of these proapoptotic factors, although complete loss of caspase-8 and caspase-9 is rare.
The influence of caspase-8 expression was mainly seen in patients with
stage III colon
carcinoma (p = 0.011), whereas the prognostic influence of caspase-9 expression was significant in
stage
II cases (p = 0.037) and just failed to be significant in
stage III
tumors (p = 0.0581).
Our data suggest that, in
colon
carcinomas, expression of caspase-8 and caspase-9 is significantly associated with poor survival.
Caspase-9 may be an independent prognosticator in
colon
carcinoma.
[MeSH-major]
Adenocarcinoma
/ metabolism.
Adenocarcinoma
, Mucinous / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Biomarkers, Tumor / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Colonic Neoplasms / metabolism
[MeSH-minor]
Aged.
Colon
/ metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20013803.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / Biomarkers, Tumor; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9
70.
Dahl O:
[Adjuvant chemotherapy for colon cancer].
Tidsskr Nor Laegeforen
; 2007 Nov 29;127(23):3094-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Adjuvant chemotherapy for
colon
cancer].
BACKGROUND: Radical resection is the main treatment for
adenocarcinoma of
the
colon
.
The background for adjuvant chemotherapy
of colon
cancer is presented.
RESULTS AND INTERPRETATION: Cure rates after curative resections
of colon
cancer (
stage III
) are improved by about 12% if patients are treated with adjuvant chemotherapy with oxaliplatin combined with 5-fluoruracil and folinat (or capecitabine) for 6 months.
Certain subgroups
of stage
II (Dukes'
stage
B) are also likely to benefit from adjuvant chemotherapy.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Colonic Neoplasms / drug therapy
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18049502.001).
[ISSN]
0807-7096
[Journal-full-title]
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
[ISO-abbreviation]
Tidsskr. Nor. Laegeforen.
[Language]
nor
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Norway
[Chemical-registry-number]
0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents
[Number-of-references]
35
71.
López-Cano M, Mañas MJ, Hermosilla E, Espín E:
Multivisceral resection for colon cancer: analysis of prognostic factors.
Dig Surg
; 2010 Aug;27(3):238-45
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Multivisceral resection for
colon
cancer: analysis of prognostic factors.
BACKGROUND/AIMS: To assess outcome of multivisceral resection in
colon
cancer patients and to identify predictors of survival.
METHODS: One hundred and thirteen consecutive patients with primary locally advanced
colon
cancer infiltrating adjacent organs undergoing multivisceral resection between 1998 and 2007 were reviewed.
The diagnosis was conventional
adenocarcinoma
in 94 patients.
Hematochezia and adjuvant chemotherapy were independent factors of favorable outcome and grade G3 and tumor
stage III
-IV of poor survival.
CONCLUSION: Hematochezia and adjuvant chemotherapy were associated with a better survival, and poorly differentiated tumors and
stage
IV disease with a poor survival.
[MeSH-minor]
Abdomen, Acute.
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ pathology.
Adenocarcinoma
/ surgery. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Gastrointestinal Hemorrhage / complications. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Recurrence
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20571272.001).
[ISSN]
1421-9883
[Journal-full-title]
Digestive surgery
[ISO-abbreviation]
Dig Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
72.
Martínek L, Dostalík J, Gunka I, Gunková P, Vávra P:
[Comparison of oncological outcomes between laparoscopic and open procedures in non-metastazing colonic carcinomas].
Rozhl Chir
; 2009 Dec;88(12):725-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
AIM: The aim of our study was to compare oncological results of laparoscopic assisted coloctomy and open colectomy in the treatment of nonmetastatic
colon
cancer.
MATERIAL AND METHODS: In this prospective nonrandomised clinical trail a group of elective laparoscopic or open resections in patients with the
colon
adenocarcinom was evaluated in the period between January 2001 and December 2006.
With a respect of the tumor
stage
, there was a tendency of higher overall survival in favour of the laparoscopic group in the
stage III
, however the difference was not statistically significant (p = 0.07).
CONCLUSION: Long-term results support laparoscopic
colon
cancer surgery as a safe and effective alternative to open surgery.
[MeSH-major]
Adenocarcinoma
/ surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparoscopy
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20662437.001).
[ISSN]
0035-9351
[Journal-full-title]
Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
[ISO-abbreviation]
Rozhl Chir
[Language]
cze
[Publication-type]
Clinical Trial; Comparative Study; English Abstract; Journal Article
[Publication-country]
Czech Republic
73.
Bachet JB, Rougier P, de Gramont A, André T:
[Rectal cancer and adjuvant chemotherapy: which conclusions?].
Bull Cancer
; 2010 Jan;97(1):107-22
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Transliterated title]
Cancer
du
rectum et chimiothérapie adjuvante: quelles conclusions?
Adenocarcinoma of
the rectum represents about a third of cases of colorectal cancer, with an annual incidence of 12,000 cases in France.
On the contrary
of colon
cancer, the benefice of adjuvant chemotherapy in rectal cancer has not been definitively proved, more because this question was assessed in few recent studies than because negative results.
The data of the "historical studies" of adjuvant treatment in rectal cancer published before 1990, of the meta-analysis of adjuvant trials in rectal cancer and of the QUASAR study suggest that adjuvant chemotherapy with fluoropyrimidines (intravenous or oral), in absence of pre-operative treatment, decrease the risk of metastatic relapse after curative surgery for a rectal cancer
of stage
II or
III
.
This benefice seems similar to the one observed in
colon
cancer.
The French recommendations are to discuss the indication of adjuvant chemotherapy by fluoropyrimidines in cases
of stage III
rectal cancer on histopathologic reports and no chemotherapy in case of
stade
II.
Despite the fact that none study have assessed a combination of fluoropyrimidines and oxaliplatin in adjuvant setting in rectal cancer, like in
colon
cancer, the Folfox4, modified Folfox6 or Xelox regimens are valid options in
stage III
(experts opinion).
[MeSH-major]
Adenocarcinoma
/ drug therapy. Rectal Neoplasms / drug therapy
Genetic Alliance.
consumer health - Rectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19965305.001).
[ISSN]
1769-6917
[Journal-full-title]
Bulletin du cancer
[ISO-abbreviation]
Bull Cancer
[Language]
fre
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
France
[Number-of-references]
58
74.
Nabeshima K, Machimura T, Wasada M, Takayasu H, Ogoshi K, Makuuchi H:
A case of primary jejunal cancer diagnosed by preoperative small intestinal endoscopy.
Tokai J Exp Clin Med
; 2008 Apr;33(1):42-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Biopsy suggested a well-differentiated
adenocarcinoma
.
Under a diagnosis of primary jejunum cancer, Partial resection of the jejunum and partial resection of the transverse
colon
was performed.
Histopathologically, the tumor was well differentiated
adenocarcinoma
exposed serosal surface.
Postoperatively, the
stage
was evaluated as
III
(T3, N1, M0).
[MeSH-major]
Adenocarcinoma
/ pathology. Endoscopy, Gastrointestinal. Intestine, Small / pathology. Jejunal Neoplasms / pathology. Preoperative Care
MedlinePlus Health Information.
consumer health - Intestinal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21318964.001).
[ISSN]
2185-2243
[Journal-full-title]
The Tokai journal of experimental and clinical medicine
[ISO-abbreviation]
Tokai J. Exp. Clin. Med.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
75.
Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J:
SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
J Biol Chem
; 2009 Jul 3;284(27):18210-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
SirT1 is an inhibitor of proliferation and tumor formation in
colon
cancer.
Immunohistochemical staining revealed high level SirT1 in normal
colon
mucosa and benign adenomas.
SirT1 overexpression was observed in approximately 25%
of stage
I/II/
III
colorectal adenocarcinomas but rarely found in advanced
stage
IV tumors.
These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment
of colon
cancer.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nature. 2000 Feb 17;403(6771):795-800
[
10693811.001
]
[Cites]
Science. 2000 Sep 22;289(5487):2126-8
[
11000115.001
]
[Cites]
Nature. 2001 Mar 8;410(6825):227-30
[
11242085.001
]
[Cites]
Cell. 2001 Oct 19;107(2):137-48
[
11672522.001
]
[Cites]
Cell. 2001 Oct 19;107(2):149-59
[
11672523.001
]
[Cites]
Nature. 2003 Sep 11;425(6954):191-6
[
12939617.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9
[
12960381.001
]
[Cites]
Cell. 2004 Feb 20;116(4):551-63
[
14980222.001
]
[Cites]
EMBO J. 2004 Jun 16;23(12):2369-80
[
15152190.001
]
[Cites]
Science. 2004 Jul 16;305(5682):390-2
[
15205477.001
]
[Cites]
Science. 1990 Jan 19;247(4940):322-4
[
2296722.001
]
[Cites]
Cancer Res. 1994 Nov 15;54(22):5947-52
[
7954427.001
]
[Cites]
Nature. 2005 Mar 3;434(7029):113-8
[
15744310.001
]
[Cites]
Cell Metab. 2005 Jul;2(1):67-76
[
16054100.001
]
[Cites]
Cell Metab. 2005 Aug;2(2):105-17
[
16098828.001
]
[Cites]
Cell. 2005 Nov 4;123(3):437-48
[
16269335.001
]
[Cites]
Cancer Res. 2005 Nov 15;65(22):10457-63
[
16288037.001
]
[Cites]
Mol Cell Biol. 2006 Jan;26(1):28-38
[
16354677.001
]
[Cites]
Oncogene. 2006 Jan 12;25(2):176-85
[
16170353.001
]
[Cites]
PLoS Biol. 2006 Feb;4(2):e31
[
16366736.001
]
[Cites]
Cancer Res. 2006 Apr 15;66(8):4368-77
[
16618762.001
]
[Cites]
Nat Cell Biol. 2006 Sep;8(9):1025-31
[
16892051.001
]
[Cites]
Mol Cell Biol. 2006 Nov;26(21):8122-35
[
16923962.001
]
[Cites]
Nature. 2006 Nov 16;444(7117):337-42
[
17086191.001
]
[Cites]
Cell. 2006 Dec 15;127(6):1109-22
[
17112576.001
]
[Cites]
Mol Cell. 2007 Feb 23;25(4):543-57
[
17317627.001
]
[Cites]
Arch Dermatol Res. 2007 May;299(2):103-6
[
17180656.001
]
[Cites]
Mol Cell. 2007 Jul 6;27(1):149-62
[
17612497.001
]
[Cites]
Cancer Res. 2007 Jul 15;67(14):6612-8
[
17638871.001
]
[Cites]
Oncogene. 2007 Aug 13;26(37):5489-504
[
17694089.001
]
[Cites]
Biochem J. 2007 Nov 1;407(3):451-60
[
17620057.001
]
[Cites]
Biotechnol J. 2007 Nov;2(11):1360-8
[
17806102.001
]
[Cites]
Nature. 2007 Nov 29;450(7170):712-6
[
18046409.001
]
[Cites]
Mol Biol Cell. 2008 Mar;19(3):1210-9
[
18184747.001
]
[Cites]
PLoS One. 2008;3(4):e2020
[
18414679.001
]
[Cites]
Cancer Cell. 2008 Oct 7;14(4):312-23
[
18835033.001
]
(PMID = 19433578.001).
[ISSN]
1083-351X
[Journal-full-title]
The Journal of biological chemistry
[ISO-abbreviation]
J. Biol. Chem.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
[Other-IDs]
NLM/ PMC2709385
76.
Chang SC, Lin JK, Lin TC, Liang WY:
Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Int J Oncol
; 2005 Jan;26(1):65-75
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal
adenocarcinoma
.
Of these, 20 were
stage
I (12%), 54
stage
II (32.3%), 58
stage III
(34.7%), and 35
stage
IV (21%).
Genetic p53 alterations were associated with advanced tumor
stage
and tumor differentiation.
Of 132 potentially cured patients, 3-year disease-free survival (DFS) was affected by: advanced TNM
stage
(I, II,
III
: 90%, 84%, and 41%), genetic p53 alteration (89% vs. 43%), intratumoral p53 accumulation (71% vs. 56%), and preoperative CEA level >5 ng/ml (74% vs. 58%).
In multivariate analysis, genetic alteration of p53 was the most significant independent prognostic factor [hazard ratio (HR) = 6.09; 95% confidence interval (CI): 2.45-15.11], followed by advanced tumor
stage
(HR = 3.93; 95% CI: 2.14-7.23), and preoperative CEA >5 ng/ml (HR = 1.98; 95% CI: 1.12-3.17).
[MeSH-major]
Adenocarcinoma
/ diagnosis. Biomarkers, Tumor / genetics. Colorectal Neoplasms / diagnosis. Tumor Suppressor Protein p53 / genetics
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15586226.001).
[ISSN]
1019-6439
[Journal-full-title]
International journal of oncology
[ISO-abbreviation]
Int. J. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
77.
Jung SH, Kim HC, Yu CS, Chang HM, Ryu MH, Lee JL, Kim JS, Kim JC:
[Clinicopathologic characteristics of colorectal neuroendocrine tumor].
Korean J Gastroenterol
; 2006 Aug;48(2):97-103
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Nine tumors were located in the rectum, two in the sigmoid, and each one in the transverse
colon
and cecum, respectively.
All patients were advanced at the time of diagnosis, with AJCC TNM staging:
stage
IIIB (n=2),
stage
IIIC (n=3), and
stage
IV (n=8).
Five patients who received chemotherapy showed median survival of 32 months (
stage III
) and 17.5 months (
stage
IV), whereas other five patients without chemotherapy died with a median survival of 6.2 months.
[MeSH-minor]
Adenocarcinoma
/ pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biopsy. Chromogranin A / analysis. Chromogranin A / immunology. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Synaptophysin / analysis. Synaptophysin / immunology
Genetic Alliance.
consumer health - Pancreatic islet cell tumors
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16929153.001).
[ISSN]
1598-9992
[Journal-full-title]
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
[ISO-abbreviation]
Korean J Gastroenterol
[Language]
kor
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Korea (South)
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin
78.
Suh KW, Kim JH, Kim YB, Kim J, Jeong S:
Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer.
J Gastrointest Surg
; 2005 Mar;9(3):336-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Thymidylate synthase gene polymorphism as a prognostic factor for
colon
cancer.
Here, we determined the significance of this polymorphism in predicting the clinical outcomes for patients with
colon
cancer.
We reviewed 121 consecutive patients with
stage
II or
III colon
cancer who underwent a curative resection.
The difference was particularly significant in the patients with
stage III
disease (41% versus 77%, P=0.0414).
Tumor
stage
and the TS polymorphism were identified as significant prognostic factors by multivariate analysis.
We found the TS polymorphism to be a significant and independent prognostic factor for
colon
cancer.
[MeSH-major]
Adenocarcinoma
/ genetics.
Adenocarcinoma
/ mortality. Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / mortality. Thymidylate Synthase / metabolism
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Clin Oncol. 2001 Dec;24(6):597-602
[
11801762.001
]
[Cites]
Clin Cancer Res. 1998 May;4(5):1227-34
[
9607581.001
]
[Cites]
Anticancer Res. 1998 May-Jun;18(3A):1515-20
[
9673363.001
]
[Cites]
J Clin Oncol. 1997 Oct;15(10):3223-9
[
9336359.001
]
[Cites]
Clin Colorectal Cancer. 2001 Nov;1(3):175-8; discussion 179-81
[
12450432.001
]
[Cites]
Biochim Biophys Acta. 1993 Dec 14;1216(3):409-16
[
8268221.001
]
[Cites]
Clin Cancer Res. 2000 Mar;6(3):1063-72
[
10741735.001
]
[Cites]
Pharmacogenomics J. 2001;1(1):65-70
[
11913730.001
]
[Cites]
Biochim Biophys Acta. 1977 Dec 23;473(2):73-92
[
145246.001
]
[Cites]
J Clin Oncol. 1994 Jan;12(1):14-20
[
7677801.001
]
[Cites]
Cancer Res. 1995 Apr 1;55(7):1407-12
[
7882343.001
]
[Cites]
J Clin Oncol. 1988 Oct;6(10):1653-64
[
3049954.001
]
[Cites]
Cancer. 1998 Jan 1;82(1):70-7
[
9428481.001
]
[Cites]
Nature. 1957 Mar 30;179(4561):663-6
[
13418758.001
]
[Cites]
Cancer Res. 2003 Jun 1;63(11):2898-904
[
12782596.001
]
[Cites]
Clin Cancer Res. 1998 May;4(5):1243-50
[
9607583.001
]
[Cites]
Cancer Lett. 2003 Feb 10;190(1):97-104
[
12536082.001
]
[Cites]
Clin Cancer Res. 2000 Apr;6(4):1378-84
[
10778966.001
]
[Cites]
Cell Struct Funct. 1995 Jun;20(3):191-7
[
7586009.001
]
[Cites]
N Engl J Med. 2001 Apr 19;344(16):1196-206
[
11309634.001
]
[Cites]
J Clin Oncol. 2002 Jun 15;20(12):2832-43
[
12065560.001
]
(PMID = 15749593.001).
[ISSN]
1091-255X
[Journal-full-title]
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
[ISO-abbreviation]
J. Gastrointest. Surg.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 2.1.1.45 / Thymidylate Synthase
79.
Sträter J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T, Möller P:
Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.
Gut
; 2005 May;54(5):661-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Impaired CD95 expression predisposes for recurrence in curatively resected
colon
carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.
BACKGROUND: Loss of CD95 expression in tumour cells occurs frequently in
colon
carcinoma and may be associated with disease progression.
AIMS: We aimed at further exploring the functional role and prognostic significance of the CD95/CD95L death inducing system in
colon
carcinomas.
PATIENTS AND METHODS: CD95 and CD95L expression was examined by immunohistochemistry in 128 R0 resected UICC (International Union against Cancer)
stage
II/
III colon
carcinomas and correlated with disease free survival.
Tumour infiltrating lymphocytes (TIL) were the major source of CD95L in
colon
carcinomas.
Moreover, a high rate of CD95L+TIL correlated with prolonged disease free survival in patients with UICC
stage
II (p = 0.05) but not in those with
stage III
.
CONCLUSIONS: Loss of CD95 in tumour cells may be an independent prognostic factor in
colon
carcinomas.
The CD95L counterattack is not a relevant feature in
colon
carcinoma but CD95L+TIL may contribute to tumour control in the early stages of the disease, exerting a concurrent selection pressure in the direction of CD95 abrogation/resistance.
[MeSH-major]
Adenocarcinoma
/ immunology. Antigens, CD95 / metabolism. Biomarkers, Tumor / metabolism. Colonic Neoplasms / immunology. Membrane Glycoproteins / metabolism
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hum Pathol. 1999 Nov;30(11):1309-13
[
10571510.001
]
[Cites]
Cell Death Differ. 2001 Mar;8(3):273-8
[
11319610.001
]
[Cites]
J Immunol. 2000 May 15;164(10):5023-7
[
10799856.001
]
[Cites]
J Pathol. 2001 May;194(1):15-9
[
11329136.001
]
[Cites]
J Immunol. 2001 Aug 15;167(4):2068-73
[
11489989.001
]
[Cites]
Cancer Cell. 2002 Aug;2(2):139-48
[
12204534.001
]
[Cites]
J Immunol. 2003 Jun 15;170(12):5973-80
[
12794124.001
]
[Cites]
Gastroenterology. 2003 Sep;125(3):708-15
[
12949717.001
]
[Cites]
J Immunol. 2003 Oct 15;171(8):4164-74
[
14530339.001
]
[Cites]
Cancer. 1981 Mar 1;47(5):930-6
[
7226044.001
]
[Cites]
Cell. 1991 Jul 26;66(2):233-43
[
1713127.001
]
[Cites]
J Biol Chem. 1992 May 25;267(15):10709-15
[
1375228.001
]
[Cites]
Lab Invest. 1993 Oct;69(4):415-29
[
7693996.001
]
[Cites]
Int J Cancer. 1994 May 1;57(3):371-7
[
8168998.001
]
[Cites]
Int J Cancer. 1996 Sep 4;67(5):709-14
[
8782663.001
]
[Cites]
Science. 1996 Nov 22;274(5291):1363-6
[
8910274.001
]
[Cites]
J Exp Med. 1996 Sep 1;184(3):1075-82
[
9064324.001
]
[Cites]
J Exp Med. 1996 Sep 1;184(3):1149-54
[
9064331.001
]
[Cites]
Cell. 1997 Feb 7;88(3):355-65
[
9039262.001
]
[Cites]
Gastroenterology. 1997 Jul;113(1):160-7
[
9207274.001
]
[Cites]
Cancer Res. 1998 Feb 1;58(3):526-34
[
9458101.001
]
[Cites]
Cancer Res. 1998 Aug 15;58(16):3491-4
[
9721846.001
]
[Cites]
J Exp Med. 1998 Nov 2;188(9):1717-23
[
9802983.001
]
[Cites]
J Pathol. 1998 Nov;186(3):240-6
[
10211111.001
]
[Cites]
J Exp Med. 1999 Oct 4;190(7):1025-32
[
10510092.001
]
[Cites]
J Exp Med. 1999 Oct 4;190(7):1033-8
[
10510093.001
]
[Cites]
J Immunol. 2000 May 1;164(9):4941-54
[
10779805.001
]
(PMID = 15831912.001).
[ISSN]
0017-5749
[Journal-full-title]
Gut
[ISO-abbreviation]
Gut
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD95; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Ligands; 0 / Membrane Glycoproteins
[Other-IDs]
NLM/ PMC1774512
80.
Hill DA, Furman WL, Billups CA, Riedley SE, Cain AM, Rao BN, Pratt CB, Spunt SL:
Colorectal carcinoma in childhood and adolescence: a clinicopathologic review.
J Clin Oncol
; 2007 Dec 20;25(36):5808-14
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PATIENTS AND METHODS: We reviewed the clinical and pathologic features, prognostic factors, and outcome of CRC in 77 children and adolescents (ages 7 to 19 years) referred to
St
Jude Children's Research Hospital between 1964 and 2003.
Tumors were evenly distributed between the right and left
colon
; 62% were mucinous
adenocarcinoma
.
At presentation, 86% of patients had advanced-
stage
disease; more than half had distant metastases.
Advanced
stage
and mucinous histology were significant predictors of adverse outcome.
Stage
-specific survival at 10 years was 67% +/- 27% (
stage
1), 38% +/- 15% (
stage
2), 28% +/- 11% (
stage III
), and 7% +/- 4% (
stage
4).
Although no patient had a diagnosis of polyposis syndrome before diagnosis of CRC, 17 (22%) had
colon
polyps and eight (including two who previously underwent pelvic radiotherapy) had multiple polyps.
[MeSH-minor]
Adenocarcinoma
, Mucinous / pathology.
Adenocarcinoma
, Mucinous / therapy. Adolescent. Adult. Child. Cohort Studies. Female. Humans. Male. Prognosis. Survival Analysis. Treatment Outcome
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18089879.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA23099
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
81.
Paduch R, Kandefer-Szerszeń M:
Transforming growth factor-beta1 (TGF-beta1) and acetylcholine (ACh) alter nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion in human colon adenocarcinoma cells.
In Vitro Cell Dev Biol Anim
; 2009 Oct;45(9):543-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Transforming growth factor-beta1 (TGF-beta1) and acetylcholine (ACh) alter nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion in human
colon adenocarcinoma
cells.
Colon adenocarcinoma
is one of the most common fatal malignancies in Western countries.
The present study was conducted to assess the influence of recombinant human transforming growth factor (rhTGF)-beta1 or ACh on nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion by three human
colon adenocarcinoma
cell lines: HT29, LS180, and SW948, derived from different grade tumors (Duke's
stage
).
Colon
carcinoma cells exhibited different sensitivities to rhTGF-beta1 or ACh dependent on the tumor grade and the culture model.
ACh exhibited significant inhibitory effects towards NO, endothelial nitric oxide synthase (eNOS), and IL-1beta secretion especially by tumor cells derived form Duke's C
stage of colon
carcinoma. rhTGF-beta1 also decreased NO, IL-1beta, and eNOS expression, but its effect was lower than that observed after the administration of ACh.
Taken together, the TGF-beta1-ACh axis may regulate
colon
carcinoma progression and metastasis by altering NO secretion and influence inflammatory responses by modulating IL-1beta production.
[MeSH-minor]
Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Humans. Nitric Oxide Synthase Type
III
/ metabolism
Hazardous Substances Data Bank.
NITRIC OXIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Biol Markers. 2005 Oct-Dec;20(4):235-41
[
16398405.001
]
[Cites]
Gastroenterology. 1996 Feb;110(2):375-82
[
8566583.001
]
[Cites]
Cell Biol Int. 2005 Jul;29(7):497-505
[
15893483.001
]
[Cites]
World J Surg. 2005 Mar;29(3):306-11
[
15711891.001
]
[Cites]
Cancer Metastasis Rev. 2006 Sep;25(3):387-408
[
17043764.001
]
[Cites]
Baillieres Clin Haematol. 1992 Jul;5(3):703-21
[
1333850.001
]
[Cites]
Med Hypotheses. 2008;70(1):43-51
[
17587508.001
]
[Cites]
Clin Immunol. 2002 Feb;102(2):169-78
[
11846459.001
]
[Cites]
Biochem Pharmacol. 2004 Jun 15;67(12):2197-205
[
15163551.001
]
[Cites]
Cancer Res. 2003 Oct 15;63(20):6744-50
[
14583469.001
]
[Cites]
J Am Coll Cardiol. 1997 Feb;29(2):308-17
[
9014982.001
]
[Cites]
Br J Cancer. 1996 Dec;74(12):1955-60
[
8980396.001
]
[Cites]
Eur J Cancer. 2000 Jun;36(10):1288-91
[
10882868.001
]
[Cites]
Lancet Oncol. 2001 Mar;2(3):149-56
[
11902565.001
]
[Cites]
Clin Exp Metastasis. 1997 Nov;15(6):557-67
[
9344040.001
]
[Cites]
Dig Dis Sci. 1999 May;44(5):916-21
[
10235597.001
]
[Cites]
J Cancer Res Clin Oncol. 2003 May;129(5):272-8
[
12748850.001
]
[Cites]
Int J Mol Med. 2002 Jun;9(6):651-7
[
12011984.001
]
[Cites]
Eur J Cancer. 2001 Jan;37(2):224-33
[
11166150.001
]
[Cites]
Ann Med. 1995 Jun;27(3):359-67
[
7546626.001
]
[Cites]
Mutat Res. 2004 Nov 2;555(1-2):107-19
[
15476855.001
]
[Cites]
Drug Resist Updat. 2006 Jun;9(3):157-73
[
16822706.001
]
[Cites]
Clin Exp Metastasis. 2005;22(4):341-9
[
16170670.001
]
[Cites]
Gastroenterology. 1995 Aug;109(2):483-9
[
7615197.001
]
[Cites]
Med Hypotheses. 2007;69(6):1272-6
[
17553629.001
]
[Cites]
Cancer Immunol Immunother. 2004 Aug;53(8):723-8
[
15034673.001
]
[Cites]
Inflamm Res. 2004 Feb;53(2):60-5
[
15021970.001
]
[Cites]
Life Sci. 2003 Mar 28;72(18-19):2159-68
[
12628474.001
]
[Cites]
J Transl Med. 2006 Nov 10;4:48
[
17096856.001
]
(PMID = 19551451.001).
[ISSN]
1543-706X
[Journal-full-title]
In vitro cellular & developmental biology. Animal
[ISO-abbreviation]
In Vitro Cell. Dev. Biol. Anim.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Interleukin-1beta; 0 / Transforming Growth Factor beta1; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase Type III; N9YNS0M02X / Acetylcholine
82.
Huerta S, Heinzerling JH, Anguiano-Hernandez YM, Huerta-Yepez S, Lin J, Chen D, Bonavida B, Livingston EH:
Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF.
J Surg Res
; 2007 Sep;142(1):184-94
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Modification of gene products involved in resistance to apoptosis in metastatic
colon
cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF.
BACKGROUND:
Colon
cancer becomes resistant to apoptosis as it acquires metastatic potential.
SW480 and SW620
colon
cancer cells were established from the same patient at different stages of tumor progression.
The
stage III
colorectal cancer cell line (SW620) is more resistant to apoptosis.
In the present report, we investigated the apoptotic gene products that might account for
colon
cancer evasion of immune attack and chemoradioresistance-induced apoptosis.
CONCLUSIONS: SW620 cells have acquired genetic defects both in the intrinsic and extrinsic pathways of apoptosis, which may explain in part the ability
of colon
cancer cells to escape the immune system and to become chemoradioresistant.
[MeSH-minor]
Adenocarcinoma
/ pathology.
Adenocarcinoma
/ physiopathology. Antibodies / pharmacology. Antineoplastic Agents / pharmacology. Apoptosomes / physiology. Cell Line, Tumor. Cisplatin / pharmacology.
Colon
/ drug effects.
Colon
/ pathology.
Colon
/ radiation effects. Colonic Neoplasms / pathology. Colonic Neoplasms / physiopathology. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Metastasis / physiopathology. Proto-Oncogene Proteins c-bcl-2 / physiology. Receptors, Death Domain / physiology. Tumor Suppressor Protein p53 / physiology
Genetic Alliance.
consumer health - Metastatic cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17603079.001).
[ISSN]
0022-4804
[Journal-full-title]
The Journal of surgical research
[ISO-abbreviation]
J. Surg. Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / APAF1 protein, human; 0 / Antibodies; 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / Apoptosis Inducing Factor; 0 / Apoptosomes; 0 / Apoptotic Protease-Activating Factor 1; 0 / CH-11 anti-fas antibody, human; 0 / DIABLO protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Death Domain; 0 / Tumor Suppressor Protein p53; Q20Q21Q62J / Cisplatin
83.
Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF:
Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution.
Surg Endosc
; 2008 Feb;22(2):506-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
(1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have
adenocarcinoma
on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
Invasive
adenocarcinoma
was found on histological analysis of the colectomy specimen in 14 out of 63 cases (22%), standard error of the proportion 0.052.
Staging of the 14 cancers were I (n = 6, 43%), II (n = 3, 21%),
III
( = 4, 29%), and IV (n = 1, 7%).
Neither dysplasia on endoscopic biopsy nor lesion diameter was predictive
of adenocarcinoma
.
Eight out of 23 (35%) patients with dysplasia on endoscopic biopsy had
adenocarcinoma
on final pathology versus 6/40 (15%) with no dysplasia (p = 0.114, Fisher's exact test).
CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive
adenocarcinoma
, some of advanced
stage
.
[MeSH-major]
Adenocarcinoma
/ surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy
MedlinePlus Health Information.
consumer health - Colonic Polyps
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 2004 May 13;350(20):2050-9
[
15141043.001
]
[Cites]
Am J Surg. 1999 May;177(5):384-7
[
10365875.001
]
[Cites]
Ann Surg. 1979 Dec;190(6):679-83
[
518167.001
]
[Cites]
Surg Endosc. 1998 Nov;12(11):1341-4
[
9788858.001
]
[Cites]
AORN J. 1992 Dec;56(6):1068-73
[
1463326.001
]
[Cites]
Dis Colon Rectum. 2006 Jun;49(6):879-82
[
16598402.001
]
[Cites]
Surg Endosc. 2005 Sep;19(9):1252-5
[
16132333.001
]
[Cites]
Surg Endosc. 2007 Mar;21(3):400-3
[
17180271.001
]
[Cites]
Int J Colorectal Dis. 1997;12(5):267-71
[
9401839.001
]
[Cites]
Br J Surg. 1999 Apr;86(4):505-8
[
10215825.001
]
(PMID = 17704872.001).
[ISSN]
1432-2218
[Journal-full-title]
Surgical endoscopy
[ISO-abbreviation]
Surg Endosc
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
84.
Tsai WS, Changchien CR, Yeh CY, Chen JS, Tang R, Chiang JM, Hsieh PS, Fan CW, Wang JY:
Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.
Dis Colon Rectum
; 2006 Jun;49(6):883-94
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Preoperative plasma vascular endothelial growth factor levels were positively correlated with tumor
stage
, T class, M class, and tumor size (Spearman correlation, P < 0.01), but were not associated with gender, N class, tumor location, histology type, or grade.
The positive rates of vascular endothelial growth factor elevation (>148.6 pg/ml) compared with carcinoembryonic antigen elevation were 36.9 to 14.6 percent in
Stage
I, 60.9 to 33 percent in
Stage
II, 62.9 to 48.7 percent in
Stage III
, and 86 to 70.2 percent in
Stage
IV, respectively.
[MeSH-major]
Adenocarcinoma
/ blood.
Adenocarcinoma
/ pathology. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. Nitrites / blood. Vascular Endothelial Growth Factor A / blood
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16741643.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Nitrites; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
85.
Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE:
The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
Am J Obstet Gynecol
; 2005 Apr;192(4):1214-21; discussion 1221-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The role of ultrasound evaluation in the detection of early-
stage
epithelial ovarian cancer.
OBJECTIVE: Epithelial ovarian cancer kills more women than all other gynecologic malignancies combined because of our inability to detect early-
stage
disease.
Ultrasonography has demonstrated usefulness in the detection of ovarian cancer in asymptomatic women, but its value for the detection of early-
stage
epithelial ovarian cancer in women of increased risk is uncertain.
We examined the usefulness of sonography in the detection of early-
stage
epithelial ovarian cancer in asymptomatic high-risk women who participated in the National Ovarian Cancer Early Detection Program.
Increased risk includes women with at least 1 affected first-degree relative with ovarian cancer; a personal history of breast, ovarian, or
colon
cancer; > or =1 affected first- and second-degree relatives with breast and or ovarian cancer; inheritance of a breast cancer mutation from an affected family member, or membership within a recognized cancer syndrome.
The detected malignancies were fallopian tube carcinoma (
stage
IIIC; n = 4 women), primary peritoneal carcinoma (n = 4 women;
stage
IIIA, 1 woman;
stage
IIIB, 2 women;
stage
IIIC, 1 woman), epithelial ovarian cancer (stages IIIA and IIIB; n = 2 women), and endometrial
adenocarcinoma
(
stage
IA; n = 2 women).
A total of 184 women with genetic predisposition (breast cancer positive) have undergone a prophylactic bilateral salpingo-oophorectomy; 23% of these procedures found atypical hyperplasia, and unexpectedly, 2 women (1%) were found to have
stage III
(A and B) primary peritoneal carcinoma.
CONCLUSION: This study demonstrates the limited value of diagnostic ultrasound examination as an independent modality for the detection of early-
stage
epithelial ovarian cancer in asymptomatic women who are at increased risk for disease.
Genetic Alliance.
consumer health - Ovarian cancer
.
Genetic Alliance.
consumer health - Ovarian epithelial cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15846205.001).
[ISSN]
0002-9378
[Journal-full-title]
American journal of obstetrics and gynecology
[ISO-abbreviation]
Am. J. Obstet. Gynecol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / UO1CA85133
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
86.
Lim SB, Choi HS, Jeong SY, Park JG:
Feasibility of laparoscopic techniques as the surgical approach of choice for primary colorectal cancer: an analysis of 570 consecutive cases.
Surg Endosc
; 2008 Dec;22(12):2588-95
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: The study times were divided into three periods based on the COST trial report and the time when the laparoscopic technique was accepted as the surgical approach of choice at our center (period I: October 2000 to May 2004, II: June 2004 to December 2005,
III
: January to December 2006).
RESULTS: The use of laparoscopic surgery increased from 2.4% in period I, to 19.2% in period II, to 66.1% in period
III
.
Over the periods, the proportion of rectal cancer and right
colon
cancer increased (p < 0.001), T- and N-
stage
became more advanced (p < 0.001, p = 0.011 respectively), and operative time decreased (p < 0.001).
The short-term favorable outcomes support the feasibility of laparoscopic technique as surgical approach of choice for
colon
cancer.
[MeSH-major]
Adenocarcinoma
/ surgery. Colorectal Neoplasms / surgery. Laparoscopy / methods
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Surg Endosc. 2010 Mar;24(3):726-7
[
19633895.001
]
[Cites]
Lancet Oncol. 2005 Jul;6(7):477-84
[
15992696.001
]
[Cites]
Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4
[
17893502.001
]
[Cites]
Surg Endosc. 2003 Apr;17(4):636-40
[
12574925.001
]
[Cites]
N Engl J Med. 2004 May 13;350(20):2050-9
[
15141043.001
]
[Cites]
Arch Surg. 1997 Jan;132(1):41-4; discussion 45
[
9006551.001
]
[Cites]
Dis Colon Rectum. 2002 Dec;45(12):1648-54
[
12473889.001
]
[Cites]
Surg Endosc. 2004 Oct;18(10):1457-62
[
15791369.001
]
[Cites]
Surg Laparosc Endosc. 1991 Sep;1(3):144-50
[
1688289.001
]
[Cites]
Br J Surg. 2004 Sep;91(9):1111-24
[
15449261.001
]
[Cites]
Surg Endosc. 2006 Aug;20(8):1197-202
[
16865622.001
]
[Cites]
Ann Surg. 2005 Jul;242(1):83-91
[
15973105.001
]
[Cites]
Lancet. 2005 May 14-20;365(9472):1718-26
[
15894098.001
]
[Cites]
Lancet. 2004 Apr 10;363(9416):1187-92
[
15081650.001
]
[Cites]
J Clin Oncol. 2007 Jul 20;25(21):3061-8
[
17634484.001
]
[Cites]
Ann Oncol. 2006 Aug;17(8):1239-48
[
16873440.001
]
[Cites]
Ann Surg. 2002 Dec;236(6):759-66; disscussion 767
[
12454514.001
]
[Cites]
Surg Endosc. 2005 Jun;19(6):757-66
[
15868256.001
]
[Cites]
Ann Surg. 2003 Mar;237(3):335-42
[
12616116.001
]
[Cites]
Colorectal Dis. 2005 Jul;7(4):369-74
[
15932561.001
]
[Cites]
Dis Colon Rectum. 1997 May;40(5):592-6
[
9152190.001
]
[Cites]
Lancet. 2002 Jun 29;359(9325):2224-9
[
12103285.001
]
[Cites]
Ann Surg. 2002 Apr;235(4):449-57
[
11923599.001
]
[Cites]
Surg Endosc. 2001 Feb;15(2):116-20
[
11285950.001
]
[Cites]
Surg Endosc. 2004 Feb;18(2):281-9
[
14691716.001
]
[Cites]
Dis Colon Rectum. 1995 Jun;38(6):600-3
[
7774470.001
]
(PMID = 19011948.001).
[ISSN]
1432-2218
[Journal-full-title]
Surgical endoscopy
[ISO-abbreviation]
Surg Endosc
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
87.
Chen HH, Chakravarty K D, Wang JY, Changchien CR, Tang R:
Pathological examination of 12 regional lymph nodes and long-term survival in stages I-III colon cancer patients: an analysis of 2,056 consecutive patients in two branches of same institution.
Int J Colorectal Dis
; 2010 Nov;25(11):1333-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pathological examination of 12 regional lymph nodes and long-term survival in stages I-
III colon
cancer patients: an analysis of 2,056 consecutive patients in two branches of same institution.
PURPOSE: Pathologic examination of at least 12 lymph nodes (LNs) is widely accepted as a standard for
colon
cancer surgery.
METHODS: Patients with stages I-
III adenocarcinoma
of the
colon
between 1998 and 2003 were identified from the Chang Gung Colorectal Tumor Registry in two branches (Linkou and Kaohsiung branches) of same institution.
Younger age, right hemicolectomy, larger tumor, higher tumor
stage
, higher caseload of surgeons, and patients at Linkou branch with an odds ratio (OR) as high as 23 (95% CI, 17-31) were independently associated with a higher frequency of ≥12 examined nodes.
Patients with examined node number of <12 had a greater risk of recurrence within stages II and
III
(
stage
II: adjusted OR 1.88, 95% CI 1.27-2.79;
stage III
: adjusted OR 1.58, 95% CI 1.15-2.17) but not within
stage
I (OR 0.73, 95% CI 0.23-2.24).
CONCLUSIONS: The results confirm that factors influencing nodal harvest are multifactorial and the examined LN number of 12 or more is associated with an increased long-term survival in stages II-
III colon
cancer.
It is possible to adequately sample and examine a sufficient number of nodes in the majority
of colon
cancer specimens by standardized conventional methods.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 2005 Dec 22;353(25):2654-66
[
16371631.001
]
[Cites]
Ann N Y Acad Sci. 2000 Jun;910:62-73; discussion 73-4
[
10911906.001
]
[Cites]
Dis Colon Rectum. 2009 Feb;52(2):260-7
[
19279421.001
]
[Cites]
J Clin Oncol. 1999 Sep;17(9):2896-900
[
10561368.001
]
[Cites]
CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308
[
15537574.001
]
[Cites]
Ann Surg. 2009 Apr;249(4):602-7
[
19300229.001
]
[Cites]
J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44
[
1912440.001
]
[Cites]
Cancer. 1998 Aug 15;83(4):666-72
[
9708929.001
]
[Cites]
Ann Surg. 2007 Jun;245(6):858-63
[
17522509.001
]
[Cites]
Arch Pathol Lab Med. 2000 Jul;124(7):979-94
[
10888773.001
]
[Cites]
Ann Surg. 2007 Jun;245(6):846-57
[
17522508.001
]
[Cites]
Colorectal Dis. 2008 Feb;10(2):157-64
[
17477849.001
]
[Cites]
N Engl J Med. 1985 Jun 20;312(25):1604-8
[
4000199.001
]
[Cites]
Ann Surg Oncol. 2009 Mar;16(3):585-93
[
19116751.001
]
[Cites]
J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90
[
12504228.001
]
[Cites]
J Clin Oncol. 2009 Dec 20;27(36):6166-71
[
19901106.001
]
[Cites]
Am J Surg. 2007 Sep;194(3):349-54
[
17693281.001
]
[Cites]
Arch Surg. 2008 Nov;143(11):1050-5; discussion 1055
[
19015462.001
]
[Cites]
Eur J Cancer. 2005 Jan;41(2):272-9
[
15661553.001
]
[Cites]
J Natl Cancer Inst. 2007 Mar 21;99(6):433-41
[
17374833.001
]
[Cites]
Ann Surg. 2004 Oct;240(4):624-8; discussion 628-30
[
15383790.001
]
[Cites]
J Clin Oncol. 2003 Aug 1;21(15):2912-9
[
12885809.001
]
[Cites]
JAMA. 2007 Nov 14;298(18):2149-54
[
18000198.001
]
[Cites]
Ann Surg Oncol. 2008 Jan;15(1):46-51
[
17985187.001
]
[Cites]
Ann Surg Oncol. 2003 Apr;10(3):213-8
[
12679304.001
]
[Cites]
Cancer. 2001 Jul 15;92(2):452
[
11466702.001
]
[Cites]
J Clin Oncol. 2005 Dec 1;23(34):8706-12
[
16314630.001
]
[Cites]
Gastroenterology. 1996 Mar;110(3):682-7
[
8608876.001
]
[Cites]
J Clin Oncol. 2006 Feb 20;24(6):878-83
[
16418493.001
]
[Cites]
J Am Coll Surg. 2008 Feb;206(2):247-54
[
18222376.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71
[
12513963.001
]
[Cites]
Arch Surg. 2010 Jan;145(1):12-7
[
20083749.001
]
[Cites]
Ann Surg. 2002 Apr;235(4):458-63
[
11923600.001
]
[Cites]
Am J Surg Pathol. 2002 Feb;26(2):179-89
[
11812939.001
]
[Cites]
J Natl Cancer Inst. 2001 Apr 18;93(8):583-96
[
11309435.001
]
[Cites]
Eur J Cancer. 2005 Sep;41(14):2071-8
[
16125926.001
]
[Cites]
J Natl Cancer Inst. 2005 Feb 2;97(3):219-25
[
15687365.001
]
(PMID = 20676662.001).
[ISSN]
1432-1262
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
88.
Fujita S, Yamamoto S, Akasu T, Moriya Y, Taniguchi H, Shimoda T:
Quantification of CD10 mRNA in colorectal cancer and relationship between mRNA expression and liver metastasis.
Anticancer Res
; 2007 Sep-Oct;27(5A):3307-11
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
TIN was higher in
colon
, pN1/pN2,
stage III
and IV, and well- or moderately-differentiated
adenocarcinoma
than in rectum, pNO,
stage
I and II, and poorly-differentiated or mucinous
adenocarcinoma
, respectively.
Although CD10 mRNA was associated with invasion depth, lymph node status and TNM
stage
, it was not associated with prognosis.
[MeSH-minor]
Adenocarcinoma
/ genetics.
Adenocarcinoma
/ immunology.
Adenocarcinoma
/ pathology.
Adenocarcinoma
/ secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction
Genetic Alliance.
consumer health - Colorectal Cancer
.
Genetic Alliance.
consumer health - Liver cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17970075.001).
[ISSN]
0250-7005
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / RNA, Messenger; EC 3.4.24.11 / Neprilysin
89.
Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J, Austrian Breast and Colorectal Cancer Study Group:
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
Br J Cancer
; 2007 Oct 22;97(8):1021-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A prospective randomised phase
III
trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with
stage
II
colon
cancer.
The purpose of this trial was to investigate the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in
stage
II
colon
cancer.
Patients with
stage
II
colon
cancer were randomised to either adjuvant chemotherapy with 5-FU/LV (100 mg m(-2) LV+450 mg m(-2) 5-FU weekly, weeks 1-6, in 8 weeks cycles x 7) or surveillance only.
In conclusion, results of this trial demonstrate a trend to a lower risk for relapse in patients treated with adjuvant 5-FU/LV for
stage
II
colon
cancer.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 1999 Nov;17(11):3553-9
[
10550154.001
]
[Cites]
Ann Surg. 2006 Oct;244(4):602-10
[
16998369.001
]
[Cites]
CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
[
12568441.001
]
[Cites]
J Clin Oncol. 2003 Aug 1;21(15):2912-9
[
12885809.001
]
[Cites]
N Engl J Med. 2004 Jun 3;350(23):2343-51
[
15175436.001
]
[Cites]
J Clin Oncol. 2004 Aug 15;22(16):3395-407
[
15199087.001
]
[Cites]
J Clin Oncol. 2004 Aug 15;22(16):3408-19
[
15199089.001
]
[Cites]
Cancer Chemother Rep. 1966 Mar;50(3):163-70
[
5910392.001
]
[Cites]
Biometrics. 1975 Mar;31(1):103-15
[
1100130.001
]
[Cites]
J Natl Cancer Inst. 1988 Mar 2;80(1):30-6
[
3276901.001
]
[Cites]
Arch Surg. 1989 Feb;124(2):180-2
[
2916939.001
]
[Cites]
N Engl J Med. 1990 Feb 8;322(6):352-8
[
2300087.001
]
[Cites]
J Clin Oncol. 1990 Sep;8(9):1466-75
[
2202789.001
]
[Cites]
J Clin Oncol. 1993 Oct;11(10):1879-87
[
8410113.001
]
[Cites]
Ann Intern Med. 1995 Mar 1;122(5):321-6
[
7847642.001
]
[Cites]
J Clin Oncol. 1999 May;17(5):1349-55
[
10334518.001
]
[Cites]
J Clin Oncol. 1999 May;17(5):1356-63
[
10334519.001
]
[Cites]
Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66
[
11602373.001
]
(PMID = 17895886.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
[Publication-country]
England
[Chemical-registry-number]
Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
[Other-IDs]
NLM/ PMC2360441
90.
Preis M, Korc M:
Kinase signaling pathways as targets for intervention in pancreatic cancer.
Cancer Biol Ther
; 2010 May 15;9(10):754-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Pancreatic ductal
adenocarcinoma
(PDAC) is the fourth leading cause of cancer related mortality in the United States.
The prognosis of patients with PDAC is extremely poor with a median survival of 6 months, in part due to the advanced
stage
at the time of diagnosis and early metastatic spread.
The relatively recent introduction of novel therapies targeting tyrosine kinase and serine/threonine kinase pathways have yielded dramatic results in certain hematological malignancies, and have resulted in significant advances in our ability to treat patients with melanoma, breast, lung and
colon
cancer, thereby leading to improved survival and quality of life.
Thus, despite encouraging phase I/II studies, the vast majority of phase-
III
studies have failed to demonstrate improved efficacy in PDAC.
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20234186.001).
[ISSN]
1555-8576
[Journal-full-title]
Cancer biology & therapy
[ISO-abbreviation]
Cancer Biol. Ther.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA-R37-75059
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Hedgehog Proteins; EC 2.7.- / Phosphotransferases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
91.
Wille-Jørgensen P, Laurberg S, Påhlman L, Carriquiry L, Lundqvist N, Smedh K, Svanfeldt M, Bengtson J:
An interim analysis of recruitment to the COLOFOL trial.
Colorectal Dis
; 2009 Sep;11(7):756-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHOD: Prospective registration of all operated patients as well as inclusions (curative resection,
stage
II or
III
disease, <or= 75 years, clean
colon
and exclusions of the individual patients in eight participating departments.
[MeSH-major]
Adenocarcinoma
/ surgery. Colonic Neoplasms / surgery. Patient Selection. Rectal Neoplasms / surgery
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19708095.001).
[ISSN]
1463-1318
[Journal-full-title]
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
[ISO-abbreviation]
Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Randomized Controlled Trial
[Publication-country]
England
92.
Fazeli MS, Adel MG, Lebaschi AH:
Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University.
Dis Colon Rectum
; 2007 Jul;50(7):990-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite,
stage
, and differentiation in Iran from 1995 to 2001 as observed in Tehran University.
These factors also are evaluated in conjunction with disease
stage
and tumor differentiation at the time of diagnosis.
METHODS: Data from 419 patients from a population that receives no screening between April 1995 and March 2001 operated on in the Cancer Institute and Imam Khomieni Hospital with a diagnosis of colorectal cancer were used to describe distribution of the colorectal carcinoma by age, gender, tumor subsite and pathology, and
stage
at diagnosis.
RESULTS: There were 403 (96.2 percent) cases
of adenocarcinoma
.
Patients were divided into two age groups (40 years and younger, and older than 40 years); 16.4 percent of patients had tumors in the proximal
colon
and 83.6 percent in distal parts.
Most patients were
Stage
II and
III
(48.1 and 33.4 percent, respectively).
Most patients in the younger age group were
Stage III
(45 percent) and in the older age group were
Stage
II (53.2 percent; P<0.001).
There were no differences in
stage
and tumor differentiation between two genders, but most of the patients with tumors in proximal
colon
were males (62.5 percent; P=0.1).
[MeSH-major]
Adenocarcinoma
/ epidemiology.
Adenocarcinoma
/ pathology. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17525859.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
93.
Sadahiro S, Mitomi T, Noto T, Kumada K, Hiki Y, Yamakawa T, Amano T, Oki S, Otani Y, Oka H, Takahashi T, Takemiya S, Nishiyama K, Yamamura T, Tsuchiya S, Ogawa N, Study Group on Postoperative Adjuvant Chemotherapy in Kanagawa Prefecture:
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Gan To Kagaku Ryoho
; 2005 Jul;32(7):997-1005
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A total of 501 patients consisting of 252 patients with
stage III
/IV
colon
cancer (Colorectal Cancer Handling Rules, 4th Ed.) for which macroscopic curative resection was possible and 249 patients with
stage
II/
III
/IV rectal cancer (ibid, 4th Ed.) were registered from 40 participating institutions.
The patients were randomly allocated to two groups with
colon
cancer and rectal cancer employed as stratification factors.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / analogs & derivatives. Rectal Neoplasms / drug therapy
Genetic Alliance.
consumer health - Colorectal Cancer
.
Genetic Alliance.
consumer health - Oral cancer
.
Hazardous Substances Data Bank.
MITOMYCIN C
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16044962.001).
[ISSN]
0385-0684
[Journal-full-title]
Gan to kagaku ryoho. Cancer & chemotherapy
[ISO-abbreviation]
Gan To Kagaku Ryoho
[Language]
jpn
[Publication-type]
Clinical Trial; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
[Publication-country]
Japan
[Chemical-registry-number]
0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 50SG953SK6 / Mitomycin; 56HH86ZVCT / Uracil; HA82M3RAB2 / 1-hexylcarbamoyl-5-fluorouracil; U3P01618RT / Fluorouracil
94.
Qureshi AU, Iqbal M, Gondal KM:
Transhiatal esophageal surgery for malignancy--a 7-year experience at a tertiary care hospital.
J Coll Physicians Surg Pak
; 2009 Jul;19(7):413-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
All underwent transhiatal esophagectomy and gastric tube or
colon
was used as the conduit to restore continuity.
The TNM staging were
stage
I, IIa, IIb,
III
and IV in zero (0), 5 (11%), 10 (22%), 24 (57.8%) and 3 (7.1%) respectively.
The frequency of complications is lower as compared to transthoracic approach and the early
stage of
presentation can lead to high 5-year survival ratios.
[MeSH-major]
Adenocarcinoma
/ surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19576147.001).
[ISSN]
1022-386X
[Journal-full-title]
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
[ISO-abbreviation]
J Coll Physicians Surg Pak
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Pakistan
95.
Park IJ, Choi GS, Lim KH, Kang BM, Jun SH:
Different patterns of lymphatic spread of sigmoid, rectosigmoid, and rectal cancers.
Ann Surg Oncol
; 2008 Dec;15(12):3478-83
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
For
stage III
disease, the local recurrence rate was significantly higher in the RA group; the disease-free survival rate was higher in the SC group, and the RS group showed results similar to those of the RA group.
Oncologic results were slightly unfavorable to sigmoid
colon
, and showed data similar to those of rectal cancer.
[MeSH-major]
Adenocarcinoma
/ secondary.
Adenocarcinoma
, Mucinous / secondary. Carcinoma, Signet Ring Cell / secondary. Lymph Nodes / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Ann Surg Oncol. 2010 Jan;17(1):346-7
[
19841983.001
]
(PMID = 18830668.001).
[ISSN]
1534-4681
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
96.
Fernandes LC, Kim SB, Matos D:
Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma.
World J Gastroenterol
; 2005 Feb 7;11(5):645-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal
adenocarcinoma
.
AIM: To evaluate the serum levels of cytokeratins and carcinoembryonic antigen (CEA) in diagnosis, staging and prognosis of patients with colorectal
adenocarcinoma
.
RESULTS: In the diagnosis of patients with colorectal
adenocarcinoma
, CEA showed a sensitivity of 56%, a specificity of 95%, a positive predictive value of 94%, a negative predictive value of 50% and an accuracy of 76.8%.
There was a statistically significant difference between the patients with
stage
IV lesions and those with stages I, II and
III
tumors.
With regard to CEA, the average level was 14.2 ng/mL in patients with
stage
I lesions, 8.5 ng/mL in patients with
stage
II lesions, 8.0 ng/mL in patients with
stage III
lesions and 87.7 ng/mL in patients with
stage
IV lesions.
In relation to TPA-M, the levels were 153.1 U/L in patients with
stage
I tumors, 106.5 U/L in patients with
stage
II tumors, 136.3 U/L in patients with
stage III
tumors and 464.3 U/L in patients with
stage
IV tumors.
CONCLUSION: Cytokeratins demonstrate a greater sensitivity than CEA in the diagnosis of colorectal
adenocarcinoma
.
[MeSH-major]
Adenocarcinoma
/ pathology. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / pathology. Keratins / blood. Neoplasm Staging
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15655814.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 68238-35-7 / Keratins
[Other-IDs]
NLM/ PMC4250731
97.
Givalos N, Gakiopoulou H, Skliri M, Bousboukea K, Konstantinidou AE, Korkolopoulou P, Lelouda M, Kouraklis G, Patsouris E, Karatzas G:
Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer.
Mod Pathol
; 2007 Feb;20(2):159-66
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Replication protein A is an independent prognostic indicator with potential therapeutic implications in
colon
cancer.
Experimental studies in
colon
cancer cell lines have shown that RPA protein may be the target of cytotoxins designed to inhibit cellular proliferation.
This is the first study to investigate the expression of RPA1 and RPA2 subunits of RPA protein and assess their prognostic value in
colon
cancer patients.
We analyzed immunohistochemically the expression of RPA1 and RPA2 proteins in a series of 130
colon
cancer resection specimens in relation to conventional clinicopathological parameters and patients' survival.
Statistical significant positive associations emerged between: (a) RPA1 and RPA2 protein expressions (P=0.0001), (b) RPA1 and RPA2 labelling indices (LIs) and advanced
stage of
the disease (P=0.001 and 0.003, respectively), (c) RPA1 and RPA2 LIs and the presence of lymph node metastasis (P=0.002 and 0.004, respectively), (d) RPA1 LI and the number of infiltrated lymph nodes (P=0.021), (e) RPA2 LI and histological grade of carcinomas (P=0.05).
Statistical significant differences according to the expression of RPA1 and RPA2 proteins were also noticed in the survival
of stage
II (P<0.00001 and 0.0016, respectively) and
stage III
(P=0.0029 and 0.0079, respectively) patients.
In conclusion, RPA1 and RPA2 proteins appear to be useful prognostic indicators in
colon
cancer patients and attractive therapeutic targets for regulation by tumor suppressors or other proteins involved in the control of cell proliferation.
[MeSH-major]
Adenocarcinoma
/ metabolism.
Colon
/ metabolism. Colonic Neoplasms / metabolism. Replication Protein A / metabolism
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17361204.001).
[ISSN]
0893-3952
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / RPA1 protein, human; 0 / Replication Protein A; EC 2.7.7.7 / RPA2 protein, human
98.
Vaccaro CA, Im V, Rossi GL, Quintana GO, Benati ML, Perez de Arenaza D, Bonadeo FA:
Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons.
Dis Colon Rectum
; 2009 Jul;52(7):1244-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lymph node ratio as prognosis factor for
colon
cancer treated by colorectal surgeons.
PURPOSE: This study was designed to assess the prognostic value of the lymph node ratio in patients with
colon
cancer treated by colorectal specialists.
METHODS: Three hundred and sixty-two
Stage III
consecutive cases were analyzed based on quartiles: lymph node ratio 1 (>0 and <0.06); lymph node ratio 2 (between 0.06 and 0.12); lymph node ratio 3 (>0.12 and <0.25); lymph node ratio 4 (>or=0.25).
CONCLUSION: A lymph node ratio >or=0.25 was an independent prognostic factor in
Stage III colon adenocarcinoma
regardless of the number positive nodes.
[MeSH-major]
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology
Genetic Alliance.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19571700.001).
[ISSN]
1530-0358
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
99.
Janson M, Edlund G, Kressner U, Lindholm E, Påhlman L, Skullman S, Anderberg B, Haglind E:
Analysis of patient selection and external validity in the Swedish contribution to the COLOR trial.
Surg Endosc
; 2009 Aug;23(8):1764-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: The
colon
cancer laparoscopic or open resection (COLOR) trial is an international, randomised controlled trial comparing outcomes of open and laparoscopic surgery for
colon
cancer.
DESIGN: At eight centres, which included 391 of the 422 Swedish patients, a local database search was performed to identify retrospectively all patients (n = 2,384) who underwent surgery for
colon
cancer during the inclusion period, and data was retrieved from medical records.
Relative to group 1, patients in group 4 had a significantly higher American Society of Anaesthesiologists (ASA) score, more advanced tumour
stage
and difference regarding the resections performed.
Results showed that 1470 patients (62%) could be calculated as feasible for laparoscopic
colon
resection (LCR) in a clinical, nontrial situation.
In Sweden, 50-60%
of colon
cancer patients can be operated on by laparoscopy.
[MeSH-major]
Adenocarcinoma
/ surgery. Colonic Neoplasms / surgery. Laparoscopy. Patient Selection
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lancet Oncol. 2005 Jul;6(7):477-84
[
15992696.001
]
[Cites]
N Engl J Med. 2004 May 13;350(20):2050-9
[
15141043.001
]
[Cites]
J Health Serv Res Policy. 1999 Apr;4(2):112-21
[
10387403.001
]
[Cites]
JAMA. 2001 Apr 18;285(15):1987-91
[
11308435.001
]
[Cites]
Lancet. 2005 May 14-20;365(9472):1718-26
[
15894098.001
]
[Cites]
Surg Endosc. 2005 May;19(5):687-92
[
15798899.001
]
[Cites]
Lancet. 2004 Apr 10;363(9416):1187-92
[
15081650.001
]
[Cites]
Anesthesiology. 1978 Oct;49(4):233-6
[
697075.001
]
[Cites]
Int J Technol Assess Health Care. 2003 Winter;19(1):8-16
[
12701935.001
]
[Cites]
Lancet. 2002 Jun 29;359(9325):2224-9
[
12103285.001
]
[Cites]
Br J Surg. 2005 Jan;92(1):94-100
[
15521083.001
]
[Cites]
Surg Endosc. 2007 May;21(5):747-53
[
17342556.001
]
[Cites]
Br J Surg. 2004 Apr;91(4):409-17
[
15048739.001
]
[Cites]
Arch Surg. 2007 Mar;142(3):298-303
[
17372057.001
]
[Cites]
Surg Endosc. 2002 Jun;16(6):949-53
[
12163961.001
]
[Cites]
Health Technol Assess. 2005 Sep;9(35):1-186, iii-iv
[
16153352.001
]
(PMID = 19057955.001).
[ISSN]
1432-2218
[Journal-full-title]
Surgical endoscopy
[ISO-abbreviation]
Surg Endosc
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
100.
Kuebler JP, Colangelo L, O'Connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N:
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
Cancer
; 2007 Nov 1;110(9):1945-50
[Fulltext service]